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Abstract  
 
Sickle cell disease (SCD) is one of the most prevalent genetic disorders worldwide that 
affects approximately 12,000 people in the United Kingdom.  Raised tricuspid 
regurgitant velocity (TRV), which may be related to left ventricular diastolic dysfunction 
(LV DD), occurs in approximately 30% of adults with SCD, and has been shown to be an 
independent risk factor for death. This thesis examines aspects of the role of LV DD in 
the development of increased tricuspid regurgitant velocity and investigates the 
hypothesis that myocardial dysfunction, affecting the right and left ventricle, is an 
important cardiovascular risk factor in patients with SCD.  
In the retrospective study, we determine the 5 year- survival of a cohort of patients with 
SCD based on their TRV. The association between raised TRV and mortality in a UK SCD 
population has been confirmed. Higher values of TRV were associated with a greater 
than 4 fold increased risk of death (HR: 4.48, 99%CI 1.01-19.8).  
In the prospective study, sixty-one patients with SCD were included in the study (mean 
duration of follow-up 17.13±3 months). In the serial  echocardiographic study , left 
ventricular average E/E´ ratio which is a predictor of increased left ventricular filling 
pressures, was independently associated with an increased tricuspid regurgitation 
velocity (p=0.007). In addition, blood urea nitrogen and global function index lateral 
showed independent association with an increased LV lateral E/E´ ratio. Biventricular 
myocardial deformation by 2D and 3D speckle tracking revealed significant changes in 
the serial measurements of systolic function. 
These findings provide novel insight into the pathophysiology of the cardiovascular 
complications of SCD and support the implementation of echocardiographic screening 
of adult patients with SCD to identify high-risk individuals for further evaluation.  
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Thesis overview 
 
The Thesis includes two major studies:  
 
- A retrospective survival study consisting of 5 years of follow-up, in which data 
from 170 Sickle Cell Disease (SCD) patients from Hammersmith Hospital and 
Central Middlesex Hospital were analysed. The population in the retrospective 
study included patients who were referred to the Echocardiographic Laboratory 
of Hammersmith Hospital and Central Middlesex Hospital from the Sickle Cell or 
Haematology Clinic. The clinical indication was either a clinical decision to 
screen for raised TRV or follow-up of previously elevated TRV. The aim of the 
retrospective study was to determine the survival cohort of patients with SCD 
based on their TRV and describe differences between those with elevated and 
normal TRV (Chapter 2).  
- A prospective study of 61 patients with SCD who were identified from the 126 
patients who participated in the Screening Phase of the WALK-PHaSST study. 
The patients were followed up for a mean period of 17 months. The 11 patients 
included in the Main Interventional Trial (sildenafil versus placebo) were not 
invited to participate in the prospective study. All of these 11 patients had  TRV ≥ 
2.7 m/s by echocardiogram, and 6MW distance of 150-500 m.  
- The primary aim of this study was to assess the impact of cardiovascular 
complications in patients with SCD and to prospectively evaluate the clinical and 
echocardiographic predictors of short term clinical outcomes (Chapter 3).  
 
Nature of study populations 
The retrospective and prospective studies were conducted simultaneously with no 
overlap or repeated use of data.  In the retrospective survival study, clinical and 
echocardiographic data was assessed at only 1 time point (data obtained between 2004 
and 2005). Of the 161 patients included, 27 patients were subsequently included in the 
prospective study where new clinical echocardiographic data was assessed at 2 time 
points (data obtained between 2008-2010).  
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Scope and structure   
 
The Thesis is structured into 9 chapters, divided into sections and sub-sections.  
 
In Chapter 1 I briefly introduce to scope and structure of the thesis, the hypothesis of 
the study and the literature review on the subject giving an overview of SCD, the latest 
cardiac imaging technologies and recent developments to study myocardial function in 
this disease, specifically Echocardiography and Cardiac Magnetic Resonance. In 
addition, it also describes the previous research that has been conducted in respect to 
SCD and the Heart. Chapter 2presentes the data analysis and results from the 
retrospective survival study of 5 years follow-up. Chapter 3 describes the methodology 
used, the aims and research questions of the study, a description of the recruitment of 
the patients and healthy volunteers, the statistical methods and the imaging protocols 
used. In Chapter 4 the results are discussed with aim to answer the research questions 
according to the findings. We characterise the left and right ventricles myocardial 
function, the interventricular dependence in the patients group, the relationship 
between estimated pulmonary systolic pressures and biventricular function. Chapter 5 
describes the associations between different variables with short term clinical 
outcomes. Chapter 6 reportes the reproducibility and reliability data regarding the test 
re-test results from the real time three-dimensional echocardiography (RT3DE) analysis 
of the left ventricle strain imaging and right ventricle volumes by 4D echocardiography. 
Chapter 7 includes the discussion of the results and a debate considering the initial 
research questions of the project.  Finally, in Chapter 8, I give a summary of the results 
and conclusions, with consideration giving to the limitations of the study and 
suggestions for future research. Chapter 9 include the References of the thesis.  
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Hypotheses of the study 
 
The hypotheses of this research are:  
 
 Mortality rates in patients with SCD and Pulmonary Hypertension (PH) are lower 
in the United Kingdom (UK) when compared to the United States (US) population.  
 Cardiac manifestations in SCD are related to age. 
 Myocardial dysfunction, affecting the right and left ventricles, is an important 
cardiovascular risk factor in patients with sickle cell disease and its severity 
differs according to sickle genotypes.  
 Right ventricle dysfunction is associated with a poor outcome in SCD. 
 Advanced echocardiographic techniques such as myocardial deformation analysis 
may add additional value in understanding abnormalities of myocardial function 
in patients with SCD. 
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Chapter 1 Background and Context of 
the Research 
  
 
1.1. Overview of Sickle cell Disease 
 
Sickle cell disease is the name given to a group of inherited conditions that affect 
haemoglobin (Hb) formation in the blood and is one of the most common 
haemoglobinopathies worldwide.  
 
Also known as sickle cell anaemia, SCD is a genetic disorder of haemoglobin that is 
transmitted on an autosomal recessive basis that results from mutations in both copies of 
the β-globin gene (Frenette and Atweh, 2007, Bunn, 1997), a major subunit of haemoglobin. 
Haemoglobin is the iron-containing oxygen-transport protein found in the red blood cells 
(RBC). Adult haemoglobin (HbA) is the normal and most common type of haemoglobin 
(Fig.1.1) seen in adults while newborn infants have predominantly fetal haemoglobin (HbF). 
HbF is mostly replaced by adult haemoglobin by the age of one year (Oni, 2006). SCD occurs 
when an infant inherits the gene for sickle haemoglobin (HbS) from both parents or the gene 
for sickle haemoglobin from one parent and another abnormal haemoglobin gene, from the 
other parent (Brawley et al., 2008) . The characteristic phenotype of SCD includes an altered 
polymerization of haemoglobin resulting in a “sickled” shape to the red blood cells (Bunn, 
1997) (Fig.1.2). Individuals with only one mutated β-globin gene and one normal working 
copy are known as sickle cell trait carriers. Sickle cell trait carriers are healthy and will not 
develop SCD.  
 
The sickle mutation is characterized as a glutamine-to-valine substitution at the sixth 
residue of the β-globin polypeptide (Ingram, 2004) resulting in the synthesis of HbS, a 
structural variable that is far less soluble than normal haemoglobin when 
deoxygenated(Bunn, 1997).   
 
Homozygosity for the HbS allele (homozygous sickle disease: haemoglobin SS disease) is 
responsible for the most common and most severe variant of SCD. Some patients are 
heterozygous resulting from several other genetic variants. This is related to the 
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interaction of different mutations of the human β-globin genes (De Montalembert, 
2008). When the βs gene interacts with the βC gene, the resulting sickling disorder will 
be HbSC disease which is typically mild. Mutation such as HbC or β-thalassemia will 
result in haemoglobin SC and Sβo and Sβ+, respectively. When a βs gene interacts with a 
β-thalassemia gene, the severity of the resulting sickling disorder depends on the 
severity of the co inherited β-thalassemia mutation. A Sβo -thalassemia tends to be of a 
severity similar to that of homozygous HbSS. In contrast, when the resulting sickling 
disorder is Sβ+thalassemia it can be clinically mild if the β+-thalassemia mutation is 
mild(Kato et al., 2007). 
 
The deoxygenated HbS molecules initially polymerize without forming fibres and 
subsequently polymerize into long fibres which deform the red cell into the typical 
sickle shape (Fig.1.3) (N.C. Hughes-Jones, 2004).      
 
SCD is  characterized by chronic haemolytic anaemia, with high susceptibility to 
infections, end-organ damage and intermittent episodes of vascular occlusion causing 
both acute and chronic pain (Frenette and Atweh, 2007).   
 
 
Fig. 1.1: Normal red blood cells.   
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Fig. 1.2: Sickle red blood cells. The figure shows a classical sickle-shaped erythrocyte.  
 
 
Fig. 1.3: The bottom half of the image (left) is a sectioned RBC. In a normal RBC, Hb is free to bind to oxygen. The red 
HbA are haemoglobin where oxygen has binded to the heme component of Hb. The purple proteins are deoxygenated 
forms of Hb. The bottom half of the image (right) is a sectional sickle cell within a blood vessel. It is shown that the Hb 
proteins form polymers due to a point mutation in the 6th position in the β-globin chain. The mutation causes 
glutamic-acid to be replaced with hydrophobic amino acid valine. The polymers within the cell tent and stretch the 
cell membrane which changes RBC into a sickle shape. 
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Fig. 1.4: Induction of Red-Cell Sickling by Polymerization of Deoxyhaemoglobin S.  
 
As red cells traverse the microcirculation, oxygen is released from oxyhaemoglobin (red 
circles), generating deoxyhaemoglobin (purple circles). The diagram at the left of the 
figure (Fig. 1.4.) shows molecules of haemoglobin S, with the globular a 2 b S 2 tetramer 
shown as a flat circle. Deoxygenation of haemoglobin S induces a change in 
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conformation in which the b subunits move away from each other. The hydrophobic 
patch at the site of the b 6 valine replacement, shown as a projection, can bind to a 
complementary hydrophobic site on a b subunit of another haemoglobin tetramer, 
shown as an indentation. This interaction is necessary for the formation of polymer, 
depicted as the interaction of three deoxyhaemoglobin S molecules on one strand (dark 
purple) with three deoxyhaemoglobin S molecules on an- other strand (light purple). At 
the bottom, a high-resolution model, shows the interaction of three deoxyhaemoglobin S 
molecules on one strand with three deoxyhaemoglobin S molecules on another strand. 
The a subunits are pale yellow- green, and the b subunits are grey (lighter in the 
foreground and darker in the background). The heme groups are shown as red spheres. 
Also shown are contacts between foreground b subunits involving b 6 valine (blue) on 
one strand and the hydrophobic acceptor site (bright green) on the other strand. Only 
one of the two b 6 valine sites in each haemoglobin S tetramer makes this contact. The 
diagram in the middle shows the assembly of deoxyhaemoglobin S into a helical 14-
strand fiber, shown as a twisted rope- like structure. The equation shows the time that 
elapses, or delay time (t d), between the deoxygenation of haemoglobin S and the 
concerted formation of polymer. The delay time is inversely proportional to the 
intracellular haemoglobin concentration (C), raised to about the 15th power; k denotes 
an experimental constant. The photograph at the bottom is a high-resolution electron 
micrograph of a fiber, provided by Dr. Stuart Edelstein. As deoxyhaemoglobin S 
polymerizes and fibers align, the red cell is distorted into an elongated banana or 
“sickle” shape, as shown in the diagram at the right. (Bunn, 1997) 
 
1.1.1. History of Sickle Cell Disease 
 
In 1846, an American doctor, R. Lebby wrote an article entitled “Case of Absence 
Spleen”. The case report was about an African American slave who has been executed 
for murder. One hour after the execution, the autopsy reported “unusual body builds”, 
describing a strange phenomenon of a man having lived without a spleen (Lebby, 1846). 
The following published reports of SCD appear later in the 1870’s where scientist began 
to investigate for causes of the disease (Bloom, 1995 ).  
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Progress in the study of SCD, lead to the discovery of sickle cell disease in 1910 by James 
B. Herrick. A dental student with complaints of pain episodes, and symptoms of anaemia 
went to Dr. Herrick who assigned a resident, Dr. Ernest Irons to the case. Dr. Irons 
examined the student´s blood under the microscope and saw red blood cells he 
described as “having the shape of a sickle”. The term “sickle-shaped” was coined to 
describe the uncharacteristic appearance of the red blood cells of this patient (Herrick, 
1910). Nevertheless, Herrick was not sure if the patient’s symptoms were related to a 
specific disease or any manifestations of another type of disease (Herrick, 1924. ).   
 
In 1927, Hahn and Gillespie discovered the role of deoxygenation when it was found that 
red blood cells from persons with the disease could be made to sickle by removing 
oxygen (Rosenthal, 2006). The peculiar elongated forms seen on oxygenated blood 
smears were irreversible sickle cells, which were later recognized as having an acquired 
membrane defect causing them to retain an abnormal shape even after the Hb is 
oxygenated. In 1949, two doctors, Dr. Col. E. A. Beet (Beet, 1949) and Dr. James V. Neel, 
an American geneticist, published independently two articles showing conclusively the 
hereditary nature of SCD (Neel, 1949a). 
 
Later on, in 1945, the famous Nobel Prize-winning chemist Linus Pauling hypothesized 
that the disease might originate from an abnormality in the haemoglobin molecule with 
an abnormal electrophoretic mobility.  This hypothesis was validated in 1949 by the 
demonstration through gel electrophoresis of the differential migration of sickle versus 
normal haemoglobin (Pauling and I.C., 1949) which encouraged Pauling and his 
colleagues to name sickle cell disease  “a molecular disease” (Pauling, 1964). It was also 
in 1949 that the  autosomal recessive inheritance of the disease was demonstrated 
(Neel, 1949b).  
 
Later  in 1958, Ingram and colleagues demonstrated that Hb S differed from normal 
haemoglobin A by a single amino acid (Ingram, 1958). Further studies analysed the 
structure and physical properties of Hb S, reporting that the mutant sickle haemoglobin 
formed intracellular polymers upon deoxygenation (Ferrone, 2004) .  
 
 
35 
 
1.1.2. Incidence and prevalence 
 
SCD is most common in people whose ancestors come from Africa, South or Central 
America, Caribbean islands, Mediterranean countries (such as Turkey, Greece, and Italy), 
India, and Saudi Arabia. The World Health Organisation estimates that sickle cell disease 
causes nine percent of deaths in under five year olds in Africa (up to 15% in some 
countries in West Africa), with infection being the main cause of death (WHO, 2006 
October). In certain areas of sub-Saharan Africa, an estimated 40 to 60% of the 
population is heterozygous, suggesting that 1 to 4% of babies born in this region may 
have the disease (Aliyu et al., 2008). In the US the disease affects between 50,000 and 
100,000 people (Brawley et al., 2008)  with an estimated one in every 375 individuals of 
African American descent affected. Approximately 1 in every 12 African Americans 
carries a SCD β-globin mutation (Wethers, 2000). 
 
It is estimated that approximately 250,000 children are born with SCD worldwide every 
year (Serjeant, 1997). According to the National Health Service (NHS) Thalassemia and 
Sickle Cell screening programme  there are approximately 240,000 carriers and an 
estimated 12,500 sickle cell patients in the UK (Streetly, 2000) (Lucas et al., 2008) being 
London one of the largest cohorts of haemoglobinopathy patients in the UK. The highest 
prevalence is among Black Africans and Black Caribbean’s (Streetly et al., 2010).  
Although there is the lack of a National registry in UK, it has been reported that the 
number of new sickle cell patients in England is approximately 250 per annum, and it is 
expected this will increase through the raising of migration (Streetly, 2000).  
 
The Cooperative Study of Sickle Cell Disease (Gaston and Rosse, 1982) made an 
important contribution for the study of the natural history of this disease. This study 
was commissioned in 1978 by the National Heart, Lung and Blood Institute (NHLBI) to 
characterize prospectively the clinical course of SCD in a cohort involving 4,000 patients 
from 23 centres across the US. This study defined the incidence and characteristics of 
virtually all the complications in SCD. Interestingly, it was found that over 20% of the 
adults suffered from fatal pulmonary complications of the disease.  
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1.1.3. Pathophysiology  
 
Sickle-cell disease covers a wide spectrum of illness. Most affected people have chronic 
anaemia with a haemoglobin concentration of around 8 g/dl. 
Clinical expression of SCD is very heterogeneous, ranging from a mild phenotype with 
survival between 60s years of age and 70s to a more severe disease with significant 
organ damage and early death (De Montalembert, 2008). 
When sickle haemoglobin (haemoglobin S) is deoxygenated, the replacement of b 6 
glutamic acid with valine results in a hydrophobic interaction with another haemoglobin 
molecule, triggering an aggregation into large polymers. The primary event in the 
molecular pathogenesis of sickle cell disease is the polymerization of deoxygenated 
haemoglobin S which results in a distortion of the shape of the RBC and a marked 
decrease in its deformability. The RBC became rigid cells and will be responsible for the 
vaso occlusive phenomena that are the hallmark of SCD (O'Malley, 2006). 
Through high resolution electron microscopy and advanced methods for imaging 
reconstruction, the fiber’s three dimensional structure has been demonstrated. The rate 
and extent of polymer formation in a circulating SS red cell depend primarily on three 
independent variables: the cell’s degree of deoxygenation, the intracellular haemoglobin 
concentration, and the presence or absence of haemoglobin F (O'Malley, 2006). Several 
studies have focused on study of the pathogenesis of the vaso-occlusive events in sickle 
cell disease, which have demonstrated by rigorous measurements of the kinetics of 
polymer formation, in haemoglobin solutions as well as in sickle erythrocytes (Asakura 
et al., 1994, Rodgers, 1997).  
The severity of sickle cell disease is mainly determined by the extent of haemoglobin S 
polymerization(Brittenham et al., 1985) and is proportional to the degree and duration 
of haemoglobin deoxygenation and to the concentration of intracellular haemoglobin S 
raised to approximately the 15th power.(Bunn, 1997)  
Haemoglobin polymerization and erythrocyte sickling shape, where red blood cells are 
rigid, sticky and elongated, can lead to small vessel obstruction, ischemia and ultimately 
necrosis, due to the decreased lifespan of these cells. Clinical manifestations of this 
process are well known in the bone, lung, spleen, retina and central nervous system and 
are highly prevalent manifestations in these patients.  
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Several studies have described the wide-ranging manifestations and complications that 
affect every aspect of the life of afflicted SCD patients (Bunn, 1997, Claster and 
Vichinsky, 2003). SCD complications are not until now all well understood, however the 
understanding of the pathophysiology of SCD has increased resulting in more effective 
treatment with reduced morbidity and mortality. This is largely because of the variable 
degree of severity, the variability of the various manifestations, and the complexity of 
the interaction of the disease process with other health-related events(Schultz WH, 
2003). 
Acute complications include stroke, acute chest syndrome, splenic sequestration, severe 
pain crisis, an increased risk of sepsis or other infections (Platt et al., 1994b, Fitzhugh et 
al., 2010). The extent to which SCD affects the heart and its function is unclear and 
remains under recognised.  
 
1.1.4. The heart in sickle cell disease 
 
Clinical manifestations of cardiovascular abnormalities in patients with SCD have been 
previously documented (Ng et al., 1967, Uzsoy, 1964, Covitz et al., 1995). Interestingly 
the earliest description of the cardiac manifestations in SCD, has been made by Jammes 
Herrick, who detected a precordial murmur and cardiac enlargement (Herrick, 1910).  
 
Lindsay, in a extended review on this subject, has referred that in patients with SCD, 
cardiac abnormalities are more frequent than in those with other forms of anaemia 
(Lindsay J, 1974). Maybe this is attributed to the chronicity and severity of the anaemia 
(Varat et al., 1972), especially in homozygous form of the disease. Theoretically, severe 
anaemia leads to inadequate oxygen delivery to tissues and the circulatory system is 
strained by sickled erythrocyte’s propensity to occlude small blood vessels which in the 
heart may perhaps cause myocyte dysfunction.  In a study by Hedge et al. it has been 
described that iron deficiency anaemia can produce left ventricular dysfunction and 
overt heart failure (Hegde et al., 2006).  
Low haemoglobin levels are associated with elevated cardiac output at rest, cardiac 
enlargement and heart murmurs due to an increased stroke volume (Serjeant, 1997). 
Many patients with SCD have elevated left-heart filling pressures as a result of a 
chronically elevated cardiac output and/or diastolic dysfunction. 
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Although not in agreement with some researchers (Lester et al., 1990, Gerry Jr et al., 
1978) a specific SCD cardiomyopathy has been described (Oliveira and Gómez-Patino, 
1963, Rubler and Fleischer, 1967, Patel et al., 2012), which may in part be related to the 
abnormal properties of sickle cell haemoglobin, by either affecting left ventricular (LV) 
function due to its differing oxygen carrying properties, through intravascular sickling, 
long-standing anaemia or intravascular thrombosis.  
The mechanism of vaso-occlusion and the sequelae of chronic intravascular haemolysis 
have addressed the highly variable clinical manifestations of SCD. The existence of a 
specific myocardial abnormality is intuitively attractive since gross cardiomegaly is 
commonly observed in these patients. The marked desaturation of coronary venous flow 
is in favour of the appearance of this vaso-occlusive phenomena that might injure the 
myocardium.  
Myocardial scintigraphic imaging using isotopes such as thallium have been used to 
detect myocardium perfusion abnormalities in children with SCD (Wang et al., 2004, 
Sherman and Sule, 2004). Several studies have reported cases of myocardial infarction 
in patients with SCD (Barrett et al., 1984, Martin et al., 1996, Mansi and Rosner, 2002), 
however this entity has been frequently  overlooked since these patients often have few 
or no traditional risk factors for coronary artery disease (Pannu et al., 2008, Martin et 
al., 1996).  
Myocardial perfusion abnormalities in SCD have been found in 23 (61%) patients aged 
12±5 years old, using scintigraphy (Acar et al., 2003). Another study was performed 
using contrast echocardiography for evaluation and quantification of myocardial 
perfusion. Twenty-six patients aged 23±5 years, all homozygotic SS were studied where 
it was found abnormal myocardial microvasculature reserve in 13 patients (Almeida et 
al., 2008). Raman et al. hypothesised in a subset of adults SCD patients, that these 
patients may have myocardial ischemia in the absence of infracted myocardium, 
myocardium iron overload or coronary artery disease. It was also described in this 
study, right ventricular dysfunction despite normal pulmonary arterial pressures 
(Raman et al., 2006).  
 
 Despite the long-standing interest in studying the heart in SCD, precise definition of the 
pathophysiologic mechanisms and clear characterization of the cardiac manifestations 
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in these patients is needed. Moreover, cardiovascular abnormalities appear to be less 
common in the heterozygous sickle patients than in homozygous sickle state and this is 
expected since in most such patients the anaemia is less severe. 
 
1.1.5. Diastolic function in Sickle Cell Disease 
 
Diastolic function is often referred as the ability of the left ventricle to accept blood at 
low pressures during diastole. Its impairment is characterized by abnormal ventricular 
distensibility and relaxation which leads to the incapacity to maintain normal 
ventricular filling, unless there is an increase in the left atrial pressure, is called diastolic 
dysfunction (Di Tullio, 2008). In SCD, it has been described that diastolic function may 
be a consequence of relative systemic hypertension, increased preload, decrease 
ventricular compliance, impaired left ventricle contractile state or direct myocardial 
damage from microvascular vaso-oclusive disease as a result of sickling episodes. 
 
Diastolic dysfunction, diagnosed by Doppler echocardiography has become the primary 
tool for identifying and grading the severity of diastolic dysfunction in SCD which has 
been reported in several studies. Due to the non-uniform use of echocardiographic 
parameters and also the no uniform classification of diastolic dysfunction, this entity has 
not been comprehensively analysed and contradictory results have been found. The use 
of echocardiographic measurements is to a great extent variable. 
 
In a paediatric study including 37 children, diastolic function was found in 95% 
according to conventional echocardiographic criteria (El-Beshlawy et al., 2006). In 
contrast, Sachdev et al reported an echocardiographic evidence of diastolic dysfunction 
in 18% of SCD adult patients contributing to PH in only one third of patients with a  
tricuspid regurgitan jet velocity (TRV) of 2.5 m/s or greater (Sachdev et al., 2007).  
Interestingly, echocardiographic signs of left ventricular diastolic dysfunction 
(evidenced by a low E/A ratio) and PH (evidenced by an elevated TRV) are independent 
and additive risk factors for death in this National Institute of Health (NIH) PH screening 
study cohort. Nevertheless, no advanced echocardiographic assessment for myocardial 
function was used in this study. 
 
40 
 
 
Another study performed in 107 patients (between 3 and 18 years old) with SCD, 
showed early systolic and diastolic dysfunction in the left ventricle (68%) and in the 
right ventricle (17%). In this study, there was no correlation with haemoglobin level or 
number of transfusions (Caldas et al., 2008a). 
More recently, a study from Knight-Perry et al. found that SCD adult patients when 
compared to a control group had larger left and right heart chambers and higher 
estimated LV and right ventricle (RV) filling pressures, whereas DTI derived measures of 
LV and RV relaxation were similar between the groups. Furthermore, noninvasive 
measures of LV ventricular relaxation or stiffness or compliance (i.e., isovolumic 
relaxation time (IVRT), E velocities, mitral E/A ratio, and mitral valve deceleration time 
(MV DT) did not differ between patients with SCD and controls, suggesting that the 
intrinsic myocardial properties in subjects with SCD remain preserved (Knight-Perry et 
al., 2011). 
 
Doppler-derived diastolic parameters do not provide specific information on intrinsic 
passive diastolic properties, thus, diastolic dysfunction cannot be diagnosed solely by 
Doppler echocardiography (Maurer et al., 2004). In fact, several authors have reported 
the need of consistency and uniformization in the use tissue Doppler imaging and 
myocardial deformation parameter for the use of load-independent echocardiographic 
parameters (Zilberman et al., 2007, Sachdev et al., 2007).  
 
Cardiac iron overload can contribute for the abnormal myocardial relaxation but it has 
been rarely reported to SCD  patients (Wood, 2008) . Nevertheless, early detection of 
myocardial iron overload is important and this is  possible with the application of 
magnetic resonance imaging (MRI) in combination with tissue Doppler 
echocardiography and deformation imaging, a promising technique enabling the 
detection of wall motion abnormalities despite preserved global heart function (Vogel et 
al., 2003). 
 
Besides some controversy among literature, it is well established that patients with SCD 
have some degree of diastolic dysfunction, however, it is not yet clear whether the 
patients have subtle and sub-clinical LV systolic dysfunction despite preserved ejection 
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fraction and a growing interest among researchers has been developed during the last 
years, with the use of more advanced cardiovascular imaging modalities.   
 
 
1.1.6. Pulmonary hypertension in sickle cell disease 
 
Pulmonary hypertension is a disorder characterized by increased pulmonary artery 
pressure and has been defined in the latest Guidelines for the diagnosis and treatment of 
pulmonary hypertension (Authors/Task Force Members et al., 2009) by a mean 
pulmonary artery pressure ≥ 25 mm Hg which based on cardiac catheterisation 
measurement, considered the gold standard definition of pulmonary hypertension. The 
echocardiographic correlate of this diagnostic criterion based on tricuspid regurgitation 
estimates systolic pulmonary arterial pressure and a cut off value of TRV≥2.5 m/s, has 
been widely used (Lee et al., 2009, Sachdev et al., 2007, Gladwin et al., 2004, Parent et al., 
2011, De Castro et al., 2008).   
 
For pulmonary arterial hypertension, additionally should be a normal cardiac output (to 
reject a hyperdynamic state, and a wedge pressure ≤ 15 mmHg to exclude causes of left 
sided-cardiac disease). 
 
Pulmonary hypertension may occur as a consequence of raised pulmonary vascular 
resistance or high cardiac output. Raised pulmonary vascular resistance may occur as a 
consequence of pre-capillary pulmonary arterial disease, post capillary disease 
(pulmonary venous disease or left heart disease) or both (J Simon R Gibbs, 2009). 
While severe pulmonary hypertension is normally a straightforward echocardiographic 
diagnosis, it is possible to miss mild cases especially when right ventricular function is 
preserved and the remainder of the echocardiographic examination at rest appears 
normal.  
 
PH has been increasingly recognised as a complication of SCD and its development 
heralds a severe clinical phenotype associated with sudden death (Fitzhugh et al., 2010, 
Gladwin et al., 2004).   
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The aetiology of PH in SCD is probably multifactorial, including haemolysis, impaired 
nitric oxide biovailability, chronic hypoxemia, thromboembolism, splenic infarction, 
portal hypertension, lung fibrosis, HIV and schistosomiasis, all considered risk factors 
for pulmonary hypertension (Roberto F. Machado, 2005).  
Autopsy studies suggest that 75% of patients with SCD have histological findings of 
pulmonary arterial hypertension (PAH) at the time of death (Odd et al., 2009), 
suggesting that PAH may be clinically silent or poorly recognized for a late 
manifestation. 
One of the controversies in relation to PH in SCD is the inappropriate use of TRV for 
defining PH. The use of TRV obtained from echo only allows for the diagnosis of 
suspected PH, being a widely and successfully tool for screening test for elevation of 
pulmonary arterial pressure (Hatle et al., 1981, Lanzarini et al., 2002) since it has a low 
false-negative rate. The diagnoses of PH still requires right heart catheterization due to 
the high negative predictive rate as stated in the latest consensus report (Authors/Task 
Force Members et al., 2009, McLaughlin et al., 2009) and evidence-based analysis 
(Hoeper et al., 2009) (Parent et al., 2011, Fonseca et al., 2012)  
 
The ability to highlight a subgroup of patients with a high predicted mortality by use of a 
non-invasive measurement such as TRV represents a significant clinical advance and has 
rightly generated a lot of research interest. Raised TRV as assessed by Doppler 
echocardiography, whether or not associated with pulmonary arterial hypertension, is 
commonly found in sickle cell disease in approximately 32 to 40% of patients (Ataga et 
al., 2004, Fitzhugh et al., 2010, Gladwin et al., 2004, Liem et al., 2007b) and has been 
reported as a marker of mortality in several major studies from the United States (Anthi 
et al., 2007b, De Castro et al., 2008, Ataga et al., 2006, Machado and Gladwin, 2010, Lorch 
et al., 2011, Gladwin et al., 2012) .  
 
Sutton and colleagues reported a 40% mortality rate at 22 months, with an odds ratio 
for death of 7.86 (2.63-23.4)(Sutton et al., 1994). Powars and colleagues reported a 
mean 2.5-year survival in SCD patients with chronic lung disease with PH (Powars et al., 
1988). De Castro and colleagues similarly reported a 50% 2-year mortality rate in SCD-
PH patients (De Castro, 2004). 
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Regarding SCD, PH has been defined based on the tricuspid regurgitant jet velocity 
(TRV) using the modified Bernoulli’s equation (4*TRV plus central venous pressure 
estimate), whereas in other PH diseases have used catheterisation for diagnosis of PH. 
Whether increase TRV in SCD is of increased risk from PAH and/or from vasculopathy or 
other associated complications of SCD, e.g. proteinuria (prevalence of 20 to 25 %), is 
important to identify. 
In the NIH PH screening study, a  TRV of at least 2.5 m/s, as compared with a velocity of 
less than 2.5 m/s, was independently associated with a marked increased risk of death 
(Risk Ratio (RR) = 10.1; 95% Confidence Interval (CI) = 2.2-47; P < .001)(Gladwin et al., 
2004). The 18-month mortality was 16% for patients with a TRV of 2.5 m/s or greater 
and was less than 2% in patients without PH. In addition, a study by Castro and 
colleagues reported a similar prevalence of PH (36% in patient with HbSS and S-beta0 
thalassemia and 25% in SC and S-beta+thalassemia) and a remarkably similar 17% 
mortality rate for patients with PH over 2 years compared with approximately 2% for 
subjects without PH(Castro et al., 2003). Ataga and colleagues have also shown a 10% 
mortality rate for patients with PH over 26 months in comparison to 1% in those 
patients without PH (Kenneth I. Ataga, 2006). 
The high prevalence of PH in the population and associated high mortality demand 
worldwide non-invasive screening of all adults with Doppler echocardiography. There 
are limited data on specific screening procedures and echocardiographic assessment, 
which uses different limits when compared to other forms of PH, probably due to the 
central controversy of whether intensification of specific therapy will contribute to 
decrease mortality and morbidity associated with the most severe cases of the disease. 
Although the precise aetiology and severity of the pulmonary hypertension in patients 
with SCD has not been well defined, several studies (Table 1) have shown that even 
modestly elevated pulmonary artery pressures when compared to other forms of PH, as 
assessed by right heart catheterization or by echo-Doppler, indicate a poor 
prognosis(Gladwin et al., 2004, Castro et al., 2003). A controversy in this field is related 
to the contribution of left ventricular dysfunction to increased pulmonary pressures. 
Castro et al has shown with invasive hemodynamic measurements a varied picture of 
high pulmonary artery pressures and elevated pulmonary capillary wedge pressure, 
suggesting that LV dysfunction (systolic or diastolic) may contribute to the high 
pulmonary artery systolic pressure (Castro et al., 2003) . In the French study by Parent 
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et al, a total of 385 patients were included and has been reported that 25% of these 
patients had elevated TRV (≥ 2,5 m/s), however, the catheterization showed that only 24 
patients ( 6% of the total population) had real PH and from this ones , only 6 had PAH, 
while over 75% were explained by pulmonary venous hypertension or a hyperdynamic 
state. On the other hand, it is important to refer, that in this study, the exclusion criteria 
were not similar to most of the studies, and patients where pulmonary hypertension 
would be expected, were excluded. This inconsistency of selection criteria among SCD 
studies regarding pulmonary hypertension, warrants the need for further investigations 
to understand the impact of left-sided cardiovascular disease in these patients, which 
apparently may be more frequent than what has been reported.  
  
Table 1.0.1 - Pulmonary hypertension SCD studies with the use of tricuspid regurgitant jet velocity.  
 
1.2. Echocardiography 
 
Echocardiography was first used in 1954 by Edler, a Swedish cardiologist and Hertz, a 
physicist (Edler I Fau - Hertz and Hertz) to record movement of heart structures and 
since than it has evolved considerably from the single spatial and temporal resolution of 
M-mode echocardiography to the 3-dimensional imaging systems.  
 
Echocardiography is considered one of the most commonly performed non-invasive 
diagnostic tests in patients with known or suspected cardiovascular abnormalities and it 
is an increasingly important investigative tool in cardiology. The assessment of cardiac 
function is becoming progressively sophisticated and the recent developments in 
cardiac ultrasound permit the utilization of many newer physical concepts with 
currently available echocardiographic machines. 
 
Unlike most medical diagnostic tests, diagnostic ultrasound exists in nature and the 
sonic imaging capability in some mammals is remarkable. True clinical use of 
echocardiography began in the mid 1970’s (Gramiak and Shah, 1971, POPP and 
HARRISON, 1970, Feigenbaum, 1996).  Interestingly, studies using echocardiography for 
the evaluation of cardiac performance, started to rise in the late 1970’s where several 
reports have been published (Lindsay J, 1974)  (Gerry Jr et al., 1978).  
Echocardiography provides comprehensive evaluation of the cardiovascular structure, 
regional and global function, and hemodynamics that be possible to provide 
comprehensive measurements to fully understand the cardiovascular structure and 
myocardial function (Thomas and Popovic, 2006, Lamers et al., 2006, Caldas et al., 
2008b). 
 
M-mode was the first clinical application of ultrasound. M-mode or motion-mode 
images are a continuous 1-dimensional graphic display that can be derived by selecting 
any of the individual sector lines from which a 2-dimensional image is constructed.  
M-mode echocardiography is useful for quantitating single dimensions of walls and 
chambers in normally shaped ventricles, with the important advantage of its high 
temporal resolution, which makes it useful for example timing valve motion(Gottdiener 
et al., 2004) and annular motion. Although some limitations of its use are related to the 
47 
 
single dimension which may not be representative in distorted ventricles and the beam 
orientation is frequently off-axis.  
 
Two-dimensional (2D) echocardiography is the spine of echocardiography. It allows for 
the comprehensive visualization of the components of the beating heart, by displaying 
in real-time tomographic images. The distance of ultrasound echoes along the vertical 
axis represents the depth of echo-producing structures, with brightness indicating the 
intensity of the returning echo. It gives information regarding cardiac chamber size, wall 
thickness, global and regional systolic function, and valvular and vascular structures 
(Lang et al., 2005).  
 
The motion of the stars caused a change in the wavelength (or frequency shift) of the light 
reaching the observer. The phenomenon has been termed “Doppler effect” and applies to 
any wave in which the source or receiver is mobbing to respect to other. This principle was 
first described by Christian Doppler an Austrian physicist who noted that stars appeared on 
different colours when observed from a stationary point at earth(Gorcsan and Tanaka, 
2011).  
 
This principle has been applied to echocardiography for detecting the direction and velocity 
of moving blood within the cardiac chambers, across the valves and in great vessels(Kleijn 
et al., 2012b).  
 
Although 2D echocardiography is the most frequent used imaging modality for LV 
quantification, its limitations are well known for the estimation of ventricular volumes. 
Two-dimensional assessment of global LV volumes and ejection fraction (EF) with 
biplane method of discs relies on geometric assumptions and has some limitations due 
to chamber foreshortening and subsequent underestimation of LV volumes.  
 
The visual assessment of LV ejection fraction and regional wall motion abnormalities 
still requires extensive skill and expertise of the reader and eventually remains 
subjective (Quiñones et al., 2003, Blondheim et al., 2010).  
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Imaging technology has advanced considerably during the last decade, considering 
equipment, software, and image processing where the advent of modalities such as real-
time 3 Dimensional echocardiography (RT3DE), tissue Doppler strain imaging and 
speckle tracking has been widely valued  (Oh et al., 2006, Teske et al., 2008, Hung et al., 
2007).  
 
Much of the progress witnessed in these techniques can be attributed to their 
application to complex problems, such as the quantification of global and regional LV 
systolic and diastolic function, as well as response to cardiac resynchronization therapy. 
The need to understand a new language is fundamental for the selection of diagnostic 
and therapeutic strategies in patients with SCD and co-existent cardiac dysfunction.  
 
Three-dimensional imaging techniques such as computed tomography and cardiac 
magnetic resonance imaging (CMR) overcome limitations posed by other methods in 
that images planes are precisely defined and geometric assumptions are unnecessary. 
However, these imaging modalities are expensive, time-consuming and have limited 
availability. 
 
The acquisition of the first 3D cardiac ultrasound images was reported in 1974. 
Developments in 3D echocardiography started in the late 1980s with the introduction of 
off-line 3D medical ultrasound imaging systems. Several review articles have been 
published, assessing the progresses and limitations of 3D ultrasound technology for 
clinical screening (Gopal et al., 1993, Sugeng et al., 2003, Jenkins et al., 2004). These 
articles reflect the diversity of 3D systems that were developed for both image 
acquisition and reconstruction. One of them was the introduction of the matrix phased 
array transducers that scan a true three-dimensional volume at each pulse. This 
technology, pioneered by Von Ramm at Duke University with the volumetric transducer, 
was fundamentally different from the former generations of 3D systems as the entire 
cardiac volume was acquired in real-time (1 scan for 1 cardiac cycle), enabling the 
cardiologist to view moving cardiac structures from any given plane over a single 
cardiac cycle (Kisslo et al., 2000). Since then, a variety of computer-based 3-dimensional 
reconstruction techniques have been developed to replace the subjective mental 
reconstruction of complex cardiac geometry.  
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With a linear 1D array, the transducer controls the direction within a slice in 3D space, 
referred to as the azimuth. With this 2D matrix array, the steering is controlled in both 
the azimuth and the elevation directions, allowing the acquisition of an entire 
pyramidal-shape (Kühl et al., 2004) . Samples are acquired slice by slice at evenly spaced 
depths. The spacing between each scanning depth is equal to 0.308 mm in radial 
coordinates. This spacing determines the resolution in the receive line direction. A 
maximum of 512 slices can be acquired with the transducer. The RT3DE transducer 
array operates at frequencies between 2.0 MHz and 3.5 MHz. The particular design of 
the transmitter and receiver lines achieves a 16:1 parallel processing mode allowing 
extremely fast acquisition. 
 
RT3DE imaging facilitates the display of simultaneous multiple-plane display on the 
same screen to convey the 3-dimensional nature of the ultrasound data and it has been 
used in several clinical settings (Sachpekidis et al., 2011, Kapetanakis et al., 2011). It 
automatically acquires the image of the entire cardiac structure along 4 cardiac cycles 
while the transducers is kept fixed on a point. 3-D images are thus easier to obtain and 
are theoretically more precise than complex non-real time methods. 
 
Real-time 3D echocardiography using second-generation matrix-array transducers 
retain all the advantages of echocardiography but provide 3D spatial registration. Image 
quality is improved, therefore offering a practical approach for assessment of the RV and 
LV function and quantification of volumes, of outmost importance evaluation in the SCD 
population. 
 
1.2.1. Assessment of Left Ventricular Volumes and Function by 
RT3DE 
 
The need for a more reproducible assessment of LV volumes and function, prompt to the 
development of three-dimensional echocardiography (Monaghan, 2006). During the last 
decade, several studies using CMR as the current gold standard technique have shown 
the accuracy and reliability of 3D over 2D echocardiography (Jacobs et al., 2006, Jenkins 
et al., 2006). 
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Since it does not require any geometric assumptions and it can guard against image 
foreshortening, the direct volumetric assessment of LV size is preferable to calculations 
made from 2D or M-Mode (Atsumi et al., 2013). 
A wide number of software packages are currently available to calculate 3D LV volumes. 
They use semi-automated border tracking techniques to create a mathematical cast of 
the whole ventricle throughout the cardiac cycle, where EF and volumes are derived 
(Fig. 1.5). 
 
Fig. 1.5: Real time 3D echocardiographic dataset showing LV endocardial cast. LV volume rendered representation 
with cut-planes of short-axis, 4 and 2-chamber views are displayed. The global volume curve is display on the bottom.  
 
1.2.2. Assessment of Right Ventricular Volumes and Function by 
RT3DE 
 
Right ventricular systolic dysfunction has been identified as a key element in 
determining prognosis of patients afflicted with pulmonary hypertension(Lopez-
Candales et al., 2005). Although echocardiography has proved invaluable to 
noninvasively assess pulmonary artery pressures, evaluation of right ventricular size 
and systolic function by echocardiography is somewhat more difficult, largely because of 
the complex RV anatomy that limits its evaluation (Ho and Nihoyannopoulos, 2006).  
The high prevalence of PH in SCD population and associated high mortality demand 
universal non-invasive screening of all adults with Doppler echocardiography. Sachdev 
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et al (Sachdev et al., 2007), reported that echocardiographic evidence of diastolic 
dysfunction is common in SCD patients, but contributes to PH in only one third of 
patients with a TRV of 2.5 m/s or greater. Interestingly, echocardiographic signs of left 
ventricular diastolic dysfunction (evidenced by a low E/A ratio) and PH (evidenced by 
an elevated TRV) are independent and additive risk factors for death in the NIH PH 
screening study cohort (Gladwin et al., 2004). Therefore, identification of early right 
ventricular dysfunction is of outmost clinical importance. 
 
 A study comparing 2D and 3D echocardiography found that 2D significantly 
overestimated right heart volume assessments compared with 3D by a factor of 45% 
and showed a greater reproducibility of 3D (Schindera et al., 2002). In other study 
(Niemann et al., 2007) a recent technology by TomTec Imaging Systems has been used 
to validate RV volumes and EF by 3D echo. The results showed a good reproducibility 
and accuracy in measuring RV volumes in healthy adult subjects.   
 
This recent software uses three-dimensional ultrasound data sets to combine the 
simplicity and speed of echocardiography with the accuracy of MRI. The software 
calculates a three-dimensional right ventricular surface model using a semiautomated 
border detection algorithm with manual correction options based on in vivo normal as 
well as pathologic RV modelling (Fig. 1.6). The model will therefore measure right 
ventricular end diastolic and systolic volumes and ejection fraction. To our knowledge 
no study was performed in SCD population with the use of 3D echocardiography with 
specific software for RV analysing.  
 
The high prevalence of PH in the SCD population and previous described high mortality, 
demand universal non-invasive screening of all adults with echocardiography and an 
accurate quantification of right and left ventricular volume and function is necessary for 
a better understanding of this complex disease.  
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Fig. 1.6: Three dimensional analysis of the right ventricular volumes, stroke volume and ejection fraction. Display of 
3D images in sagital views in systole (top) and diastole (bottom), with manual tracing and adjustments in all planes.  
 
1.2.2.1. Limitations of RT3D  
 
The limitations of 3D echocardiography are well known. One of the limitations is 
concerning the additional training which is need to capture 3D images and also for the 
correct use of the dedicated software. This may be related with the fact that RT3D is not 
yet so currently available and included as a routine as is 2D imaging 
 
RT3D images are not yet fully integrated with data storage systems used for 2D 
echocardiography. In addition, it is not fully incorporated into major society guidelines 
and differences in data derived from different software packages need to be further 
delineated.  As in 2D imaging, patients with poor acoustic windows secondary to body 
habitus, chest deformities or lung pathology remain a challenge(Atsumi et al., 2013). 
 
Technically, 3DRT has reduced temporal and spatial resolution which may be a 
limitation especially when trying to image larger ventricles and/or at higher heart rates. 
Also “stiching” artefacts particularly in those with arrhythmia or those unable to 
breathhold for a sufficient period, need careful check on the images prior to analysis.  
 
Left ventricular volumes quantification, which is currently the most clinically applicable 
RT3D technique, appears to have a significant underestimation of volumes. Although, 
this limitation maybe overcome by experience and was independent of software use 
(Aessopos et al., 2007).  
53 
 
It has been described, that this is mainly related to the difficultly in differentiating left 
ventricular trabeculations from true myocardium. There is an urgent need for widely 
agreed cut-off values for certain analyses according to software programs.  
Concerning the assessment of RV, there are reported difficulties in imaging the near field 
by 3D echo which results in poor definition of the anterior free wall of the right ventricle 
with potential inaccuracies for extrapolation of the endocardial contour. (Seo et al., 
2009) 
 
 
1.2.3. Myocardial deformation imaging 
 
Myocardial deformation imaging is a novel echocardiographic method for assessment of 
global and regional myocardial function. The assessment of the contractile function of 
the heart has traditionally been restricted to volumetric assessments of left and right 
ventricles and the estimation of ejection fraction. The regional wall motion 
abnormalities have been evaluated with visual estimation which undoubtedly, it’s a 
method that lacks of reproducibility and standardization.  
 
Myocardial imaging can be performed with 3 methods: Doppler Tissue Imaging (DTI), 2-
dimensional speckle tracking (2DSTE) or 3-dimensional speckle tracking (3DSTE).  
 
1.2.3.1. Doppler Tissue Imaging  
 
DTI has proven to be effective in measuring ventricular function (Sohn et al., 1997, Yu et 
al., 2007) (Teske et al., 2008). The method of strain rate imaging by tissue Doppler was 
developed at the Norwegian University of Science and Technology in Trondheim. The 
derived parameters from DTI, strain and strain rate (SR), offer a quantitative evaluation 
of regional myocardial deformation and deformation rate. The myocardial time-velocity 
curve can be reconstructed either on line as spectral pulsed DTI or off line from  2D 
colour-coded DTI image loops(Yu et al., 2007) . Importantly, the peak systolic velocity is 
a sensitive marker of mildly impaired LV systolic function, even in those with a normal 
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ejection fraction  or apparently preserved LV systolic function, a common finding in SCD 
(Thomas H Marwick, 2009, George R. Sutherland, 2006) 
 
Tissue Doppler use the velocity gradient along the length of the myocardium in order to 
calculate strain rate, which is afterwards integrate to derive strain (as percentage) 
(Heimdal et al., 1998).  
 
The concept of strain is complex, but linear strain can be defined by 
the Lagrangian formula:  
 
Where ɛ is strain, L0 = baseline length and L is the instantaneous length at the time of 
measurement. Thus strain is deformation of an object, relative to its original length. By 
this definition, strain is a dimensionless ratio, and is often expressed as percentage. 
It is important to refer, that strain and strain rate only describe the part of the 
myocardial relating to volume changes and not to pressure, and both systolic and 
diastolic deformation is load dependent. The assessment of regional dysfunction, have to 
take into account the segment interaction and the load dependency, so it may enable us 
for assessing relatively contractility, since contractility cannot be measured directly.  
 
One of the limitations of DTI method for strain analysis is the angle dependency since it 
assesses only the plane incident with the ultrasound beam. The second limitation is the 
requirement for the acquisition of images with high frame rate.  
 
1.2.3.2. 2D Speckle Tracking 
 
Speckle tracking echocardiography (STE) is a new developed technique for the 
assessment of LV and RV global and regional function. It analyses motion by tracking 
speckles in the ultrasonic image in two dimensions (Perk et al., 2007). During the 
systole, the ventricular myocardium simultaneously shortens in the longitudinal and 
circumferential planes and thickens in the radial plane. Reciprocal changes are found 
during diastole. 
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STE analyses myocardial motion by frame-by-frame tracking of natural acoustic markers 
(≈20 to 40 pixels in size and variably referred to as “speckles,” “patterns,” or 
“fingerprints”) that are produced by constructive and destructive interference (i.e., 
reflections, interference, scattering) between ultrasound and myocardium within a user-
defined region of interest.  
The movement of individual speckles towards or away from one another represents 
regional myocardial shortening or lengthening and thus giving information regarding 
the strain and strain rate (Shah and Solomon, 2012, Perk et al., 2007). Longitudinal and 
circumferential shortening results in negative strain values, while radial thickening 
results in a positive strain value (Fig. 1.7). Unlike DTI, 2-STE analyses Lagrangian strain. 
Speckle tracking is an offline technique that is applied to previously acquired 2D images, 
attention is therefore needed for the acquisition of the images since Frame rates of ≈40 
to 80 are required to avoid speckle decorrelation, and good image quality is needed for 
accurate tracking(Marwick et al., 2009a). Usually, the myocardium is analysed in six 
different planes: three short-axis views (basal, mid-ventricular, and apical) and three 
other apical views (four-chamber, two-chamber, and three-chamber).  
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Fig. 1.7: Myocardial motion and deformation. A-motion components that can be assessed based on 
echocardiographic imaging. B-contains both normal deformation (longitudinal shortening/lengthening, radial 
thickening/thinning and circumferential shortening/lengthening) and shear(base-apex twisting) C- longitudinal 
velocity and displacement D- deformation (strain) and speed of deformation(strain-rate)  
 
STE gives information regarding myocardial deformation in the 3 principal planes: 
transmural (also referred as radial), circumferential and longitudinal (Fig. 1.8) and 
because it is performed in 2-dimensional B-Mode images, it is independently of both 
cardiac translation and the angle of incidence (Wang et al., 2007a). STE has been 
validated by reference sonomicrometry (Urheim et al., 2000), tagged cardiac magnetic 
resonance (Amundsen et al., 2006) and in an animal model (Pirat et al., 2008). 
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Fig. 1.8: Graphic representation of the principal myocardial deformations: longitudinal (A), radial and 
circumferential (B), and torsion (C). The direction of deformation in systole is shown as solid lines and that in diastole 
is shown as dashed lines. LONG indicates longitudinal; RAD, radial; and CIRC, circumferential.  
 
 
Fig. 1.9: Two dimensional longitudinal strain analysis of the left ventricle by speckle tracking (4 chambers apical 
view). 
 
2DSTE overcomes in part the strain derived DTI limitations since uses the movement of 
the uniform ultrasound backscatter speckle pattern, within 2D images, to assess 
myocardial strain throughout the cardiac cycle (Fig. 1.9). Another advantage of 2DSTE 
over DTI is the time required to complete analysis, where less time is required with 
2DSTE. 
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Fig. 1.10: Doppler versus Speckle Tracking Approach for Tissue Motion Analysis.  
 
The limitations of the technique are known and are related with the myocardial 
deformation measurements being affected by loss of speckles due to motion outside the 
imaging plane. Since the technique follows speckles in 2D planes, but speckle moves in 
three dimensions, only a portion of the real motion can be detected. In addition, the 
technique possesses limited reproducibility, especially when applied to suboptimal 
images and there is poor intervendor agreement, attributed to a lack of standardization 
in image analysis (Zimbarra Cabrita et al., 2013a).  
 
1.2.3.3. 3D Speckle Tracking  
 
Recent developments in RT3DE imaging resulted in improved image quality and higher 
frame rates allowing an automated endocardial tracking and a quantitative assessment 
not only on LV volumes and EF but also on both global and regional myocardial 
deformation of the entire LV (Mor-Avi et al., 2011) which has been studied more 
commonly using 2-dimensional speckle tracking echocardiography. Although, few 
studies(Maffessanti et al., 2009) have shown that 2DSTE may underestimate myocardial 
strain because of its inability to see through-plane motion.  Both technologies use 
ultrasound image data to detect movement of the myocardium, 2D tracking tracks 2D 
movement or the projection of 3D movement into a 2D plane, while 3D tracking assesses 
real movement in 3D space (Perez de isla, 2008). Therefore, translation remains a 
problem using 2DSTE, as error is introduced to strain measurements when the heart 
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swings out of the imaging plane and out-of-plane motion occurs as the result of rotation 
and motion of the heart; as a result, only a portion of the real motion can be detected.  
3DSTE is a purely 3D technology, having the capability of displaying the entire 
myocardium using a single set; with a great benefit for truly assess global left ventricular 
function. When using 3DSTE, a speckle particle moves through a volume and so the 
vector can be detected along the movement (Fig.1.11).  
 
  
 
Fig. 1.11: Advantages of three-dimensional speckle tracking. A - When using two-dimensional tracking, a speckle 
particle can move through the scan plane. B- Three-dimensional speckle tracking avoids this limitation. 
 
Has can be demonstrated in Fig. 1.12 , 3D tracking allows for the 3D dataset to include 
the total area in which the speckle may move, therefore the accuracy in detection of 
tissue movement is improved.  
3D tracking generates more than 3000 vectors per volume, and the temporal resolution 
is the same as the volume rate of cardiac 4D datasets (20-30 volumes per second). Being 
currently still a research tool, it provides new insights in the assessment of LV function, 
in particular for strain analysis, rotation and twist estimations, with the advantage of 
simultaneous calculations of 3D LV volumes and EF, presenting nowadays as a potential 
clinical tool for assessing myocardial strain in SCD patients. 
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Fig. 1.12: A- Tracing endocardium in apical four, three and two-chamber views. The tracked mesh in end diastole at 
apical views and its intersections with three short-axis. B- Three-dimensional speckle tracking display of longitudinal 
strain. 
 
Area strain is a novel parameter obtained by 3DSTE, with a high potential clinical 
application. The new parameter combines an analysis of both the longitudinal and 
circumferential shortening of the left ventricle(Støylen, 2011) providing an estimate of 
the subendocardial surface deformation, which is inversely proportional to the radial 
deformation of the ventricular wall (Fig. 1.13). 
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Fig. 1.13: Area strain. As the ventricle contract, the end diastolic area of the selected region (red) would be reduced 
in both the longitudinal and circumferential direction, the area reduction being the product of longitudinal and 
circumferential shortening. Thus, the magnitude of the area change would be greater than the circumferential or 
longitudinal shortening alone  
 
Importantly, the relatively low frame rates used in 3DSTE have been referred as a 
potential limitation. In a recent study by Yodwut et al, it has been demonstrated that 
3DSTE assessment of myocardial deformation is not compromised by low frame rates 
when derived from 18 or 25 frames/sec data sets but it may be underestimated with 
lower frame rates (Yodwut C 2012).  
Kleijn et al. in a recent study with 45 consecutive healthy subjects, shown that even 
though 3DSTE-derived underestimates LV volumes (when comparing with MRI), 
measurement of the left ventricle ejection fraction (LVEF) revealed excellent accuracy 
(Kleijn et al., 2012a). 
 
 
1.2.3.3.1. Limitations of 3DSTE 
 
One of the limitation of the 3DSTE technique is related to the  concern that 3D STE–
derived strain measurements may be underestimated because the frame rates of real-
time 3D echocardiography are not sufficiently high to accurately capture all phases of 
the cardiac cycle. It has been described that loss of deformation information occurs 
somewhere between 10 and 18 frames/sec, below which frame rates are not sufficient 
to accurately capture all phases of the cardiac cycle (Victor and Barron, 2010). 
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Furthermore, this technique is not yet interchangeable among different manufacturers, 
so its use in the clinical setting is still limited.  
 
Left ventricular torsion (or twist) plays an important role with respect to LV ejection 
and filling. Streeter et al (STREETER et al., 1969). has described fiber orientation in the 
canine in the lates 1960’s and since then, interest in fiber architecture and the resulting 
LV torsional deformation during contraction, has developed significantly in the last 
years (Rüssel et al., 2009). During the cardiac cycle, there is a systolic twist and an early 
diastolic untwist of the LV about its long axis because of oppositely directed apical and 
basal rotations (Fig. 1.14). As viewed from the LV apex, systolic apical rotation is counter 
clockwise and basal rotation, clockwise. LV torsion is followed by rapid untwisting of the 
ventricle which contributes to active suction of blood from the atria (Wu and Kovács, 
2006). The way of contraction for subendocardial fibers is right-hand orientated while 
subepicardial fibers are left-handed and because of its direct relation to fiber 
orientation, LVtor is considered a valuable addition to strain measures such as 
transversal, circumferential or longitudinal thickening. 
 
The characteristics of this torsional deformation have been described in different clinical 
and experimental studies (Helle-Valle et al., 2005, Amundsen et al., 2006), and it is well 
established that LV rotation is sensitive to changes in both regional and global LV 
function (Rüssel et al., 2009). During the past decades, tissue tagging magnetic 
resonance imaging has enable noninvasive measurement of LV myocardial deformation 
in 3D space (Buchalter et al., 1990, Moore et al., 2000b) and has driven  several 
investigations of LV torsion in various diseases, including SCD (Ahmad et al., 2012)  
2DSTE estimation of LV torsion (LVtor) has been validated by tagged MRI and the 
results have provided evidence that LVtor by STE is concordant with those analysed by 
MRI (Notomi et al., 2005). With its better temporal resolution and widespread 
availability, 2DSTE LVtor may lead to a fast introduction of LV torsion as an effective 
noninvasive index of global LV contractility (Kim et al., 2009)   
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Fig. 1.14: (Left) - (Right) - Corresponding rotation and torsion (circumferential-longitudinal shear angle) curves, 
starting at end-diastole and showing the entire cardiac cycle. 
 
The effect of preload and afterload on LV torsion have been widely studied (Buchalter et 
al., 1990, Kroeker et al., 1995) and it has been shown that an increase in preload 
(increased end-diastolic volume) caused an increase in twist angles and twist angles 
decreased under increasing afterload (increased end-systolic volumes). The 
understanding of the influence of LVtor in the cardiovascular system of patients with 
sickle cell disease need to be better understood, in particular in patients with suspected 
pulmonary hypertension which has not been fully explored.  
 
The classification of diastolic dysfunction (DD) is debatable. 
 
The ability of the left ventricle to accept blood at low pressures during diastole is often 
referred to as “diastolic function”. Abnormal ventricular distensibility and relaxation 
and the consequent inability to maintain a normal ventricular filling (unless the left 
atrial pressures increases), is called diastolic dysfunction. The basic mechanisms of DD 
may be intrinsic to the cardiomyocite, due to abnormalities in the extracellular matrix, 
neurohormonal influences and cardiac endothelial dysfunction (Gaasch, 1994). The 
study of DD, had a great improvement in the 1990’s with the introduction of 
echocardiography and Doppler based techniques, which provided a noninvasive 
assessment of the diastolic performance of the LV and its application in larger cohorts of 
patients. 
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Cardiac complications are a common feature of SCD and more recently, has been 
considered an important cause of associated morbidity and mortality (Fitzhugh et al., 
2010). The chronic anaemia results in an increase in cardiac output, and has been widely 
demonstrated that LV dilatation is closely linked to the degree of anaemia (Ahmed et al., 
2004).  
Recent studies have shown that LV diastolic dysfunction is common in children. 
Importantly,  Schadev et al  found in a study with 235 adults with SCD, that LV diastolic 
dysfunction, reflected by a low E/A ratio, was an independent risk factor for mortality 
with a risk ratio of 4.8 (95% CI: 1.9 to 12.1, p< 0.001) (Sachdev et al., 2007). 
Additionally, the same study found that the combination of diastolic dysfunction 
measures and suspected PH (TRV≥2.5 m/s), increases the mortality risk ration to above 
12.  
 
As it has been observed the diastolic manifestations are associated with age, increases in 
blood pressure, increased LV mass and higher creatinine levels. Although, the presence 
of a systemic vasculopathy affecting after load, is not well understood.  Microvascular 
disease may reflect directly on myocardial function. In addition, on the same NIH study 
(Sachdev et al., 2007) significant associations between systolic blood pressure and both 
increased pulmonary pressures and LV filling pressures have been found.   
Anthi et al., in a study with invasive right heart catheterization measurements in 
patients with suspected PH, have shown evidence of LV diastolic dysfunction in 33% of 
the PH diagnoses with pulmonary venous hypertension(Anthi et al., 2007a) Castro et al.  
The difficult in the assessment of diastolic function is well-know and its difficulty 
increases in the setting of preserved LV systolic function, which is find out in the 
majority of patients with SCD. Doppler-derived E/E’ ratio above 15 has  been accepted 
as a predictor of high LV filling pressure, however, milder degrees of LV dysfunction are 
more commonly found.   
The possibility of racial/ethnic differences is susceptibility to the development of DD has 
received far less attention.  
 
The Anglo-Scandinavian Cardiac Outcomes Trial has reported a decrease in left 
ventricular diastolic performance in African-Caribbean hypertensive patients, when 
65 
 
compared to European matching patients(Sharp et al., 2008). Importantly, the effect of 
African-Caribbean ethnicity on diastolic function persisted after adjustment for the most 
important confounding factors (age, gender, systolic blood pressure, pulse pressure, 
cholesterol, smoking, ejection fraction, left ventricular mass index, and diabetes 
mellitus), leading the hypothesis of the existence of an intrinsic difference in the 
diastolic function of the left ventricle between the 2 racial groups. Interestingly, in a 
study by Russo et al, performed in unselected sample of a multi-ethnic population, 
disparities in modifiable cardiovascular risk factors and sociodemographic variables, 
rather than intrinsic race-ethnic differences, seemed to account for most of the 
differences  observed is diastolic dysfunction, suggesting a role for risk factor control in 
reducing race-ethnic disparities in diastolic function (Russo et al., 2010). 
Studies with patients living in the same geographic area and with similar access to 
health care may help minimize this important confounding factor and improve 
comparability between the racial/ethnic groups particular in SCD. 
 
In patients with heart failure, anaemia has been linked to more severe cardiac 
dysfunction, increased plasma BNP (brain natriuretic peptide) and a worse prognosis, 
even after adjustment for conventional risk factors such as coronary heart disease, 
smoking, hypertension, Dyslipidaemia and renal function. Amin et al have found that 
anaemia has a range of effects on cardiac structure, including myocyte hypertrophy and 
interstitial ﬁbrosis, leading ultimately to left ventricle hypertrophy (Amin et al., 2004). 
More understanding is needed in which extend anaemia reflects the diastolic 
dysfunction observed in SCD. 
 
Although it is important to mention, that the majority of the studies in SCD, use 
conventional echocardiographic parameters for assessing diastolic function. The more 
extensive use of Tissue Doppler and Myocardial deformation has been lacking and 
prospective studies for profounder understanding of the mechanics behind diastolic 
dysfunction are needed for a better comprehension the impact of impairment of 
ventricular filling as opposed to a decrease in contractile function. The detection of both 
sub-clinical systolic and/or diastolic impairment provides the clinical with an 
opportunity to act before clinical symptoms develop.  
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Two-dimensional, Doppler, colour flow imaging, and myocardial (tissue Doppler) 
imaging are currently the most practical diagnostic modality, with good reproducibility, 
to identify patients with diastolic dysfunction.  
 
Furthermore, a recent study that combined global myocardial strain rate during the 
isovolumetric relaxation period (by speckle tracking) and transmitral flow velocities 
showed that the mitral E velocity/global myocardial strain rate ratio predicted LV filling 
pressure in patients in whom the E/e´ ratio was inconclusive and was more accurate 
than E/e´ in patients with normal EFs and those with regional dysfunction (Wang et al., 
2007b). Therefore, a more complete evaluation of diastolic function by deformation 
imaging is necessary in SCD and its incremental clinical value has not been fully 
investigated.  
 
1.3. Cardiovascular Magnetic Resonance  
 
1.3.1. General overview 
 
Since the acquisition of the first magnetic resonance signal in the 1952 by Herman Carr, 
and the first magnetic resonance images in the early 1970s by the Nobel laureates Paul 
Lauterbur and Sir Peter Mansfield, MRI has progressed enormously to become a popular 
technique in the medical community. MRI is most frequently useful in the evaluation of 
the nervous and musculoskeletal systems, but can be applied to the cardiovascular 
system as well. This chapter comprehends the basic principles of MRI, image acquisition 
of the moving heart, and general applications to the cardiovascular system.  
 
Cardiac magnetic resonance imaging has an increasingly valuable role to play as an 
adjunct to routine cardiovascular imaging modalities (De Vinuesa et al., 2008, Duerden 
et al., 2006). CMR is an accurate and reproducible method to provide non-invasive 
myocardial-tissue characterization at a high spatial resolution is still considered the gold 
standard for measuring ejection fraction and ventricular volumes(Task Force of the 
European Society of Cardiology, 1998).  
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1.3.2. Synchronising with the cardiac cycle 
 
For routine CMR, cardiac synchronization with the electrical activity is required for both 
pulse sequence and signal acquisition.  The electrocardiogram (ECG) tracing is 
transmitted by a wireless system to the CMR console for processing. Computer software 
is programmed to detect the R wave of the QRS complex, which marks the electrical 
systole and the beginning of the cardiac cycle (Lanzer et al., 1985). Based on the ECG 
information, images of the beating heart can either be obtained at a single time point 
(still imaging) or at multiple time points throughout the cardiac cycle (cine imaging) 
(Ridgway, 2010). 
 
1.3.3. Cine Imaging 
 
Cine imaging can be accomplished by using gradient echo-based pulse sequences with 
very short repetition times. It involves data acquisition at multiple time points, known 
as cardiac phases, throughout the cardiac cycle (Ridgway, 2010). Data acquired within 
each cardiac phase fills a separate k-space (temporary image space) resulting in the 
reconstruction of a separate image corresponding to each cardiac phase. The combined 
images can then be displayed as a movie, thus enabling functional assessment of the 
heart. 
 
1.3.4. Perfusion imaging 
 
Myocardial perfusion imaging is commonly used in coronary artery disease to assess the 
blood flow in the myocardium (Greenwood et al., 2012) It requires ultra-fast imaging 
techniques able to acquire several images of the myocardium (usually 3-5 short-axis 
slices) per cardiac cycle while a gadolinium based contrast agent transits through the 
coronary arteries. The single shot images are usually presented as a movie where the 
resulting myocardial signal correlates with the coronary blood flow and gadolinium 
concentration in the myocardium. Regional imbalances in contrast concentration under 
maximal pharmacological dilatation may evidence areas of hypoperfusion indicating 
myocardial ischemia. The sequences normally employed for perfusion images are based 
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on spoiled gradient echo, balanced steady stated free precession, and hybrid-echo 
planar imaging (efficient method of filling k-space via a combination of radiofrequency 
pulses and gradients). T1-weighting and a saturation recovery preparation pulse are 
necessary to maximise the effect of the contrast agent (Biglands et al., 2012) 
 
1.3.5. Volumes and function 
 
CMR is currently the most reliable method for volume assessment, and is frequently 
used as the benchmark for validation of other imaging modalities (Hoffmann et al., 
2003). Ejection fraction (derived from the end-diastolic and end-systolic volumes) is the 
parameter measured by CMR to assess systolic function. Diastolic ventricular function 
can also be assessed by CMR, but is not usually performed as echocardiography remains 
the preferred approach. 
 
1.3.6. Myocardial tissue tagging 
 
One of the reference modality for measuring myocardial deformation is tagged MRI.  
 
In 1988, Zerhouni et. al(Zerhouni et al., 1988) introduced a magnetic resonance based 
noninvasive imaging method for tracking myocardial motion: myocardial tissue tagging. 
The method allows for automatically extracting of local/global deformation parameters 
at the pixel and myocardial segment scales (Petitjean et al., 2004). Non-invasive 
markers, known as tags, are created within the tissue by locally induced perturbations of 
the magnetization with selective radiofrequency saturation of multiple, thin tag planes 
in a plane perpendicular to the imaging plane prior to image acquisition (Shehata et al., 
2009). These perturbations then produce regions of reduced signal intensity that appear 
as dark lines in the acquired images. Improving this technique Axel and Dougherty (Axel 
and Dougherty, 1989) then developed spatial modulation of magnetization to allow the 
application of tags in two orthogonal directions that, combined, form a grid of sharp 
intrinsic tissue markers (Fig.15 ).  One of the approaches to measure myocardial motion 
from tagged MRI image sequences is the phased-based optical flow methods such as 
harmonic phase analysis (Harmonic phase analysis) (O'Regan et al., 2012), which are in 
some extent, sensitive to artefacts.  
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Mid wall LV circumferential strain (ECC) is the most frequently computed parameter for 
quantifying regional function. ECC measure is preferred due to myocardial geometry 
contributing an abundance of tagging data around the mid wall myocardial 
circumference compared to along the width of radial wall thickness (Moore et al., 
2000a). This makes ECC data less sensitive to noise and more suitable for assessing the 
transmural strain gradient. In the normal heart, circumferential strain increases 
gradually from the base towards the apex. With respect to transverse regions, the 
greatest shortening is consistently observed in the anterior and lateral myocardial 
segments with the least deformation seen in the inferior wall. Moreover, ECC appears to 
increase from epicardium towards endocardium (Zwanenburg et al., 2005). 
 
 
 
Fig. 1.15: Short-axis tagged image  
 
The application of CMR tagging in the RV includes several technical challenges. The very 
thin wall (<5 mm) of the normal RV offers less than the minimum optimal tag spacing 
(≥6 mm) and therefore limits the number of tag stripes that would be required for 
accurate quantification (Fayad et al., 1998). An attempt to overcome these limitations 
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has been done and several studies have been investigating RV patterns of mechanical 
deformation. 
 
1.3.7. CMR in Secondary Cardiomyopathies 
 
The heart can be affected by a number of systemic conditions, such as sarcoidosis, 
amyloidosis, Anderson-Fabry and other metabolic storage disorders, muscular 
dystrophies, iron-overload cardiomyopathy and in transfusion-dependent 
hemoglobinopathies. These patients are usually referred to CMR when there is 
suspected cardiac involvement, although sometimes these conditions can be detected 
unexpectedly in the evaluation of heart failure or left ventricular hypertrophy 
(Alpendurada et al., 2012). Late gadolinium enhancement (LGE) imaging is extremely 
helpful in this setting, where infiltration or fibrosis depicted by LGE shows good 
correlation with endomyocardial biopsy (Smedema et al., 2005, Vogelsberg et al., 2008).  
Iron overload cardiomyopathy is a peculiar condition in this group of systemic diseases 
because diagnosis by CMR is not based on the presence of LGE (Kirk et al., 2011), but 
rather by documentation of iron deposition in the myocardium. This is possible by 
assessment of T2* relaxation, which has an inverse correlation with the amount of tissue 
iron (Carpenter et al., 2011). CMR has the unique ability of investigating iron deposition 
and ventricular function at the same time, and has contributed to the significant decline 
in mortality of iron-overload cardiomyopathy in the United Kingdom(Modell et al., 
2008) and can be considered as the reference technique for in vivo quantification of 
infarct size in SCD. In a study performed in 47 patients with SCD, it has been shown by 
CMR that LV changes are partly result of a chronic anemia, however a homogeneous 
fibrotic disorder affecting the LV could not be excluded (Westwood et al., 2007). 
Accurate quantification and timing of regional myocardial function allows early 
identification of dysfunction and its etiology, and therefore becomes  increasingly 
important for clinical risk assessment, SCD patients management, and evaluation of 
therapeutic efficacy. 
 
Despite providing the most comprehensive information, CMR is an expensive technique 
and not readily available in most institutions. Image acquisition is technically 
challenging and image interpretation requires adequate training. In CMR studies, scans 
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times are relatively long, patients have to lie flat, and monitoring or perfusion devices 
inside the magnet room have to be magnetic resonance-compatible. Therefore, CMR is 
not suitable for the very unstable patient and should be avoided in these patients if 
other studies can give similar information. Despite pacemakers and implantable 
electronic devices being regarded as contra-indications, CMR can potentially be safely 
performed in experienced centres when appropriate precautions are taken(Naehle et al., 
2009) . 
 
CMR currently offers the most comprehensive cardiovascular information of all imaging 
techniques.  Extensive research in the last decade has validated this technique in several 
clinical settings and supports its use in daily practice. However, lack of availability, 
medical training and cost constrains a more widespread use of this technique. 
Therefore, it is regarded as complement to echocardiography, since most of the general 
indications are similar. 
 
1.4. Potential benefits from this research  
 
Investigations into how the heart is affected in patients with SCD are widely reported as 
shown earlier in the critical review of the literature. Although, there is a certain amount 
of variability in the results and methodology approach and a thorough understanding of 
the subject is needed.  
 
Importantly, the majority of these previous investigations used conventional cardiac 
imaging techniques and were mainly performed in the US population, which may have 
different results. We believe that the use of the latest imaging techniques in 
echocardiography may benefit these patients for the identification of early 
manifestations of subclinical myocardial dysfunction and its relation to the presence of 
elevated tricuspid regurgitant jet by Doppler echocardiography.   
 
This thesis represents the first prospective investigation to study a group of patients 
with SCD, followed up at SCD referral UK centres, with the latest cardiac imaging 
technologies for the understanding of the cardiac function and existence of early 
markers of myocardial dysfunction. This study may defines the normal ranges and 
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variability of myocardial deformation derived from 3-dimensional speckle tracking and 
speckle tracing in a SCD population. 
 
In addition, we will study the variability of the different softwares packages for the 
assessment of myocardial deformation and ventricular volumes quantification which 
plays an important role in the clinical and research settings.   
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Chapter 2 A 5-year survival study in a 
North West London population of 
patients with sick cell disease 
 
2. Introduction 
 
This Chapter describes the retrospective survival study which was the first part of the 
research described in this thesis. The retrospective study has been published in the 
British Journal of Haematology (doi: 10.1111/bjh.12391), as mentioned in Introduction. 
 
2.1. Background of retrospective study 
 
Sickle cell disease is one of the most prevalent genetic disorders worldwide, affecting 
approximately 12,000 people in the United Kingdom (Fitzhugh et al., Hickman et al., 
1999, Lucas et al., 2008).  Although life expectancy is reduced in SCD (Platt et al., 1994a, 
Schultz WH, 2003), advances in management has led to a significant improvement in 
survival (Telfer et al., 2007, Quinn et al., 2010).  
The development of pulmonary arterial hypertension in SCD heralds a severe clinical 
phenotype, and is associated with death (Fitzhugh et al., 2010, Gladwin et al., 2004). Autopsy 
studies suggest that 75% of patients with SCD have histological findings of PAH at the time 
of death (Odd et al., 2009), suggesting that PAH may be clinically silent or poorly 
recognized. A raised TRV on echocardiography is predictive of  a raised systolic pulmonary 
arterial pressure (Hatle et al., 1981, Lanzarini et al., 2002), although this has a high negative 
predictive rate (13) and cardiac catheterization is required to confirm the diagnosis of 
pulmonary hypertension (Parent et al., 2011, Fonseca et al., 2012). The ability to highlight a 
subgroup of patients with a high predicted mortality by use of a non-invasive measurement 
such as TRV represents a significant clinical advance and has rightly generated a lot of 
research interest. Raised TRV as assessed by Doppler echocardiography, whether or not 
associated with pulmonary arterial hypertension, is commonly found in sickle cell disease 
(Ataga et al., 2004) and has been reported as a marker of mortality in several major studies 
from the United States (De Castro et al., 2008, Ataga et al., 2006, Machado and Gladwin, 
2010, Lorch et al., 2011, Gladwin et al., 2012, Anthi et al., 2007a) . Raised TRV has been 
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found in 32 to 42% of patients with SCD (Gladwin et al., 2004, Fitzhugh et al., Akgul et al., 
2007, Liem et al., 2007a, Parent et al., 2011). 
Studies in the UK using similar measurements and valuations have not been carried out, 
where differences in organization of health services and socio-demographics may lead to 
different findings. 
The purpose of this study was to determine the survival of a cohort of patients with sickle cell 
disease, attending two hospitals in North West London, based on their TRV and describe 
differences between those with elevated and normal TRV. 
 
2.2. Material and Methods 
 
2.2.1. Patient population 
 
All patients with SCD who were referred to the echocardiography laboratory of 
Hammersmith Hospital or Central Middlesex Hospital, London from the Sickle Cell or 
Haematology Clinics between August 2004 and May 2012 were studied retrospectively.  
The clinical indication for requesting the echocardiogram was either a clinical decision 
by their haematologist to screen for raised TRV or follow-up of previously elevated TRV.    
Only patients in stable condition were included; patients who had a vaso-occlusive crisis 
within the preceding two weeks or an episode of acute chest syndrome within four 
weeks were excluded.  
The local research ethics committee issued a consent waiver to allow the review of the 
medical records. The authors had full access to the data and take responsibility for its 
integrity. All authors have read and agreed to the manuscript as written. 
 
2.2.2. Laboratory and Clinical data 
 
Laboratory data used for analysis were those recorded at the date closest to that of the 
echocardiogram. Only steady state results were included. The cause of death when 
known was obtained from the death certificate, medical records or general practitioner 
of the patient. 
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2.2.3. Transthoracic echocardiography 
 
All studies were performed by an experienced sonographer using the Philips Sonos 
7500, equipped with a transducer S3 1.8-3 MHz. 
An electrocardiogram was simultaneously recorded from all subjects. Images were 
recorded and stored in digital format for subsequent off-line review and frame-by-
frame analysis with ProSolv CardioVascular Analyzer 3.5 (FUJIFILM, USA). Two-
dimensional echocardiographic examination and colour Doppler data were collected 
according to the recommendations of the American Society of Echocardiography 
(Gottdiener et al., 2004, Lang et al., 2005) using a standardized protocol. 
Paraesternal long axis, short axis, right ventricular inflow, apical four, three and two 
chamber views were obtained. Transvalvular flow, Doppler determinations of the 
severity of the valvular regurgitation and left ventricular diastolic function were 
assessed.  
Tricuspid regurgitation velocity was assessed in a minimum of four views and five 
sequential complexes were recorded. Continuous-wave Doppler of the peak regurgitant 
jet velocity was used to estimate the right-ventricular systolic pressure gradient using 
the modified Bernoulli equation (4x [tricuspid regurgitant velocity]). Pulmonary arterial 
systolic pressure (PASP) was estimated by adding the estimated mean right atrial 
pressure. The mean right atrial pressure was calculated according to the degree of 
collapse of the inferior vena cava with inspiration (Howard et al., 2012).  
 
Left ventricular diastolic dysfunction was assessed using conventional 
echocardiographic parameters: mitral inflow peak early (E) and peak late (A) flow 
velocities, the E/A ratio, the deceleration time of early mitral flow velocity (DT), and 
IVRT at rest and during the Valsalva manoeuvre. LV diastolic dysfunction was 
characterized  either normal (E/A ratio 0.9 to 1.5, DT 160 to 240 ms, IVRT 70 to 90 ms), 
restrictive (E/A ratio >2, DT<160 ms, IVRT < 70 ms), or delayed relaxation (E/A 
ratio<0.9, DT>240 ms, IVRT > 90 ms).  (Quinones et al., 2002, Lester et al., 2008) . Left 
atrial (LA) diameter was obtained from the paraesternal long axis view at the end-
ventricular systole when the LA chamber was at its greatest dimension. Right atrial 
volume was calculated by 2D-mode apical 4-chamber view using the area – length 
method. (Lang et al., 2005, Quinones et al., 2002)  
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2.2.4. Statistical analysis 
 
Statistical analysis was performed using the Stata software (version 9.2, StataCorp, 
USA).  
Normally distributed variables were compared between groups using an unpaired t-
test, while variables which lacked a normal distribution were compared using a Mann-
Whitney test. 
Distributions of continuous variables were shown by the mean ± standard deviation 
(SD) for normally distributed data or median and interquartile range for skewed data. 
Demographic, clinical and echocardiographic findings were compared according to TRV 
<2.5 versus TRV ≥2.5 m/s by the Student’s t-test for normally distributed continuous 
variables or the Kruskal-Wallis test for skewed continuous variables. 
The relationship between two qualitative variables was analysed using the two sided 
Fisher’s exact test. The association between variables and TRV was examined using 
linear regression.  
Patient survival was illustrated graphically using a Kaplan-Meier plot. Additionally the 
effect of clinical and laboratory variables (Table 5) on patient survival was examined 
using Cox regression analysis. Subsequently the joint effect of the explanatory variables 
upon survival was examined in a multivariate analysis. This multivariate analysis was 
restricted to those variables which showed some evidence of a significant effect from 
the univariate analyses (p<0.1). A backwards selection procedure was used to retain 
only those variables that were statistically significant. Before performing the 
multivariate analyses, the colinearity between variables was examined using variance 
inflation factors. 
Due to large number of factors analysed, p-values of less than 0.01 were considered 
significant for the univariate analyses. A higher significance level of 0.05 was used for 
the multivariable analyses, so as not to omit potentially important predictors from the 
final model. 
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2.3. Results  
 
2.3.1. Clinical characteristics of study population  
 
A total of 170 adults with SCD were referred to the echocardiography laboratory and 
evaluated at Hammersmith and Central Middlesex hospital between August 2004 and May 
2012. Echocardiogram and laboratory data were complete in 164 cases.  Echocardiographic 
measurements of left ventricular diastolic dysfunction were complete in 145 patients. 
The median age of the 164 patients was 42.3 years (range 15–82 years) where 114 were 
female (70%) and the median PASP was 28.0 mmHg (IQR 22.9-32.6) One hundred and two 
patients had HbSS (62.2%), 41 HbSC (25%), 8 HbS-β0 thalassaemia 4.9%), 11 HbS-β+ 
thalassaemia (6.7%), and 2 had other genotypes, S-D Punjab and S/HPFH, (1.2%). The 
median follow-up interval was 68.1months (IQR 48, 78) (Table 2.1).  
 
Elevated TRV was present in 29.1 % of patients (n=48): 12.8 % had TRV ≥ 2.5 – 2.69 m/s, 
10% had TRV 2.7 – 2.99 m/s and 6.1% had TRV ≥ 3.0 m/s. Left ventricular dilatation was 
seen in 8 patients (5%) and reduced LV systolic function (ejection fraction <55%) in 2 
patients. Twenty-six patients (16%) were on hydroxycarbamide therapy, of whom 19 had a 
TRV<2.5 m/s and 7 patients had a TRV≥2.5 m/s (p=0.814).    
Five patients (3%) out of the 145 patients had echocardiographic evidence of left ventricular 
diastolic dysfunction.  
 
2.3.2. Associations with tricuspid regurgitation velocity 
 
Results of the univariate analyses show that age, LA diameter and right atrial (RA) 
volume were significantly associated with TRV and a trend for an association with 
haemoglobin, ferritin and creatine (Table 2.2).  
Multivariate analysis indicated that both age and LA diameter were significantly 
associated with TRV (Table 3). An increase in both of these two variables was 
associated with an increase in TRV. A 10-year increase in age was associated with a 0.06 
unit (m/s) increase in TRV, while a 10-mm increase in LA diameter was associated with 
TRV values increasing by 0.18.  
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Patients in the study were further categorized according to TRV <2.5 m/s versus 
TRV≥2.5 m/s. The results suggested that there was some evidence of a difference in SCD 
genotype between groups. HbSS or HbS-β0 thalassaemia genotype was more common 
(80%) in patients with a TRV ≥ 2.5 when compared to a TRV< 2.5 (64%), although the 
result was of borderline statistical significance (p=0.05). Age, left ventricular end-
diastolic diameter (LVEDD), LA diameter, RA volume, haemoglobin and haematocrit 
were all found to vary significantly between the two groups (TRV <2.5 m/s versus 
TRV≥2.5 m/s or more) (Table 2.4). The LV ejection fraction was within normal limits in 
both groups. There were no differences in lung function tests between the two TRV 
groups. 
 
Table 2.1- a) Clinical characteristics of SCD patients. 
Clinical characteristics N SCD patients 
  Mean (SD)/Median (IQR)*    
Age  (years)                     164 42.3 (33,50)* 
Sex    (male/female)   %      164 (30/70) 
Systolic blood pressure (mmHg) 136 120 (113,129)* 
Diastolic blood pressure (mmHg) 136 71.7 (11.6) 
Body mass index (kg/m2) 125 24 (22,)* 
Hydroxycarbamide therapy (%) 162 16 
White cell count (x10E9/l) 157 9.1 (7.4,10.9) * 
Haemoglobin (g/l) 155 94 (80,110)* 
Ferritin (ug/L) 116 173 (83,474) 
Haematocrit (ratio) 150 0.27 ( 0.24,0.32)* 
Red blood cell (10^12/l) 153 3.32 (0.97) 
Mean corpuscular volume (fl) 154 86.15 (79,92)* 
Creatinine (µmol/L) 156 70 (59,85)* 
Lactate dehydrogenase (IU/L) 102 606 (385,879)* 
Bilirubin (µmol/L) 149 35 (20-52)* 
Tricuspid regurgitant velocity  (m/s) 164 2.28 (0.42) 
Pulmonary artery systolic pressure (mmHg)                 164 28.04 (24,33)* 
SD: standard deviation, * Median , IQR: interquartile range  
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Table 2.2 - b) Clinical associations with tricuspid regurgitation velocity in a univariate analysis of all patients. 
Variable Category Coefficient (99% CI) P-value 
Age (***)  0.10 (0.03, 0.16) <0.001 
Systolic Blood Pressure (***)  0.03 (-0.03, 0.10) 0.18 
Genotype HbSS / HbS-βº               0  
 Other genotypes -0.09 (-0.28, 0.10) 023 
Interventricular septum  0.04 (-0.02, 0.10) 0.09 
Left ventricular posterior wall  0.02 (-0.03, 0.08) 0.26 
Mitral valve E/A   -0.08 (-0.30, 0.13) 0.30 
Mitral valve decelaration time(****)  0.06 (-0.04, 0.16) 0.10 
Left atrium diameter  (***)  0.22 (0.08, 0.36) <0.001 
Right atrium volume (***)  0.09 (0.01, 0.17)   0.006 
Body mass index (**)  -0.03 (-0.13, 0.07) 0.42 
White cell count  (**)  -0.02  (-0.16, 0.13) 0.73 
Haemoglobin  -0.03 (-0.07, 0.01) 0.06 
Fetal haemoglobin  -0.02 (-0.07, 0.03) 0.30 
Platelet (****)  -0.01, (-0.05, 0.02) 0.26 
Ferritin (†)  0.16 (-0.05, 0.38) 0.05 
Creatinine (†)  0.48 (-0.02, 0.98) 0.01 
(**)     Coefficients given for a 5 unit increase in explanatory variable 
(***)   Coefficients given for a 10 unit increase in explanatory variable 
(****) Coefficients given for a 50 unit increase in explanatory variable 
(†)      Variable analysed on the log scale (to base 10) 
 
Table 2.3 - Clinical associations with tricuspid regurgitant velocity in a multivariate analysis of all 
patients. 
Variable Coefficient (95% CI) P-value 
Age (***) 0.06 (0.01, 0.11)   0.02 
Left atrium diameter  (***) 0.18 (0.07, 0.29)   0.001 
 (***)  Coefficients given for a 10 unit increase in explanatory variable.  Variables entered into the analysis 
were age, left atria diameter, right atria volume, haemoglobin, ferritin and creatinine. 
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Table 2.4 - Clinical characteristics of all SCD patients without and with raised TRV.  
Variable 
TRV < 2.5m/s 
n=116; Mean (SD) 
TRV ≥ 2.5m/s 
n=48; Mean (SD) 
P-value 
Age (years) 41 (12) 46 (13) 0.04 
Systolic Blood pressure (mmHg) 121 (14) 123 (15) 0.40 
Diastolic blood pressure (mmHg) 72 (12) 72 (11) 0.76 
Interventricular septum(mm) 8.6 (1.5) 9.0 (1.3) 0.10 
Left ventricular posterior wall(mm) 9 (8, 10)* 9 (8, 10)* 0.21 
Left ventricular end-diastolic diameter (mm) 49 (5) 51 (6) 0.02 
Left ventricular ejection fraction (%) 72 (7) 73 (6) 0.22 
Mitral valve E/A 1.49 (0.35) 1.41 (0.56) 0.26 
Mitral valve deceleration time (ms) 180 (160, 200)* 200 (162, 210)* 0.06 
Left atrium diameter(mm)  37.2 (5.9) 40.7 (6.2)   0.001 
Right atrial volume (cm3)  53 (16) 69 (21)   0.003 
Body mass index (Kg/m2) 25 (5) 24 (6) 0.20 
Haemoglobin (g/l) 99 (20) 91 (21) 0.04 
Haematocrit (ratio) 0.29 (0.06) 0.26 (0.07) 0.05 
Red blood cell (10^12/l ) 3.4 (0.9) 3.1(1.1) 0.06 
Automated absolute reticulocyte count (10^9/l) 214 (96) 216(100) 0.91 
White cell count  (x10E9/l) 9.1 (7.7, 10.8)* 9.3 (7.3, 11.6)* 0.80 
Fetal Haemoglobin (%) 4.2 (2.6, 8.6)* 3.5 (1.5, 6.0)* 0.41 
Platelet (10^9/l ) 317 (213, 393)* 301(203, 390)* 0.73 
Ferritin (ug/L) 155 (85, 395)* 267(63, 692)* 0.19 
Lactate dehydrogenase (IU/L) 562 (355, 816)* 784 (500, 993)* 0.06 
Bilirubin (µmol/L) 34 (19, 48)* 44 (23, 62)* 0.08 
Creatinine (µmol/L)  70 (58,83)* 70 (61,91)* 0.23 
Hydroxycarbamide (%) 15.5 17.5 0.81 
Number of admissions 0 (0, 1)* 0 (0, 2)* 0.38 
Follow-up duration (months) 72.5 (47-79) 49.5 (33.7-76.7) 0.11† 
SD, standard deviation,* Median (Interquartile range) † deceased cases not considered. 
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2.3.3. Survival analysis 
 
There were 15 deaths during follow-up (9.1 %).  Seven of these patients had increased 
TRV giving a mortality, in the high TRV group, of 16.67% ( 8 out of 48) after 68 months 
median of follow up time (range 4.0-84.3 months) compared to 6.9% in the lower TRV 
group (8 out of 116). In addition, A Kaplan-Meier analysis of the 5-year survival rates 
was 95.0% (with 95% CI of 89.7% to 97.6%). 
The causes of death of patients with and without raised TRV are shown in (Table 2.5). 
One patient with an unknown cause of death did not have an elevated TRV.  
 
The effect of each variable upon survival was examined separately. When TRV was 
considered a continuous variable, there was a statistically significant association with 
survival (p=0.009). Higher values of TRV were associated with an increased risk of 
death (hazard ratio (HR): 4.48, 99%CI 1.01-19.8). A one-unit (1 m/s) increase in TRV 
was associated with the risk of death at any time increasing by more than four-fold.  
When TRV was considered as a categorical variable (TRV <2.5 m/s and TRV≥2.5 m/s) as 
reported in previous studies, there was a trend to reduced survival in the group with 
raised TRV (p=0.06), conforming with the association of TRV with an increased risk of 
death when assessed as a continuous variable (Fig. 2.1).  
Higher values of Hb, haematocrit (HCT) and RBC were all associated with a decreased 
risk of death at any time in the univariate analysis. A 0.1 unit increase in HCT was 
associated with the hazard of death being only 20% as large (Table 2.6). 
The results of the multivariable analysis indicated that decreased Hb, increased mean 
cell volume (MCV) and increased MV DT were all still significantly associated with 
reduced patient survival (Table 2.7). The effects of TRV after adjusting for these three 
significant variables, has showed that there is no additional effect of TRV upon patient 
outcome. TRV was not found to be an independent risk factor for death. 
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Table 2.5 - Cause of death and clinical characteristics in patients with SCD. 
ID Gender Age 
Follow up 
time 
(months) 
Phenotype TRV (m/s) Cause of death 
159 F 42 68 HbSS 1.8 Respiratory failure 
062 F 40 53 HbSS 1.9 Sudden death from sickle cell disease 
059 F 35 80 HbSS 2.0 Intracerebral haemorrhage 
123 M 58 74 HbSS 2.1 Liver failure (secondary to iron overload) 
161 F 54 38 S-HPFH 2.1 Renal failure 
124 0 75 71 HbSC 2.2 Post surgery complications 
048 F 82 20 HbS-β0 2.4 Unknown cause 
078 M 49 70 HbSS 2.4 Cirrhosis Liver failure 
069 F 42 69 HbSS 2.7 Cardiomyopathy Renal failure 
120 F 49 43 HbSS 2.7 Hepatocellular cancer 
037 0 25 20 HbSS 2.8 Road traffic accident 
122 M 62 5 HbSS 3.0 
Decompensated alcoholic liver disease ; other 
problems : sepsis, haemolysis secondary to SCD 
014 F 32 4 HbSS 3.1 Multiple organ failure,sepsis 
030 F 68 70 HbSS 3.2 Cardiac failure 
170 F 50 70 HbSS 3.4 Cardiac failure 
 
Table 2.6 - Proportional hazards (Cox) regression analysis of mortality. 
Variable Category Hazard Ratio (99% CI) P-value 
Age (***)  1.48 (-0.92, 2.38) 0.03 
Systolic Blood Pressure (***)  0.61 (0.31,1.20) 0.06 
Diastolic Blood Pressure (***)  0.54 (0.25,1.18) 0.04 
Genotype HbSS / HbS-β0 thalassemia 1  
 Other genotypes 0.30(0.04,2.11) 0.11 
Body Mass Index (**)  0.58 (0.28,1.21) 0.06 
Hydroxycarbamide (%)  1.35(0.26,7.22) 0.641 
White cell count  (**)  0.70 (0.20,2.42) 0.46 
Haemoglobin  0.62 (0.404,0.97) 0.006 
Fetal Haemoglobin  1.04 (0.86, 1.27) 0.59 
Platelet (****)  0.95 (0.72,1.26) 0.64 
Ferritin (†)  2.77 (0.79,9.80) 0.04 
Creatinine   5.24 (0.18,158) 0.21 
Haematocrit (*)  0.20 (0.05,0.76) 0.002 
Red blood count  0.33 (0.11, 0.93) 0.006 
Mean Corpuscular Volume (***)  1.59 (1.06, 2.41)   0.004 
LDH (****)  0.99 (0.89, 1.11) 0.91 
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Variable Category Hazard Ratio (99% CI) P-value 
Bilirubin (†)  1.02 (0.11, 9.56) 0.98 
LVEDD (***)  1.24 (0.36, 4.17) 0.65 
LVESD (***)  1.79 (0.43, 7.42) 0.29 
Left atrium diameter  (***)  2.24 (0.79, 46.35) 0.05 
Right atrium volume (***)  0.81 (0.38, 1.71) 0.47 
Mitral valve E/A  0.39 (0.06, 2.46) 0.19 
Mitral valve DT (****)  1.89 (1.23, 2.90)  <0.001 
TRV (continuous)  4.48 (1.01, 19.8) 0.009 
TRV < 2.5 1  
 ≥ 2.5 2.71  (0.71, 10.4) 0.06 
LDH: Lactate dehydrogenase , LVEDD: left ventricular end-diastolic diameter , LVESD: left ventricular 
end-systolic diameter, DT: deceleration time, TRV: tricuspid regurgitant velocity 
(*)       Hazard ratios given for a 0.1 unit increase in explanatory variable 
(**)     Hazard ratios given for a 5 unit increase in explanatory variable 
(***)   Hazard ratios given for a 10 unit increase in explanatory variable 
(****) Hazard ratios given for a 50 unit increase in explanatory variable 
(†)      Variable analysed on the log scale (to base 10)  
 
 
Table 2.7 - Multivariate analysis of mortality. 
Variable Hazard Ratio (95% CI) P-value† 
Haemoglobin 0.58 (0.37, 0.93) 0.03 
MCV (***) 1.89 (1.50, 2.77)   0.001 
MV DT (****) 2.69 (1.74, 4.17) <0.001 
(***)   Hazard ratios given for a 10 unit increase in explanatory variable 
(****) Hazard ratios given for a 50 unit increase in explanatory variable 
† P-value used based on the Wald method.  
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Fig. 2.1: Kaplan-Meier Survival curves according to the tricuspid regurgitant velocity. The upper line is the 
survival estimate for SCD patients without PH (TRV<2.5 m/s). The lower line is the survival estimate for 
SCD patients with PH (TRV≥2.5 m/s).The number of patients at risk at the time of each death is shown for 
both groups. (p=0.06). 
 
2.4. Discussion 
 
The major findings of this retrospective follow-up study of adults with sickle cell disease 
are a mortality of 16.67% in patients with a TRV ≥2.5 m/s after a median of 68 months 
follow-up, compared to a mortality of 6.9% in the lower TRV group, and the association 
between raised TRV and mortality with a greater than 4 fold increased risk of death 
when TRV was analysed as a continuous variable.  
Although this association of increased mortality rate in patients with a raised TRV 
reflects previous studies from the US (Gladwin et al., 2004, Sutton et al., 1994), the 
overall mortality rates are much less marked in our study.    
Three contemporary cohort studies in the US have reported a relationship between 
survival and raised TRV. Gladwin et al (Gladwin et al., 2004) reported that a TRV of ≥2.5 
m/s, as compared with a velocity <2.5 m/s, was independently associated with a 
marked increased risk of death (RR = 10.1; 95% CI = 2.2-47; P < .001). During 18.3 
months mean follow-up the mortality was 16% for patients with a TRV of ≥2.5 m/s and 
was less than 2% in patients with a TRV < 2.5 m/s. Follow-up data from this cohort 
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continues to be updated and demonstrates that raised TRV remains a strong 
independent risk factor for death and carries a 40% mortality rate at 45 months.  The 
estimated risk ratio of death for patients with TRV 2.5-3.0 m/s was 4.4 (95%CI= 1.6-
12.2; P<.001) and for a TRV >3.0 m/s was 10.6 (95%CI = 3.3-33.6; P < .001). With 
regard to hydroxycarbamide use, 37 % of the patients of the US cohort were on 
hydroxycarbamide therapy whilst in our cohort only 16% patients were on this 
treatment. In addition, we did not find an association with hydroxycarbamide use and 
mortality.  
 Castro et al (De Castro, 2004)  reported a similar prevalence of raised TRV (36% in 
patients with HbSS and HbS-β0 thalassemia and 25% in HbSC and HbS-β+ thalassemia 
and a similar 17% mortality rate at 24 months for patients with raised TRV after 2 years 
compared with approximately 2% mortality for patients without raised TRV. This last 
study used a different definition of raised TRV from other studies which was corrected 
for age, sex and body mass index, and the TRV was measured whilst the patient was 
hospitalized, not in steady state. Castro et al. (Castro et al., 2003) in a study with 34 
adults patients, reported a 2 year mortality rate of 55% in patients with a raised mean 
pulmonary artery pressure (> 25 mmHg) obtained by right heart catheterization, 
compared to a mortality rate of 21% in SCD without raised mean pulmonary artery 
pressure (≤25 mmHg) .    
    
Two older studies also reported increased mortality.  Sutton et al found that a raised 
TRV was associated with a 40% mortality rate at 22 months in 60 patients, with an odds 
ratio for death of 7.86 (2.63-23.4) (Sutton et al., 1994). Powars et al found a mean 
survival of 2.5 years in patients with chronic lung disease and elevated TRV (Powars et 
al., 1988). Recently, a large multinational study with unselected 632 screened patients 
(Gladwin et al., 2012) where a more conservative cut-off value of TRV ≥ 3.0 m/sec was 
used,  showed that the association between TRV and mortality remained significant 
after adjustment for all other risk factors. In this study, 22 deaths were observed over 
median follow/up time of 29 months, of which, 11 patients had TRV of at least 3.0 
m/sec.  Current hydroxycarbamide use was not associated with mortality in this cohort.  
In addition, we have re-analysed the data using the conservative cut off value of TRV ≥ 3 
m/s.  We have found no change in the results. Of the 164 patients included in our study, 
only 10 patients (6,1%) had a TRV value of 3.0 m/s or higher. Using the same time point 
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as Gladwin´s Study (24 months) we have found similar survival estimates of 99% for 
TRV<3.0 m/s and 80% for TRV≥3.0 m/s. Nonetheless, using a time point of 68 months, 
there was no significant difference (p=0.125) in the survival estimates: 95% for 
TRV<3.0 m/s and 80% for TRV≥3.0 m/s.  We also found that patients with higher TRV 
values had a higher risk of death (HR: 6.52; 95% CI 2.97-20.6; p=0.001) when other 
factors are not considered (in comparison to a HR of 11.14 found in Gladwin’s Study), 
however this risk disappears after adjustment for other variables associated with 
survival.  
The lower mortality in our United Kingdom cohort raises the possibility that we studied 
a lower risk group of patients. On the other hand, our patients were selected randomly 
from those at higher risk attending out-patients clinics, whereas in  Gladwin’s study 
patients were recruited from the community through multimedia advertisements, 
community outreach, and regional clinics, and it was not certain if these patients were 
receiving comprehensive care for SCD.  In the Castro paper (Castro et al., 2003) the 
selected patients were all hospitalized. This study preceded routine echo screening in 
the UK, so any selection bias is likely to have been positive rather than negative (ie 
patients who had symptoms of shortness of breath, or were thought to be at higher risk 
of pulmonary hypertension, or had a previous abnormal echo) were more likely to be 
referred for an echo, and this should have increased, not decreased mortality rates. In 
addition comparing our results to those of Gladwin et al., our study had significantly 
higher percentage of female patients and older patients, with a mean age of 42 years 
compared to 36 years and the latter should have biased the results in favour of 
increased mortality.  
There was no significant difference in the sickle cell genotypes between the two studies 
(HbSS p=0.45; HbSC p=0.7; HbS β thalassemia p=0.68) and no significant difference in 
the mean TRV (p=0.15).  In both studies the overall number of deaths was small which 
is reflected by the width of the CI for TRV ≥2.5 m/s relative to TRV<2.5 m/s.  This means 
that the true hazard ratio in Gladwin’s study could be from 2.2 to 47 (p<0.001), whereas 
in our study the limits are from 0.71 to 10.4 although not significant (p=0.06), when 
TRV was categorized in the two groups (TRV<2.5 m/s. and TRV ≥2.5 m/s). One 
explanation could be that the National Health Service in the UK ensures that health care 
is free at the point of access and this may lead to patients with milder phenotypic 
disease being more likely to attend outpatients clinic and increase the numbers of 
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patients with milder disease (and lower mortality) in the UK cohorts. On the other hand, 
easier NHS access to specialist sickle cell centres in the UK may result in better 
outcomes in terms of severity and overall quality of life. In addition, the mortality 
figures from the US data seem very high when compared with the UK experience. 
Although there are not sufficient longitudinal data for mortality of patients with SCD in 
the UK, the recent National Confidential Enquiry into Patient Outcome and Death (Lucas 
et al., 2008) report which collected data on all deaths in patients with 
haemoglobinopathies between January 2005 and December 2006 had only 81 reported 
deaths (including 7 patients with thalassaemia), which in an estimated population of 
12,000 for SCD in the UK, is a very low mortality rate.  In essence, the reasons for this 
difference in mortality with United States cohorts is not explained by the clinical 
measurements which were made and further studies to confirm our findings are 
warranted. 
 
In our study, the effect of TRV on outcome was dependent on markers of haemolysis 
such as Hb and MCV. This is in contrast to the US studies which found raised TRV was an 
independent risk factor for death even after adjusting for causal factors such as those 
related to haemolysis. This and the greater overall mortality suggest a greater severity 
of SCD in these US patient cohorts. Why should this influence TRV as a marker of 
mortality? In the context of less severe SCD, end organ damage may be more directly 
related to haemolysis, whereas processes such as inflammation, endothelial 
hypertrophy and fibrosis may be more prominent in severe disease. These factors may 
in turn have influenced the relationship between haemolysis and survival.  
In conclusion, we have confirmed the association between raised TRV and mortality in a 
UK SCD population attending two North West London specialist SCD centres, whose 
disease severity appears less than that reported in previous studies. Importantly, we did 
not find TRV as an independent risk factor for death.  Nonetheless, of key importance to 
our study is the difference between mortality rates in this UK SCD population as 
compared to the US. Further prospective studies will enable us to more clearly 
characterize which patient factors modify survival in SCD patients with raised TRV.  
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2.5. Study limitations 
 
In our study, a limited number of echocardiographic measurements were made at the 
time of these clinical studies and early studies did not include tissue Doppler. The 
assessment of RV function and dimensions was qualitative. The value of the mitral valve 
E/A ratio in evaluating left ventricular diastolic dysfunction may be limited and is 
dependent on intravascular volume status.  Its results in SCD may be confounded by 
volume overload and may not accurately reflect the diastolic function of the left 
ventricle. Since this is a retrospective study, the selection of patients was not controlled 
so selection bias may have arisen. However, this remains one of the largest cohorts 
published to date and to the best of our knowledge with the longest follow-up period 
reported. 
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Chapter 3 General Methodology: 
Prospective Study 
 
 
3.1. Regulatory Procedures 
 
This study received ethical approval from the Hammersmith, Queen Charlotte’s and Chelsea 
Research Ethics Committee of the National Research Health Service (Ref. 09/H0707/73) 
(see Appendix I). It was registered with the Research and Development department of 
the Hammersmith Hospital NHS Trust (Project reference: ZIMI1001). All participants, 
patients and healthy volunteers, gave written informed consent before participation 
and the research was conducted in accordance with Good Clinical Practice guidelines. 
Copies of the ethical approval letters, Research and Development approval, patient 
information sheets and consent forms are included in Appendix I and II. 
 
The patients included in the screening visit were participants recruited from  the 
observational study of Walk–PHaSST (Treatment of Pulmonary Hypertension and Sickle 
Cell Disease with Sildenafil Therapy) , a multicentre trial looking at the treatment of 
pulmonary hypertension in SCD patients with sildenafil therapy 
(http://www.clinicaltrials.gov; unique identifier, NCT00492531). The Walk-PHaSST 
trial was conducted in 9 US centres and 1 UK Centre, which was the National Heart and 
Lung Institute (Hammersmith Hospital). All participants gave written informed consent 
for the use of their clinical data in this study. No patients who participated in the 
interventional part of Walk-PHaSST were included in this study. 
 
3.2. Aims of the project 
 
The primary aim of the project described in this thesis is to assess the impact of 
cardiovascular complications in patients with sickle cell disease.  
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3.2.1. Specific Aims 
 
This thesis has the following specific aims: 
 
1. To conduct a retrospective mortality study in a cohort of 164 patients with SCD and 
pulmonary hypertension in a North West London population. This study has been 
described in Chapter 2 
2. To describe a cardiovascular phenotype according to age in a cross-sectional study 
of cardiac abnormalities in patients with SCD from the age of 18 years old upwards 
in a UK cohort.  
3. To assess left and right ventricle function, both systolic and diastolic, by new 
advanced echocardiographic techniques. In particular to study the impact of 
myocardial deformation, torsion, function and volumes in a longitudinal study. Test 
the clinical importance and association of echocardiographic findings with markers 
of haemolysis, clinical history and disease severity. Describe the associations of 
cardiac findings with 6 minute walk test (6MWT) and brain natriuretic peptide. 
4. To prospectively evaluate the clinical and echocardiographic predictors of short-
term clinical outcomes in patients with SCD in an Observational Follow-up Study. 
5. To assess the relationship between elevated tricuspid velocity regurgitation and 
biventricular function by 2D and 3D Speckle Tracking. 
6. To assess ventricular volumetry, ejection fraction and mass, iron overload and 
myocardial fibroses by cardiac magnetic resonance in a subgroup of SCD patients 
with LV diastolic dysfunction. 
7. To assess the correlation between LV 2D Strain by speckle tracking and LV 3D 
Strain and LV 3D Strain with LV MRI Strain by myocardial tagging. 
8. To assess the inter-observer, intra-observer and test re-test reproducibility of LV 
3D Strain and RV 4D volumetry quantification with a novel semi-automated border 
detection software. 
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3.3. Recruitment of Study Participants 
 
All study visits and data collection was carried out at Hammersmith Hospital, Imperial 
College NHS Trust, London. Participants in the study included patients with SCD (Group 
A) and a group of Healthy Volunteers to act as controls (Group B). 
Subjects who agreed to participate were registered and booked at the Sir John 
McMichael Clinical Research Centre for the study visit and asked to sign three separate 
research consent forms: participant copy, participant clinical notes copy and study file 
copy (Appendix II).  
 
All information sheets and consent forms had been approved by the local research 
committee. Participants were also clearly informed that they were free to withdraw 
from the study at any time. In order to reduce travelling costs and facilitate recruitment, 
all participants were offered reimbursement of their travel expenses 
3.3.1. Group A: Patients with Sickle Cell Disease 
 
Patients with a diagnosis of Sickle Cell Disease who had participated in the WALK-
PHaSST study and who met the study inclusion criteria were invited at random to 
participate in this observational study. The WALK-PHaSST was conducted between June 
2007 and October 2009, in collaboration with the National Institutes of Health with the 
SCD clinic and the Pulmonary Hypertension Service at Hammersmith Hospital as one of 
the Centres.  
 
The recruitment of the patients in this study was conducted between January 2010 and 
June 2010. The WALK-PHaSST Executive Committee approved the use of study data in 
this study. There was no overlap between studies, patients were invited to participate 
after WALK-PHaSST has been completed. 
 
An informal research consultation to inform patients of the study’s aims and design was 
conducted by the investigator by phone or on the day of their appointment at the SCD 
Clinic. If they were interested in participating the relevant information sheet (see 
Appendix II) was provided explaining the purpose of the research. This information 
sheet was given in person if the consultation was done at the hospital or sent by post to 
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their home address with a cover letter (see Appendix II). Patients were given at least 24 
hours to read the information sheet and they were contacted at their convenience to 
discuss the study and given the opportunity to ask any questions. Patients who agreed 
to participate were booked at the Sir John McMichael Clinical Research Centre for the 
follow-up visit and asked to sign three separate research consent forms listed: patient 
copy, patient clinical notes copy and study file copy (see Appendix II).  
An additional information letter was also sent to the general practitioner/consultant of 
each patient, once they consented for this purpose.  
All information sheets and consent forms had been approved by the local research 
committee. Patients were also clearly informed that they were free to withdraw from 
the study at any time. 
In order to reduce travelling costs and facilitate recruitment, all participants were 
offered reimbursement of their travel expenses and the study visit was booked, when 
possible, to coincide with prearranged outpatient clinic appointments. 
 
3.3.1.1. Inclusion criteria  
 
The inclusion criteria were chosen with the aim of recruiting a heterogeneous cohort of 
SCD patients and a range of disease severity.  
 
The inclusion criteria for this study were as follows: 
 
 Males or females aged 18 years or older with a diagnosis of sickle cell disease 
(documentation of sickle cell disease, including but not limited to, HbSS, HbSC, 
HbSD, or Sβ°/+ thalassemia phenotype). 
 Steady state patients. 
 Able to provide written informed consent prior to any study-mandated 
procedures. 
 
3.3.1.2. Exclusion criteria  
 
The exclusion criteria for this study were as follows: 
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 Unwilling or unable to give written informed consent. 
 A recent (less than 3 weeks) vaso-occlusive crisis, episode of acute chest 
syndrome, severe anaemic events or any other acute complications of SCD. 
 Admission to hospital or acute transfusion within 3 weeks. 
 At least moderate valvular heart disease. 
 Evidence of systolic heart failure (LV Ejection fraction <= 40%) 
 Congenital heart disease.  
 Known cardiac diseases 
  Uncontrolled atrial fibrillation. 
 
3.3.2. Group B: Healthy volunteers 
 
Healthy, age and race matched volunteers with no clinical or echocardiographic 
evidence of cardiovascular disease were included in the study to serve as control 
subjects. 
  
The healthy volunteers participants were recruited at the Hammersmith Hospital by 
local advertisement (see Appendix II) or word of mouth and included relatives and 
acquaintances of participants with no SCD or SCD trait, who were not hospitalised or 
who had not presented to a doctor in the previous 3 weeks.  
 
Healthy volunteers were given at least 24 hours to read the Information Sheet (see 
Appendix II) and they were contacted at their convenience to discuss the study and 
given the opportunity to ask any questions.  
 
3.4. Method of data collection 
 
3.4.1. Screening visit: patients  
 
Participants in Group A underwent a baseline study which included: 
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 Self reported medical history 
 Physical examination 
 Standard laboratory tests (including documentation of haemoglobin   phenotype 
and cardiac biomarker) 
 A 6 minute walk test (6MW) 
 Transthoracic 2D and 3D echocardiogram 
 
No patients were excluded for poor echocardiographic imaging quality. This means that the 
study population resembled that of everyday clinical practice, so the precision limits were 
the level of precision to be expected in a clinical setting. 
 
After analysis of the transthoracic echocardiogram at the screening visit, patients  were 
split according to a cut off value of 2.5 m/s for the TRV velocity.  Subsequently, they 
were included in two groups in relation to the LV diastolic function status  (with and 
without LV diastolic dysfunction) according to the European Association of 
Echocardiography/American Society of Echocardiography recommendations for the 
evaluation of LV diastolic function (Nagueh et al., 2009a) which will be described later 
in this Chapter. 
 
The groups were defined as: 
 
Group A1 –SCD patients with normal left ventricular diastolic function 
 
Group A2 –SCD patients with abnormal left ventricular diastolic function 
 
One year after the screening visit, there was a follow-up visit and the procedures 
undertaken will be described later in this Chapter.  
 
3.4.2. Screening visit: Healthy Volunteers  
 
All participants underwent a structured interview 
These subjects were assessed for: 
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 Self reported medical history 
 Physical examination 
 Transthoracic 2D and 3D echocardiogram 
 
3.4.3. Follow-up visit 
 
A second visit was conducted approximately after 1 year (mean 17.14±3 months) after 
the screening visit. 
Patients who had participated in the observational study of the Walk-PhASST trial, were 
consecutively  assigned to this study until the sample size was completed to achieve a 
sample size that gives 80% power at the 0.05 level of significance (two- sided).  
Twelve patients declined to participate and 7 patients were excluded due to the 
exclusion criteria. 
 
Follow-up investigations included a health status interview, laboratory tests, collection 
of blood for brain natriuretic peptide, and a transthoracic 2D and 3D echocardiogram. 
All participants underwent the transthoracic echocardiogram performed by I.Z.C. at the 
screening visit. 
Additionally, patients from Group A2 ( with LV diastolic dysfunction diagnosed by 
echocardiography), were invited to perform a cardiac magnetic resonance for 
assessment of concomitant causes of diastolic function (e.g. ischemic heart disease, left 
ventricular hypertrophy, myocardial infarction). 
 
All patients were given a study ID number with 4 digits: the first two digits 
corresponding to consecutive numbers in sequence from 01 to 61 following the first and 
last name initials) so all data was anonymised on the ultrasound equipment and when 
transferred to the computer.  
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 Fig. 3.1: Study design  
 
3.5. Measurements and data confidentiality 
 
The screening visit included the assessment of vital signs, self-reported medical history, 
medication, functional class by New York Heart Association Classification (NYHA), 
standard laboratory tests, a 6MWT and a transthoracic 2D and 3D echocardiogram. 
These data were taken from the WALK-PHaSST study patient´s record after informed 
consent had been obtained. 
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The follow-up visit included the recording of clinical events, number of hospital 
admissions, standard laboratory tests, functional classification system by NYHA and the 
evaluation of the echocardiogram.  Additionally, the 3D echocardiogram was repeated 
after 1 hour of the first 3D image acquisition (test re-test), in order to evaluate the 
ability of the test to yield the same result for a single patient at 2 different test periods, 
which are closely spaced so that any variation detected reflects reliability of the test 
rather than changes in the patient status.  
 
Data regarding laboratory tests was obtained from the Electronic Patient Record (ICHIS 
and ICE) from the Hammersmith Hospital.  A study spread sheet was used to collect 
data from the screening visit and the follow-up visit. Three patient identifiers (patient 
ID, initials and date of birth) were used on all spread sheets. A database of 
demographics, echocardiography data, cardiac magnetic resonance and laboratory tests 
was generated. 
 
3.5.1. Vital Signs 
 
The assessment of the vital signs included the measurements of heart rate, blood pressure and 
oxygen oximetry.  
Heart rate and blood pressure were measured at the time of the echocardiogram using an 
electronic blood pressure measuring device after the patient had been seated for five 
minutes. Regarding blood pressure, if the difference between 3 readings was greater 
than 10 mmHg systolic or diastolic, the measurements were repeated. The left arm was 
used in all readings. 
Haemoglobin oxygen saturation was measured by finger pulse oximetry, using a finger 
clip oximeter probe. Oximetry provides a measure of the average oxygen saturation of 
haemoglobin. It relies on the principle that the light absorption characteristics of 
haemoglobin are altered by the binding of oxygen. An oximeter probe contains two 
LEDs emitting light at red (660nm) and infrared (910nm) wavelengths, and a photo 
detector to measure transmitted light. When an oximeter probe is applied to the 
fingertip a constant proportion of emitted light will be absorbed by the soft tissues. The 
absorption of light by blood constituents can be determined from changes in the 
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quantity of transmitted light occurring during fluctuations in arterial volume with each 
cardiac cycle. 
The ratio of red and infrared light absorbed is used to calculate the oxygen saturation of 
haemoglobin. 
 
3.5.2. Self-reported medical history and additional information 
 
Details of each participant’s medical history were collected, including history of vaso 
occlusive pain, acute chest syndrome, leg ulcers, total number of transfusion in lifetime, 
transfusion treatment, and record of history of multi organ disease (heart, kidney, lungs, 
spleen, liver, neurological problems). Alcohol, drugs and tobacco intake were also 
assessed.  
A record was also made of all prescribed and over the counter medications.   
 
3.5.3. New York Heart Association Classification 
 
The functional class of the patients was assessed according to the NYHA.  
The NYHA classification is based upon symptoms and exercise capacity reported by the 
patient (Table 3.1) (The Criteria Committee of the New York Heart Association, 1994). It 
is a commonly used measure to asses. 
functional capacity in several diseases and the NYHA class has been shown to be a 
strong predictor of mortality in PAH (2008). 
 
Table 3.1 - New York Heart Association Classification of Heart. 
Class I No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitation, or dyspnoea. 
Class II Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in fatigue, palpitation, or dyspnoea. 
Class III Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity results in fatigue, palpitation, or dyspnoea. 
Class IV Unable to carry on any physical activity without discomfort. Symptoms at rest. 
If any physical activity is undertaken, discomfort is increased. 
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3.5.4. Laboratory measurements: blood sample collection 
 
Laboratory tests were performed at the Hammersmith Hospital laboratory and were 
undertaken in accordance with quality assured and approved techniques. 
Blood samples were collected at the screening and the follow-up visit. An experienced 
research nurse was responsible for the collection and preparation of laboratory 
samples. Routine laboratory tests included a complete blood count, reticulocyte count, 
serum chemistry profile, and lactate dehydrogenase). After blood collection, results 
were obtained from the Electronic Patient Record (ICHIS and ICE) from the 
Hammersmith Hospital. 
 
At the screening visit, Serum N-terminal pro-brain natriuretic peptide concentration 
was measured by a sandwich immunoassay using polyclonal antibodies that recognize 
epitopes located in the N-terminal segment (1– 6) of pro-BNP (1–108) (Elecsys 
analyser; Roche Diagnostics, Mannheim, Germany). 
 
At follow-up visit, the biomarker assessment included the brain natriuretic peptide 
levels. All samples were collected by venepuncture into EDTA tubes. The blood samples 
were kept at room temperature and analysed within 4 hours of the draw time (Abbott 
i2000SR instrument reagents). Before analysis, each tube was inverted several times to 
ensure homogeneity. 
 
3.5.5. 6 Minute Walk Test  
 
The 6MWT was performed during the screening visit at the Sir John McMichael Clinical 
Research Centre by an experienced research nurse, in a 30 metre hallway. This test 
measured the distance that the patient could walk on a flat, hard surface in a period of 6 
minutes (2002). It evaluates the global and integrated responses of all the systems 
involved during exercise, including the pulmonary and cardiovascular systems, systemic 
circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. 
The 6MWT was done at least one hour before the echocardiogram. 
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3.5.6. Cardiac Imaging Analysis 
 
3.5.6.1. Two-dimensional echocardiography   
 
3.5.6.1.1. Image Acquisition and Processing 
 
Transthoracic 2-dimensional echocardiography (2DE)  was performed by the same 
experienced sonographer (certified by the European Association of Cardiovascular 
Imaging) at both visits (screening and follow-up) using a digital commercial harmonic 
imaging ultrasound system with an S 5-1MHz variable frequency phased-array 
transducer (Philips IE33, Philips Medical Systems, Bothell, WA, USA).  
 
A single channel electrocardiogram (ECG) recording was performed, with ECG 
electrodes (Blue sensor, Ambu Ltd., Cambridgeshire, UK) placed below the right 
sternoclavicular joint and in the left axilla (modified lead II position). The ECG was 
sampled at 256 Hz.  
All the studies were saved with the study Patient ID and were stored after digital 
acquisition to guarantee a high image quality and reproduction off line of the images 
without loss of information. The recorded echocardiography files were transmitted to a 
computer, and stored on DVD for off-line analysis of the ultrasound images. Off-line 
analysis of standard echocardiographic variables was performed with the use of 
dedicated software (Prosolv CV Analyser 3.0; Prosolv CardioVascular, Indianapolis, IN, 
USA).  
 
3.5.6.1.2. Protocol overview 
 
Echocardiography was the investigation of choice for the non-invasive assessment of 
cardiac structure and function. The scanning time was approximately 30-40 minutes 
which included the acquisition of the full volume images for 3D quantification. The 
participant was required to rest (lay supine) for 10 minutes before the scan was 
conducted. The sonographer verified the optimal ultrasound window with the patient in 
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supine position and when requested, the participant was asked to lay on his/her side 
with their left arm on the pillow.  
 
During 2DE, we practiced the following protocol: two- dimensional images and Doppler 
blood flow measurements were obtained from four-, two- and three chamber, as well as 
parasternal long-axis ( including RV inflow and outflow tract)  , sub costal views and 
suprasternal view  by manually rotating and angulating the transducer according to the 
guidelines of the American Society of Echocardiography (Lang et al., 2005) and the 
European Association of Echocardiography (Gordeuk et al., 2008).  All patients were 
examined using greyscale second-harmonic 2D imaging technique with adjustment of 
image contrast, frequency, depth and sector size for adequate frame rate and optimal LV 
and RV border  visualization. The recorded loops had at least 3 beats in each frame. All 
Doppler measurements were performed at 100mm/second sweep with low filter; with 
an average over three consecutive beats, to account for variations in heart rate.  No 
measurements were performed at a premature beat of after following a premature beat. 
 
The 2D-echocardiography study protocol included standard echocardiographic 
measurements of LV size, geometry, mass, systolic and diastolic function, right 
ventricular function, estimation of RV systolic pressure, qualitative and quantitative 
analysis of valvular regurgitation. Care was taken to avoid LV foreshortening in apical 
views and image acquisition was done during breath hold to minimize respiratory 
movements. 
 
 
3.5.6.1.3. Standard echocardiography    
 
The following echocardiographic parameters were assessed for chamber quantification: 
LV end-systolic and end-diastolic diameters, LV wall thickness, LV mass, LV ejection 
fraction, left atrial volume, RV diameter and fractional area change, right atrium volume 
and bi-ventricular global and regional wall motion abnormalities.  
 
LV dimensions were obtained in the parasternal long axis view, with measurement of 
interventricular septal and posterior wall thickness. We estimated LV end-diastolic, 
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end-systolic volume and ejection fraction from the biplane Simpson method by tracing a 
contour around the LV cavity during end-diastole and end-systole in apical 4- and 2-
chamber views (Lang et al., 2005). LV mass and LV mass index waere calculated using 
the area-length formula at short-axis view as described in the 1989 ASE document on 
LV Quantitation (Schiller et al., 1989). Relative wall thickness was calculated as septal + 
posterior wall thickness/LV end-diastolic diameter.  
 
Left atrial volume was measured with the biplane method of disks incorporating apical 
4- and 2-chamber views. Global and regional assessment of any wall motion 
abnormalities was performed visually by the sonographer in all views. 
 
RV assessment was performed based on the echocardiographic protocol described in 
the Standard Operating Procedure of the Hammersmith Hospital for the 
Echocardiographic Assessment of Pulmonary Hypertension(Howard et al., 2012) . RV 
dimensions were obtained in the apical 4-chambers view, with measurements of the 
end-diastolic and end-systolic area which were derived by manually tracing the 
endocardial borders at end-diastole (onset of the QRS complex) and end-systole 
(smallest ventricular area). Before making any measurements, care was taken to obtain 
a true no foreshortened apical-4 chamber view, oriented to obtain the maximum RV 
dimension. RV fractional area change was calculated as: 100x (RV diastolic area-RV 
systolic area)/RV diastolic area. RV dysfunction was defined by a fractional area change 
< 32%. Global and regional assessment of any wall motion abnormalities was 
performed visually by the sonographer in all views. Additional measurements included 
the tricuspid annular peak systolic excursion (TAPSE), presence of pericardial effusion, 
RV myocardial performance index, tricuspid annulus assessment and inferior vena cava 
diameter. TAPSE was calculated using M-mode echocardiography with the cursor 
placed through the lateral tricuspid annulus in real-time. TAPSE (reference value < 0.16 
cm) was measured as the total displacement of the tricuspid annulus from end diastole 
to end systole (Ghio et al., 2000).  
 
Right atrium volume was measured with the area-length method with 4 chambers 
apical view (4C Apical), where RA volume = 0.85 X (RA area)2 / (RA systolic diameter).  
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The valvular assessment included the evaluation of morphology and function of the 
mitral, aortic, pulmonary and tricuspid valves in multiple views following the 
recommendations of the European Society of Echocardiography/American Society of 
Echocardiography (Zoghbi et al., 2003, Baumgartner et al., 2009). 
   
Indexed parameters (e.g., LV diastolic volume, LV mass) were calculated by dividing 
each parameter by body surface area (BSA). BSA was calculated as follows: BSA (m2) = 
0.20247 × ht (m) 0.725 × wt (kg) 0.425, where ht is height and wt is weight.  Parameters 
such as RVOT acceleration time and IVRT were indexed to heart rate (HRate). 
 
3.5.6.1.4. Conventional Doppler  
 
Standard continuous-wave and pulsed wave Doppler examinations were performed in 
mitral, aortic, pulmonary and tricuspid valves in multiple views. 
 
Mitral inflow assessment 
 
Mitral inflow recordings were obtained with the pulsed Doppler from the apical four 
chamber view, with the Doppler sample volume being placed at the level of the mitral 
valve leaflet tips during maximal opening in diastole in order to measure peak early (E) 
wave and atrial contraction (A) wave velocities and early filling deceleration time. 
Isovolumic relaxation time was measured by placing the Doppler sample volume at the 
LV outflow tract.  Pulmonary vein flow analysis was also recorded. Mitral inflow 
propagation velocity by Colour-M mode was measured. From the apical view, colour 
flow imaging was used to demonstrate mitral inflow. A cursor was placed along the 
centre of the mitral inflow colour jet, and the colour baseline was shifted upward until 
the centre of the jet became blue.  
 
Estimation of right ventricular systolic pressure 
 
Continuous-wave Doppler sampling of the tricuspid peak regurgitant jet velocity was 
used to estimate the right-ventricular-to-right-atrial systolic pressure gradient with the 
use of the modified Bernoulli equation (4x[tricuspid regurgitant velocity]2). Velocity of 
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the TR jet was assessed, comparing the quality and peak measurements of the 
continuous-wave Doppler waves, obtained from different views, in particular the 
parasternal long-axis and apical 3-chamber view (modified) where the RV was 
visualised by tilting the probe anteriorly.   
Careful attention was paid in obtaining optimal Doppler signals for both tricuspid and 
pulmonary regurgitation. The TR signal by continuous-wave Doppler was recorded initially 
from the low parasternal right ventricular inflow view, and it was optimised in multiple 
other views including parasternal short-axis and apical views. Apical views were optimised 
by moving the transducer medially towards the sternum in order to improve alignment 
with the TR jet. The wave with the highest quality and deepest peak was considered the 
most accurate. The mean right atrial pressure was calculated according to the degree of 
collapse of the inferior vena cava with inspiration (Lang et al., 2005).  
No estimation of RV systolic pressure was done in cases of severe free-flow tricuspid 
regurgitation or RV outflow obstruction. A cut-off value of 2.5 m/s was used since it has 
been the most widely used approach in patients with sickle cell disease as described in 
Chapter 1 of this thesis. There was not sufficient pulmonary regurgitation in all patients 
to provide an adequate RV-end-diastolic pressure measurement.  
 
Valvular assessment  
 
Regarding valvular assessment, colour Doppler echocardiography was performed in all 
views after optimising gain and Nyquist limit. Valvular regurgitation was graded as 
absent/physiological trace (grade 1), mild (grade 2), moderate (grade 3) or severe 
(grade 4) using multiple parameters (Evangelista et al., 2008). 
 
Stroke volume, Cardiac Output and Pulmonary Vascular Resistance 
 
Echocardiography uses the combination of 2D and pulsed-wave Doppler imaging to 
measure cardiac output.  Stroke volume (SV) can be derived from the product of the 
velocity-time integral (VTI) of the Doppler profile and the cross-sectional area of the LV 
outflow tract (LVOT). Cardiac output (CO) is the product of SV and  HRate. 
 
SV = VTI (LVOT) x cross-sectional area (LVOT)     ;      CO = SV x HR 
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Similarly, right ventricular SV and CO can be measured from the proximal right 
ventricular outflow tract (RVOT), just within the pulmonary valve from the parasternal 
short-axis view.  Care should be taken to ensure that the Doppler cursor is in line with 
the axis of theRVOT, otherwise a significant error will appear in the measurements.  In 
order to calculate pulmonary vascular resistance (PVR), continuous-wave Doppler is 
used to determine the peak tricuspid regurgitant velocity as described above: the 
highest velocity is used. In patients with atrial fibrillation, the average of five 
measurements should be taken. 
 
PVR (Wood units) = 10(TRV/VTIRVOT) + 0.16 
 
This measurement has been shown to correlate well with PVR measured at cardiac 
catheterisation over a range of right and left atrial pressures (Scapellato et al., 2001, 
Abbas et al., 2003).  A value of TRV/VTIRVOT less than 0.2 has 94% sensitivity for a PVR 
of less than two Wood Units at catheterisation26.   
 
 
3.5.6.1.5. Tissue Doppler Imaging 
 
Longitudinal myocardial function was assessed using TDI with a real-time pulse wave 
tissue Doppler technique. Tissue Doppler recordings of the left ventricle were measured 
with sample volumes at both septal and lateral mitral annulus. Measurements of the 
mean peak systolic (s´), early diastolic (e´) and late diastolic (a´) myocardial velocities, 
were recorded. The ratio of early diastolic LV inflow velocity to both septal and lateral 
mitral annular velocity (LV lateral E/e´) was calculated as an estimate of LV filling 
pressure. All the values were analysed but for specific analysis we have used the LV 
lateral E/e´ to estimate left ventricular diastolic diameter in this study, as has been used 
previously in SCD(Sachdev et al., 2011). Its use has also been suggested in the setting of 
non-cardiac pulmonary hypertension (Nagueh et al., 2009a). Global function index 
(GFI), is defined as a ratio between a diastolic parameter (E mitral inflow/e´) measured 
at one point and the peak systolic tissue Doppler velocity (GFI= [Emi/e´]/s´ [s x cm-1]), 
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where E is E wave, s is systolic wave, and mi is mitral inflow. GFI was determined at 
septal and lateral levels (Núñez et al., 2004). 
Right ventricular myocardial tissue velocities were also derived from the junction of the 
RV lateral wall and tricuspid valve annulus. Peak annular RV lateral wall velocities 
during systole (S wave) and E´ and A´ for early and late diastolic velocities were 
measured by the same method. Tissue Doppler RV isovolumic relaxation time (tIVR) 
was obtained between cessation of S-wave and onset of E´wave (Zimbarra Cabrita et al., 
2013b)(Fig. 3.2). 
 
Myocardial performance measured with Tissue Doppler Imaging (tMPI) was the 
parameter used for the evaluation of RV global function. MPI is defined as the sum of 
isovolumetric contraction and relaxation intervals divided by ejection time. Isovolumic 
contraction time (tIVC) was measured between cessation of A’ wave and onset of S-
wave; TDI ejection time (tET) was obtained between onset and cessation of S wave; TDI 
isovolumic relaxation time  was obtained between cessation of S wave and onset of E’ 
wave. tMPI was calculated as the sum of isovolumic contraction time and isovolumic 
relaxation time divided by ejection time (tIVC+tIVR)/ (tET). Special attention was paid 
to keep the best possible alignment between the tricuspid annulus motion and the 
ultrasound beam. tMPI is relatively unaffected by heart rate, loading conditions and RV 
geometry and importantly has the advantage of simultaneously recording the systolic 
and diastolic velocity patterns from the same cardiac cycle (Zimbarra Cabrita et al., 
2010). 
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Fig. 3.2: A- Right ventricle measurements from tissue Doppler obtained from the lateral tricuspid annulus. A - Peak 
annular RV free wall velocities during systole (S wave) and E´ and A´ for early and late diastolic. B- Right ventricle 
isovolumic relaxation time measured from pulsed tissue Doppler 
 
3.5.6.1.6. Left ventricular diastolic function 
 
Diastolic function was assessed in all patients using pulsed Doppler  where peak E and A 
velocities, E/A ratio, deceleration time  and IVRT were assessed (Quinones et al., 2002). 
 
Transmitral flow: the mitral flow velocities were recorded at sweep speed of 100 cm/s, 
using pulse waved Doppler with the sample volume placed at the tip of the mitral valve 
leaflets in the apical view. From the mitral valve inflow velocity curve the following 
measurements were made: peak E-wave velocity and its deceleration time; peak A-wave 
velocity; ratio of E-wave to A-wave (E/A) velocities and the IVRT was measured from 
the aortic valve closure to mitral valve opening. 
 
Pulmonary venous flow was assessed from 4-chambers apical view, rotating the probe 
slightly anticlockwise (towards left) and ante-flexing the probe at a scan angle of 30 to 
visualize the LA appendage and left upper pulmonary vein. Sample volume was 
positioned about 1 cm into the pulmonary vein and spectral Doppler was recorded to 
measure peak S wave height, peak D wave height, peak atrial reversal wave depth, atrial 
reversal duration and blunting or S wave reversal. 
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LA volume was calculated from three measurements of LA dimension taken at 
ventricular end-systole using the formula for an ellipse. Indexation to body surface area 
was then performed. 
 
Mitral inflow propagation velocity was obtained by colour M-mode of the mitral inflow. 
From the apical view, colour flow imaging was used to demonstrate mitral inflow. A 
cursor was placed along the centre of the mitral inflow colour jet, and the colour 
baseline shifted upward until just the centre of the jet turned blue.  
 
Tissue Doppler imaging was also assessed since there have been several reports of 
elevated pulmonary capillary wedge pressure in SCD patients undergoing cardiac 
catheterisation (Gladwin et al., 2004, Castro et al., 2003).  The longitudinal diastolic 
function and estimate of end-diastolic pressure were assessed by measuring the early 
(e´) and late (a´) diastolic velocities were measured from the basal lateral annulus and 
basal septal myocardial segments. Using the same tissue Doppler pulsed wave signal, 
the systolic myocardial velocity was measured. An estimate of LV filling pressure could 
then be obtained from the ratio of the transmitral E-wave velocity to the tissue Doppler 
Ea velocity (E/e´ ratio).  LV diastolic function was not assessed in patients in atrial 
fibrillation. As it has been described (Lester et al., 2008, Nagueh et al., 2009b) , the 
assessment of diastolic function in patients with atrial fibrillation have limited accuracy 
where the loss of atrial contraction and relaxation reduces pulmonary venous systolic 
flow regardless of filling pressures, The Doppler estimation of LV filling pressures is 
limited by the variability in cycle length, the absence of organised atrial activity, and the 
frequent occurrence of LA enlargement. 
In order to classify the various patterns for LV diastolic filling we used previously 
published criteria (Nagueh et al., 2009c) and divided the patients into four groups: 
Group 0 = normal filling pattern, Group 1 = abnormal relaxation, Group 2 = 
pseudonormal  flow pattern, and Group 3 = restrictive flow pattern (Fig. 3.3).  
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Fig. 3.3: Scheme for grading diastolic dysfunction. Av., Average; LA, left atrium; Val., Valsalva  
 
3.5.6.1.7. 2D Speckle tracking imaging 
 
Greyscale images for offline speckle-tracking analysis were acquired at frame rates of 
55 to 90 frames/sec during breath-hold, usually with forced expiration.  Parasternal 
short-axis images were acquired at the basal, mid and apical ventricular level and from 
standard apical two-three- and four-chamber views. At least three cardiac cycles were 
stored for offline analysis. 
 
2D Left Ventricular Strain  
 
LV longitudinal and circumferential strains were assessed using the 2D speckle tracking 
method at the follow-up visit. The apical four-,two-, and three-chamber images and 
short axis views at the papillary muscles, mid and apical level were analysed off line (Q-
Lab 8.1, Philips Medical System) by automated tracking analysis after visual inspection 
of the tracking result. LV end-systolic longitudinal and circumferential strain for basal, 
mid and apical segments of the anterior, antero-septal, lateral, posterior, inferior and 
infero-septal segments were assessed. The LV was divided according to the 16-segment 
model (6 basal, 6 mid-LV, and 4 apical) of the American Society of Echocardiography, 
and each segment was individually analysed. 
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Apical 4C view was used to determine global strain by manually positioning three 
reference points: one on each side of the mitral valve annulus and the third at the apical 
endocardial border. Immediately, the software creates a region of interest (template) 
with the automatic delineation of endocardial and epicardial borders, tracking the 
speckles throughout the cardiac cycle, thus deriving the transmural global strain. 
The thickness of the region of interest was adjusted to include the entire myocardium. 
The software used automatically tracks the myocardial deformation on the subsequent 
frame. If the tracking was not satisfactory, manual adjustments were made to the 
tracking points throughout the cardiac cycle. If satisfactory tracking was not 
accomplished after attempting 3 times, the non-tracking segments were excluded from 
analysis. Lagrangian strain curves were provided by the software. Aortic valve closure 
was measured with the use of electrocardiographic trace to estimate the timing of end-
systole and early diastole. (Fig. 3.20). All ofﬂine measurements with QLAB were 
performed by the same observer (I.Z.C.). 
 
  
Fig. 3.4: Two-dimensional LV longitudinal myocardial left ventricle strain in an apical three-chamber view. Top: 
template originated by dedicated software after the points defined by the operator. Bottom: the curves of 
deformation, colored according to the corresponding segment depicted in the template; the points at the nadir of 
each curve correspond to peak systolic strain 
 
The software was able to represent myocardial deformation in time–strain graphs to 
identify the different phases of cardiac cycle. When myocardial deformation was 
graphically represented as time–strain curves, cardiac cycle phases were recognised as 
follows: from the original length, during systole there is a negative wave which reaches 
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its negative peak at the aortic valve closure, representing the maximal longitudinal 
myocardial shortening during contraction (Fig. 3.4)(Marwick et al., 2009b). In diastole, 
strain values progressively increase towards the original length.  
 
2D Right Ventricular Strain 
 
The apical four-chamber view was obtained using the same ultrasound system with the 
same probe used for standard echocardiography; end-systole was chosen as the single 
frame for the endocardial-to-epicardial region of interest to include maximum RV 
lateral wall thickness for strain calculation. The reference points were manually 
inserted: first point on the basal septum and second point on the basal RV lateral wall. 
The region of interest then included the entire RV myocardial wall and the epicardial 
border was then adjusted to correspond closely to the RV lateral wall thickness. The 
tracking algorithm followed the endocardium from this frame through the cardiac cycle. 
For RV longitudinal strain, myocardial thickening was represented with a negative value 
colour coded as red and thinning was represented as a positive value colour coded as 
blue. These were superimposed in the conventional 2D image, with the mean values for 
each segment showing on the display. Longitudinal strains for each individual segment 
were measured and averaged for RV septal and lateral walls. In addition, the software 
calculated the RV Global longitudinal strain by averaging segmental strains along the 
entire RV (Fig. 3.5).  
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Fig. 3.5: Two-dimensional right ventricle strain in an apical four-chamber view. 
 
3.5.6.2. Three-dimensional echocardiography 
 
Real-time 3D echocardiography data set acquisition was obtained from an apical 
window using a matrix array ultrasonic transducer with 2,400 elements (X3-1 
transducer, Philips IE33, Philips Medical Systems, Bothell, WA, USA). ECG tracing was 
optimised before images acquisitions to increase R wave peaks.  
Images were gathered over four cardiac cycles during breath-hold. Care was taken to 
avoid a Valsalva manoeuvre while on breath-hold, which could degrade image quality 
and alter cardiac volumes. Full volume and harmonic imaging was used. Depth, time 
gain compensation and focus position were adjusted to obtain best image quality and 
care was taken to encompass the entire LV cavity in the data set. The quality of the 
acquisition was verified in each patient to exclude artefact motions and to ensure the 
entire LV was included in the full volume. When necessary, the data set was re-acquired.  
Data sets were stored digitally and exported to a DVD. The DICOM files were later 
exported to a separate workstation equipped with a commercially available software for 
off line analysis of LV volumes and Ejection fraction (Q-Lab 9.0, CMQ, Philips Medical 
System)  and to a dedicated software for 3D Strain myocardial deformation analysis (4D 
LV-Analysis, TOM-TEC, Germany). All 3D images were acquired in the beginning of the 
study and repeated in 38 patients after 1 hour of the first acquisition to provide 
measures of reproducibility for inter-observer and test-re test variability.  
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3.5.6.2.1. Left Ventricle Volumetric Acquisition  
 
Frames for end-diastolic and end systolic volumes were identified by the same method 
as for 2-D echocardiography.  Contour tracing was performed with semi-automatic 
border detection after first identifying the apex and mitral annulus, a pre-configured 
ellipse was fitted to the endocardial borders of each frame and adjusted as required. All 
examinations were performed by the same operator (I.Z.C.). 
 
 
Fig. 3.6: 3D LV echocardiographic image, slice plane view with global volume curve display. 
 
3.5.6.2.2. Right Ventricle Volumetric Acquisition 
 
Images were acquired from apical four chamber views with the patient in the left 
decubitus position breath hold. Through careful manipulation and rotation of the probe 
the optimal projections were obtained. The best window available was used in a 
modified apical transducer location to centre the RV on the display and the RV lateral 
wall was visible within sector. 
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Fig. 3.7: RT3DE imaging of the right ventricle. (Left) For full coverage of the right ventricle by the 3D pyramidal data 
volume, (Top right) Colour-coded 3D image of the right ventricle. (Bottom right) (A) Modified 4-chamber view of the 
right ventricle. (B) Corresponding 90_ rotated image with good visualization of the outflow tract (asterisk).  
 
 
Acquisitions were performed using a modified apical view to enable full coverage of the 
entire RV by pyramidal volume. Care was taken to the upper anterior Wall and RV 
outflow tract (Fig.3.7). 
 
The optimisation of the position of the probe was achieved by stepwise 360o rotation of 
the modified apical view. To obtain the highest possible frame rate, the sector size and 
depth were set up carefully. The data set was recorded over 4 cardiac cycles and at least 
4 data sets were acquired per patient. The data set with the highest quality image was 
used for analysis.  
 
The 3D data sets were posteriorly analysed offline using a novel dedicated software 
(4DRV-function CAP1.1; TomTec Imaging Systems, Inc, Unterschleissheim, Germany) 
and a software platform for data management (Research Arena 2.0; TomTec Imaging 
Systems, Inc.). 
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The analyses of the images were peformed as follows (3.8): 
 
Step 1: within the 3D data set, 3 orthogonal main cut planes were selected and the 
operator defined the end-diastolic and end-systolic frames within the sequence as well 
as several landmarks. 
 
 Step 2: according to the previous view, the program automatically provided 4-
chamber, sagittal, and coronal views of the right ventricle. The observer draws the end-
diastolic and end-systolic contours manually in each view. In case of suboptimal 
endocardial visualisation of this region, contours of the RV outflow tract were 
extrapolated on the basis of the adjacent endocardium with improved visualisation to 
close the envelope and to advance within the predefined steps of the software. 
Trabeculations were included in the RV volume.  
 
Step 3: the application defined a dynamic polyhedron model of the right ventricle on 
the basis of the initial contours. This model is automatically adapted to the endocardial 
surface of the ventricle over all frames of the cardiac cycle. If necessary, the observer 
manually corrected the contours  
 
Step 4: finally, the RV analysis display offers the dynamic model and a table with the 
values of RV volumes and functions 
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Fig. 3.8: Contour revision and final reconstruction of the dynamic RV polyhedron model of a dilated right 
ventricle. (A) Three different short-axis views of the right ventricle (base, middle, and apex). (B) Four-
chamber view. (C) Coronal view depicting the inflow/outflow tract of the right ventricle. (D) The final 
reconstruction results in a polyhedron model of the right ventricle. Display of the end-diastolic volume 
as white polyhedron mesh and the end-systolic volume as green body surface RVEDV, RV end-diastolic 
volume; RVEF, RV ejection fraction; RVESV, RV end-systolic volume; RVSV, RV stroke volume. 
 
 
3.5.6.2.3. Left Ventricle 3D Speckle Tracking Imaging 
 
3DT was performed with an X3-1 transducer, Philips IE33 (Philips Medical Systems, 
Bothell, WA, USA). The 3D data sets were posteriorly analysed offline using a novel 
dedicated software (4D-LV-analysis 3.0 ; TomTec Imaging Systems, Inc, 
Unterschleissheim, Germany) and a software platform for data management (Research 
Arena 2.0; TomTec Imaging Systems, Inc). 
 
 Apical full volume acquisition was obtained in all patients to visualize the entire LV in a 
volumetric image. For acquisitions of a full-volume data set, 4 smaller real-time 
volumes, acquired from alternate cardiac cycles, are combined to provide a larger 
pyramidal volume. In this study, a frame rate of 20 to 30 Hz was used. To optimise the 
frame rate of acquisition, depth was minimised to include only the LV. Data sets were 
stored digitally for offline analysis. 
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After the LV long axis was manually aligned in the three apical views (four, three, and 
two chamber), the software automatically identified the LV endocardial border (Fig.3.9). 
No foreshortened apical views were identified by finding the largest long-axis 
dimensions. The LV boundaries were initialised by manually pointing at a small number 
of anatomic landmarks (mitral annulus and LV apex). In all cases, papillary muscles 
were included in the LV cavity. Endocardial contours were manually adjusted when 
necessary to optimise boundary position and tracking. Then, the 3D endocardial surface 
was automatically reconstructed and tracked in 3D space throughout the cardiac cycle. 
 
The 3D images of the LV wall were automatically divided into 16 segments using 
standard segmentation. The software automatically tracked the contour on the 
subsequent frames in 3 different vectors simultaneously to calculate each strain data 
and resulting in a dynamic cast of the LV cavity. The following parameters of global LV 
deformation were evaluated: global longitudinal strain (GLS), LV twist and LV torsion. 
LV twist was calculated as the difference between basal and apical rotation measured in 
LV short-axis images. To measure basal rotation, the image plane is placed just distal to 
the mitral annulus and for apical rotation just proximal to the level with luminal closure 
at end-systole. LV torsion was defined by LV Twist normalized to LV end-diastolic 
length. 
The time curves of the three principal components of segmental myocardial strain, 
longitudinal, circumferential and radial), as well as the corresponding strain rates were 
obtained using the standard 16-segment model. In addition, for each segment, a time 
curve of 3D strain was calculated as the vector sum of the longitudinal and 
circumferential components. The strain rates values were obtained by calculating the 
difference between strain values for each two consecutive points and dividing by the 
time interval as follows:  SR (t) = dS(t)/dt (Fig. 3.10).   
The peak value of each index was defined as its maximum absolute value with the sign. 
All time curves were interpolated, resulting in effective temporal resolutions of 150 to 
200 samples/sec. 
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Fig. 3.9: Four dimensional speckle tracking left ventricle analysis. A) Standard long axis views and positioning 
of the landmarks (mitral valve, apex and aortic orientation). B) Four-, three- and two chamber views with the 
initialized LV boundaries. The system automatically tracks the complete endocardium. C) LV model with global 
volume curve. D) LV twist graph display. 
 
 
Fig. 3.10: Examples of strain (blue line, primary y axes) and the corresponding strain rate (red line, 
secondary y axes) over time throughout the cardiac cycle obtained in a patient with sickle cell disease. 
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3.5.6.3. Reproducibility  
 
The reproducibility of the 2DE and RT3DE strain measurements was evaluated by 
calculating the intra- and inter-observer variability of both techniques. Analysis of the 
2DE and RT3DE images obtained in all patients was repeated 2 weeks later by the 
primary reader and by an additional expert reader, who were both blinded to the 
previous measurements and the CMR-derived volumes when appropriate.  
Intra- and inter-observer variability was assessed for each technique by calculating the 
absolute difference between the corresponding repeated measurements, which was 
also expressed in per cent of their mean. Absolute differences between repeated 
measurements were subjected to Bland–Altman analysis.  
 
In addition, the inter- examination variability of the RT3DE technique for LV Strain data 
and RV Volumes was studied by repeating image acquisition 1 hour later in a group of 
40 patients selected at random.  
 
3.6. Cardiac magnetic resonance acquisitions 
 
3.6.1. Protocol overview 
 
Cardiac magnetic resonance was performed in the group of patients with LV diastolic 
dysfunction (Group A2). All acquisitions were obtained by the same radiologist at 
consultant level, expert in CMR imaging using a 1.5T Philips Achieva system (Best, 
Netherlands). A 32-element cardiac phased-array coil was used for signal reception. A 
retrospective cardiac gating was achieved with a vector-ECG system.  
Coil sensitivity based uniformity correction was performed to correct signal variation 
within the heart (Bydder et al., 2002). Cine balanced steady-state free precession  
images used the following parameters: field of view, 320×320 mm; matrix, 160×151; 
repetition time, 3.0 ms; echo time, 1.5 ms; in-plane resolution,2.0×2.2 mm; number of 
cardiac phases, 30; section thickness, 8 mm. Myocardial oedema was imaged with a 
navigator-gated black blood T2-weighted turbo spin echo sequence with spectrally 
selective inversion recovery  fat suppression using the following parameters: field of 
view, 350×280 mm; matrix, 256×123; repetition time 2 R–R intervals; echo time, 100 
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ms; in-plane resolution, 1.4×2.3 mm; section thickness, 8 mm. Strain mapping was 
performed using a grid pattern of tag lines (complementary spatial modulation of 
magnetisation (Fischer et al., 1993) with the following parameters: field of view, 
350×350 mm; matrix, 144×144; repetition time, 30 ms; echotime, 2.2 ms; in-plane 
resolution, 2.4×2.4 mm; section thickness, 8 mm; tag line spacing, 7 mm. An intravenous 
bolus of gadobutrol 1.0 mmol/mL (Gadovist; Bayer Schering Pharma, Berlin, Germany) 
was administered at a dose of 0.15 mmol/kg. Early enhancement imaging was 
performed to assess microvascular obstruction with a single breath hold 3D inversion 
recovery gradient echo sequence within 1 min of contrast medium injection using the 
following parameters: field of view, 350×290 mm; matrix, 252×135; repetition time, 4.4 
ms; echo time, 1.3 ms; inversion time, 400 ms; in-plane resolution, 1.4×2.1 mm; section 
thickness, 8 mm. LGE imaging was performed to assess necrosis after a 10-min delay 
with a 2D inversion recovery gradient echo sequence using the following parameters: 
field of view, 320×320 mm; matrix, 200×147; repetition time, 5.5 ms; echo time, 2.5 ms; 
in-plane resolution,1.6×2.2 mm; section thickness, 8 mm.  
 
Contraindications to CMR were as follows:  
 
 Pregnancy: Pregnant women were excluded as were women who planned to 
become pregnant during the menstrual cycle of the CMR study. We also excluded 
women who had no effective measure of birth control.  
 Mental handicap, incompetence or confusion 
 Cardiac pacemaker 
 Mechanical heart valve 
 Intra-ocular foreign body 
 Orthopaedic implant within 8 weeks 
 Surgical clips in the brain 
 Intrauterine contraceptive devices 
 Vascular stents (these were assessed on a case by case basis) 
 Surgical clips in the body (these were assessed on a case by case basis) 
 Intolerance of confined spaces 
 Inability to lie supine for 60 minutes 
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 Clinical instability 
 Significant arrhythmias 
 
3.6.2. Magnetic resonance image analysis 
 
Analyses of the MRI data sets were performed with the system implemented standard 
software (Philips View Forum R.4.1.) by an experienced observer who is blinded to 
patient details and to the results of existing examinations.  
Axial slices of the RV from base to apex were planned from horizontal and vertical long 
axis images of the heart in the plane of the atrioventricular groove (short axis) 
(Fig.3.11). At the basal slice, non-trabeculated atrium was excluded from the RV cavity 
measurement (Lorenz et al., 1999)  (Pattynama et al., 1995)  
Image window and level settings were individually adjusted for each examination to 
achieve the best contrast between the myocardium and blood as well as adjacent 
pericardial tissue. All analysis was performed by an investigator experienced in the 
interpretation of CMR images (with level III accreditation) who was not aware of the 
echocardiographic measurements. 
 
 
Fig. 3.11: CMR short-axis view. The plane is cut perpendicular to long axis on 2C view, and parallel to atrial-
ventricular valves (between anterior & posterior groves) and almost perpendicular to interventricular septum on 4C 
views. 
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3.6.3. Left ventricular function and volumetric assessment  
 
The endocardial and epicardial borders were traced semi-automatically at both end-
diastole and end-systole on short-axis cine images and were then corrected manually at 
the base of the heart. Corrections to other images were allowed if visual inspection 
revealed obviously incorrect borders. The papillary muscles were included in the blood 
pool and excluded from the LV mass measurement. All image contours were checked by 
a cardiac MR physician after contouring was finished by the technologist. 
 
LV end-diastolic volume and LV end-systolic volume were calculated using Simpson’s 
rule (the summation of areas on each separate slice multiplied by the sum of slice 
thickness and image gap) in order to follow the same protocol as with 
echocardiography. LV mass was determined by the sum of the myocardial area (the 
difference between endocardial and epicardial contour) times slice thickness plus image 
gap in the end-diastolic phase multiplied by the specific gravity of myocardium (1.05 
g/mL). 
 
3.6.4. Right ventricular function and volumetric assessment  
 
Assessment of the RV volumes/mass was performed using steady state free precession 
techniques. Imaging parameters were: repetition time/echo time of 3.4/1.7 ms, in-plane 
pixel size of 2.3 × 1.4 mm, section thickness of 8.0 mm, flip angle of 70º, and acquisition 
time of 12 heartbeats. Breath-hold scout images and subsequent vertical and horizontal 
long-axis cine images were initially acquired. Short-axis sequential slices were piloted 
from these, starting from the atrioventricular ring, covering both ventricles to beyond 
the apex. 
Manual delineation was used to generate areas for RV endocardium and epicardium in 
end-diastole and endocardium in end-systole. These time points were defined by the 
largest and smallest endocardial areas. The method of disk summation was then 
employed to provide volumetric and mass data for the RV. Trabeculations were not 
included in the RV myocardium and they were included in blood pool. 
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3.6.5. Myocardial tagging 
 
Tagging is created from the QRS complex detection of the electrocardiogram. 
Myocardial motion is followed during the cardiac cycle, thus reflecting the underlying 
myocardial deformation. However, fading of the tag lines close to end-diastole, as a 
result of T1 tissue relaxation, has limited its application to the systolic part of the 
cardiac cycle. Although spoiled gradient echo imaging is the commonly used sequence 
for tag generation at the widely available 1.5T magnets, recent studies have proposed 
implementing steady state free precession to achieve better contrast and longer tag 
persistence. Using high field strength magnets for tagging acquisition may also reduce 
the problem of tag fading. In fact, despite the potential increase in susceptibility effects 
during cardiac imaging, applying myocardial tagging at higher field strength appears to 
provide a better contrast to noise ratio as well as improve tag persistence (Fig.3.12).  
 
Strain calculations were performed at LV mid-level (short-axis) using harmonic phase 
analysis (Harmonic phase analysis, Diagnosoft, NC, USA) (Osman et al., 1999). Peak 
Eulerian circumferential (Ecc) strain ( midwall, transmural, epicardial and endocardial) 
was measured and an Ecc of greater than −15 % was considered as dysfunctional 
(Fig.3.13) (O'Regan et al., 2013). 
 
 
Fig. 3.12: (Left) Parallel tags on a systolic spin-echo ECG gated image in the four-chamber plane. (Right). Short axis 
tagging at the mid ventricular level, tagging is applied upon detection of QRS complex at end diastole. Tag lines 
follow the myocardial deformation during systole; a mesh model derived from manually segmented 
myocardium surfaces is represented. 
 
126 
 
 
Fig. 3.13: Circumferential Strain curves from 6 segments, obtained from myocardial tagging. 
 
3.7. Statistical Analysis  
 
Data processing 
 
Data were entered in Excel spreadsheets prior to statistical analysis and SPSS v20.00 
(SPSS, Inc., Chicago, IL) was used for the analysis. 
 
Power calculation 
 
The PS power and sample size windows based calculator was used to calculate sample 
size and/or power.  
Power is normally set at a modest 80 %. Since power is the chance of rejecting the null 
hypothesis when it is indeed false, as it increases, the chance of making a mistake 
decreases. Increasing sample size often means a better more powerful analysis but 
other factors such as the magnitude of difference (which can be obtained from previous 
similar studies), the frequency of the event amongst controls, variability of the 
observations and the ratio of controls to cases are also taken into consideration. The 
purpose of a power analysis is to find an appropriate balance among these factors by 
taking into account the substantive goals of the study, and the resources available to the 
researcher. 
 
Sample size was determined regarding the evaluation of left ventricular diastolic 
function in pediatric sickle cell disease patients. According to Zilberman (Zilberman et 
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al., 2007) we would need a total of 60 patients to detect a difference of 1.8 on E/Ea ratio 
for the assessment of diastolic dysfunction, where the SD in each group is 2 with power 
of 80% using an unpaired 2 sample t-test at significance level 5%.  
 
Data presentation and analysis 
 
Data are presented as absolute numbers, percentages, mean (±standard deviation, SD), 
or median and interquartile range. The continuous variables were assessed for 
normality. The best transformation was then used to change to a normal distribution. 
The student t-test and the Kruskal-Wallis test (whichever was appropriate) were used 
to compare continuous variables between patients with SCD and control subjects, and 
the Pearson Chi square test and the Man-Whitney test was used to compare 
dichotomous variables Stepwise linear regression.Pearson and Spearman rank 
correlation was used to assess the relationship between echocardiogram parameters 
and clinical variables in patients with SCD. Group comparisons between a continuous 
and a dichotomous variable were evaluated using the Wilcoxon rank-sum test. Logistic 
regression was used for evaluating the ability of LV E/E´ to identify increased TRV. The 
diagnostic use of LV E/E´ was assessed through the use of receiver operating 
characteristic (ROC) curve. Multiple linear regression modelling was used to identify 
sets of independent variables that were associated with increased elevated E/E´ratio 
and predictors of increased pulmonary pressures. This modelling used a stepwise 
procedure in which a potential independent variable was considered if it had a p value 
<0.10 for bivariate association with TRV; the final model included variables with p≤ 
0.05 in multiple regression. Multiple regression using ranks for all variables was used to 
confirm the most important correlates.  
Multiple linear regression modeling is going to be used to identify sets of variables that 
are independently associated. 
 
Due to the large number of comparisons there was an increased risk of finding 
significant results due to chance. As a result the level of statistical significance was 
reduced from 5% to 1%, consequently, p-values of less than 0.01 were considered to be 
statistically significant. Cox regression analyses identified prognostic predictors. 
Variables were removed at p>0.10. 
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For comparison of the difference in values between the screening and follow-up 
timepoints the normality of the changes from screening to follow-up were examined. 
Where the changes over time were approximately normally distributed, the paired t-
test was used to compare the two set of measurements. Where the changes were not 
normally distributed, the Wilcoxon matched-pairs test was used instead. 
Binary variables were compared between timepoints using the paired exact test. 
Categorical variables with more than two categories were analysed using the McNemar-
Bowker test. 
 
Reproducibility study 
 
Inter-observer and intra-observer variability of the echocardiographic measurements 
was assessed by calculating the standard deviation of the differences between 
measurements of the volumes performed by two independent observers blinded to the 
results achieved by the other observer. One observer (I.Z.C.) analysed all of the images 
twice, leaving at least a one week gap and blinded to the previous results, providing 
intra-observer variability. 
 
The study of reproducibility index between the measurements of intra-observer and 
inter-observer was done using the Altman and Bland method for calculation of limits of 
agreement. (Bland and Altman, 1986). 
 
TEST re-test of LV 3D Strain analysis  
 
Repeatability of the echocardiographic parameters (Test re-test) were done using the 
intra class correlation coefficient. All LV 3D strain outcomes were measured on a 
continuous scale. Two methods of analyses, were used to assess the agreement between 
the test and re-test values. 
 
The first method of agreement used was the Bland-Altman limits of agreement method. 
This method measures, in real terms, the size of differences between test and re-test 
values on the same patients that are likely to occur. 
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The measure is obtained by first calculating the difference between the two values for 
each patient. The 95% limits of agreement (within which 95% of all differences between 
values should occur) are then calculated as follows:  
 
Mean difference +/- 1.96*(standard deviation of differences) 
 
Clinical judgement were required to decide whether the level of differences between the 
pairs of measurements is acceptable or not. 
 
The second method of agreement was the intra-class correlation (ICC) method. This 
method involves splitting the total variation in the data into two sources, variation 
between patients, and variation within patients (i.e. variation between the test and re-
test values for the same patient). The ICC is the proportion of the total variation that is 
between patients. If there is good agreement, there should be very little within patient 
variability, and so most variability should between patients, and thus the ICC values 
should be close to 1. 
 
Two different analyses of the strain variables were produced. Initially the mean value of 
each of the 16 segments was calculated, and only this mean value was analysed. 
Subsequently, the agreement between the results of individual segments were analysed.  
 
All calculations were performed with SPSS 20.0 (SPSS, Inc., Chicago, IL). 
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Chapter 4 Study results  
4. Study subjects characterisation: general overview 
 
The population studied in the prospective study included two groups of subjects: a 
group of patients with SCD and a group of healthy volunteers (race, age and sex 
matched). The 2 groups were comparable for the main traditionally cardiovascular risk 
factors.  Eleven patients who were invited to participate in the study were not recruited 
The reasons were due to: recent hospitalization or SCD crisis (2), failure to keep an 
appointment (5), failure to agree to follow up (2) and no interest in participation in the 
study (2). Subject’s characterisation will be described in the following points. 
 
4.1. Baseline descriptive data of study cohort 
 
4.1.1. Sociodemographics and Clinical characteristics 
 
Of sixty one patients with SCD (55.7% female; mean age 40.22±11.79), the vast majority 
(96.7%) had non Hispanic or latino ethnicity. Africa was the most frequent country 
regarding ancestry (45.9%). Thirty two patients were born in Europe (52.2%), and 18 
patients were born in West Africa (29.5%).  Regarding the genotype, 44 patients 
(72.1 %) were Homozygous (HbSS), following HbSC in 15 patients, and representing 
24.6% (Fig.4.1). All patients were of black race.  Thirty-one patients (51%) were on 
Class I of the NYHA , twenty four (39%) on class II and six patients (10%) on Class III. 
 
Fig. 4.1. Distribution of SCD genotype in study subjects 
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Baseline patient demographic characteristics for all 61 patients recruited are detailed in 
Table 4.1 
 
Table 4.1 - Subjects demographic characteristics of patients. 
 
 
The participant’s clinical history was collected during the study interview at the 
screening visit. Nine patients (14.8%) never had a transfusion during their lifetime. 
Information regarding the patients’ clinical history (common SCD complications and 
related organ disease) is detailed in Table 4.2.  
 
 
 
 
 
 
 
 
 
 
 
 
Gender
Female 34 (55.7%)
Male 27 (44.3%)
Ethnicity
Not Hispanic or Latino 59 (96.7%)
Hispanic or Latino 2 (3.3%)
Country of Birth
Europe 32 (52.5%)
West Africa 18 (29.5%)
West Indies 8 (13.1%)
Central Africa 3 (4.9%)
Sickle Cell Genotype
HbSS 44 (72.1%)
HbSC 15 (24.6%)
HbSβ thalassemia + 1 (1.6%)
HbSβ thalassemiao 1 (1.6%)
NYHA functional class
Class I 31 (50.8%)
Class II 24 (39.3%)
Class III 6 (9.8%)
All SCD patients
N (%)
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Table 4.2 - Subjects clinical history at screening (data refers to events over lifetime) 
 
 
The baseline clinical characteristics of the 61 patients and the 42 age and sex matched 
black control subjects are summarised in Table 4.3. The median age of the SCD patients 
was 40.2 years (range 18–72 years) where 34 were female (55.7%) and the mean BMI 
was 24.34 mmHg (range 18.39-33.38). Forty two healthy volunteers (mean age 
37.8±11.5 years; range, 19–71 years) were included in the study. Significant differences 
between patients and healthy volunteers were observed regarding the weight, body 
surface area, body mass index and systolic blood pressure. Compared with controls, 
subjects with SCD had lower systolic blood pressures, lower body weight and higher 
body mass index. We found no significant difference in heart rate between SCD patients 
Clinical History N (%)
Total number of transfusion in lifetime
0 9 (14.8%)
1-5 23 (37.7%)
6-20 16 (26.2%)
21-100 6 (9.8%)
> 100 7 (11.5%)
History of smoking
None 40 (65.6%)
Former smoker 12 (19.7%)
Current smoker 9 (14.8%)
History of Alcohol 
None 28 (45.9%)
Formerly drank alcohol 4 (6.6%)
Currently drink alcohol 29 (47.5%)
History of drug use 
None 50 (82.0%)
Former drug use 7 (11.5%)
Current drug use 4 (6.6%)
History of Neurologic or Stroke Sequelae Present 1 (1.6%)
Vaso-Occl, Pain Crisis 45 (73.8%)
Leg Ulcers since Screening 20 (32.8%)
Kidney/urinary/genital problems 29 (47.5%)
Liver problems 28 (45.9%)
Spleen problems 23 (37.7%)
Lung Problems 48 (78.7%)
Lung, pneumonia/acute chest syndrome 40 (65.6%)
Lung, pulmonary embolism 2 (3.3%)
Lung, pulmonary hypertension 9 (14.8%)
Heart problems 28 (45.9%)
Splenomegaly 1 (1.6%)
Hepatomegaly 10 (16.4%)
Gastrointestinal, other 9 (14.8%)
Neurological problems 31 (50.8%)
Blood problems, other than sickle cell 10 (16.4%)
Infections 9 (14.8%)
Other diseases/aliments 30 (49.2%)
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and control patients, despite the fact that, as expected, haemoglobin levels were 
decreased in SCD patients. 
 
Table 4.3 - Baseline clinical characteristics of patients versus healthy. 
 
*Two-sided P values for continuous variables were calculated with the use of the t-test and and P values 
for categorical variables were calculated with the use of Mann-Whitney U test. BP: blood pressure. 
 
 
 
4.1.2. Medication at screening 
 
The patients’ history of medication use is detailed in Table 4.4. Fourteen patients (23%) 
were receiving hydroxyurea therapy.  Fifty nine patients (96.7%) were on folic acid and 
54 patients (88.5%) were on treatment with penicillin (prophylactic) or other 
antibiotics. Only 2 patients (3.3%) were on chronic transfusion therapy at the time of 
the study. 
 
 N  Mean  ±  SD  Min  Max  N  Mean  ±  SD  Min  Max 
 Demographics 
 Female (%) 61 na na 42 na na 0.73
Age(years) 61 40.2 ± 11.8 18.4 72.0 36.2 - 44.2 42 37.9 ± 11.6 19.0 71.0 33.0 - 42.7 0.32
Height (cm) 61 168.8 ± 9.8 151.0 192.0 165.5 - 172.2 42 1.7 ± 0.1 1.5 1.9 1.6 - 1.7 0.54
Weight (kg) 61 69.2 ± 10.8 50.6 93.5 65.6 - 72.9 42 75.8 ± 13.9 45.0 110.9 70.0 - 81.6 0.01
 Body surface area 
(kg/m^2) 
61 1.8 ± 0.2 1.5 2.2 1.7 - 1.9 42 1.9 ± 0.2 1.4 2.2 1.8 - 2.0 0.04
 Body Mass Index (kg/m^2) 61 24.3 ± 3.6 18.4 33.4 23.1 - 25.6 42 22.6 ± 4.3 14.0 36.2 20.9 - 24.4 0.02
Heart rate (bpm) 61 76.0 ± 10.1 56.0 109.0 72.6 - 79.4 42 70.7 ± 10.5 47.0 96.0 66.3 - 75.1 0.12
Oxygen saturation on air (%) 61 97.2 ± 3.4 84.0 100.0 96.0 - 98.4 42 98.4 ± 1.6 94.0 100.0 97.9 - 98.9 0.16
Systolic BP (mmHg) 61 119.1 ± 14.3 93.0 163.0 114.2 - 123.9 42 124.4 ± 15.2 96.0 169.0 118.1 - 130.8 0.04
Diastolic BP  (mmHg) 61 70.4 ± 11.4 43.0 98.0 66.5 - 74.3 42 75.5 ± 8.9 59.0 108.0 72.8 - 78.3 0.16
55.70 na 52.40 na
 P 
value 
* 
 Labels 
Sickle Cell Patients
 99%CI  99%CI 
Healthy volunteers
135 
 
Table 4.4 - Patient’s medication at Screening. 
 
 
4.1.1. Laboratory results and 6 minute walking test 
 
Among subjects with SCD, the mean hemoglobin was 9.14 g/dL (range 6-14 g/dL), the 
red blood cell count was 3.09 x10^6/U (range 1.72-5.06). The reticulocyte count is 
increased with a mean of 8.66 (%) (range 1.60 -21.9). ProBNP was abnormal in 9 
patients (15%). Full haematological and biochemical characteristics of all patients are 
presented in table 4.5. 
Medication N (%) Medication (Cont.) N (%)
Anticooagulants Prophylactic penicillin or other antibiot
Past 14 (23.0%) Past 1 (1.6%)
Current 3 (4.9%) Current 54 (88.5%)
Anticonvulsants NSAIDS
Past 2 (3.3%) Past 5 (8.2%)
Current 0 (0.0%) Current 4 (6.6%)
Antidepressants Other Pain Medications
Past 3 (4.9%) Past 1 (1.6%)
Current 2 (3.3%) Current 8 (13.1%)
Erythropoietin/darbopoietin PDE-5 inhibitor
Past 1 (1.6%) Past 1 (1.6%)
Current 0 (0.0%) Current 2 (3.3%)
Folic Acid Ace inhibitors
Past 1 (1.6%) Past 2 (3.3%)
Current 59 (96.7%) Beta Blockers
Hydroxyurea Past 1 (1.6%)
Past 7 (11.5%) Current 2 (3.3%)
Current 14 (23.0%) Calcium Chanel Blockers
Hydroxyurea, Cumulative Past 6 (9.8%)
Never 40 (65.6%) Diuretics
< 1 Year 10 (16.4%) Past 2 (3.3%)
1-5 Years 5 (8.2%) Vasodilators
> 5 Years 6 (9.8%) Current 0 (0.0%)
Inhalers Pulmonary Hypertension, Other, Specify
Past 6 (9.8%) aspirin (for transient ischemic attack) 1 (1.6%)
Current 8 (13.1%) digoxin 1 (1.6%)
Iron Chelation therapy irbesartan 1 (1.6%)
Past 5 (8.2%) losartan 2 (3.3%)
Current 1 (1.6%) pulmicort inhaler 1 (1.6%)
Oxygen at home On chronic transfusion therapy 2 (3.3%)
Past 2 (3.3%) Type Simple 26 0.426
Current 4 (6.6%) Type Exchange 26 (42.6%)
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Pro-BNP measured at screening, was considered elevated (≥ 160 pg/ml) in 9 patients 
(15%). Lactate dehydrogenase (LDH) mean was 414.85 IU/L (range 167 -1323) and the 
mean 6 minute walking test distance was 406.4 meters (range 180 -615 meters). 
 
Table 4.5 - Patients baseline clinical characteristics: laboratory tests and 6MW test. 
 
N Mean ± SD Min Máx
Full blood count
Absolute neutrophil count 59 4.83 ± 2.69 1.90 17.30 (3.90 - 5.77)
Absolute Reticulocyte Count (x10^3 cells/uL) 60 238.81 ± 108.64 42.90 456.90 (201.48 - 276.14)
Hematocrit (SI units) 59 0.26 ± 0.05 0.16 0.38 (0.24 - 0.28)
Haemoglobin(g/dl) 60 9.14 ± 1.73 6.00 14.10 (8.55 - 9.74)
Mean cell hemoglobin concentration (g/L) 60 352.12 ± 13.30 317.00 382.00 (347.55 - 356.69)
Mean cell volume (fl) 60 86.89 ± 14.48 57.70 122.90 (81.92 - 91.87)
Neutrophils (%) 16 55.30 ± 9.52 40.40 76.50 (48.28 - 62.31)
Platelet count (x10^3 cells/ul) 60 331.47 ± 171.64 86.00 936.00 (272.49 - 390.45)
Red cell distribution width (%) 58 19.95 ± 3.30 14.20 26.60 (18.79 - 21.10)
Red blood count (x10^6/ul) 60 3.09 ± 0.88 1.72 5.06 (2.79 - 3.40)
Reticulocytes (%) 60 8.66 ± 5.05 1.60 21.90 (6.92 - 10.39)
White blood cell count (x10^3 cells/ul) 60 9.02 ± 3.76 3.20 22.80 (7.73 - 10.31)
Mean corpuscular haemoglobin (pg) 59 35.26 ± 1.54 31.70 42.00 (34.73 - 35.80)
Laboratory tests and 6MW test
Chemistry Albumin (g/L) 58 41.69 ± 3.10 34.00 48.00 (40.61 - 42.77)
Alkaline Phosphatase (U/L) 58 100.34 ± 61.13 30.00 403.00 (78.95 - 121.74)
Alanine aminotransferase 58 24.98 ± 17.84 7.00 92.00 (18.74 - 31.22)
Aspartate aminotransferase (u/l) 57 40.95 ± 23.75 14.00 131.00 (32.56 - 49.34)
Blood urea nitrogen (mmol/L) 60 4.02 ± 3.07 0.90 23.00 (2.97 - 5.08)
Calcium (mmol/L) 55 2.32 ± 0.08 2.13 2.51 (2.29 - 2.35)
Chloride 60 106.97 ± 2.48 99.00 115.00 (106.11 - 107.82)
Bicarbonate (mmol/L) 58 20.48 ± 2.28 15.00 25.00 (19.68 - 21.28)
Creatinine (umol/l) 60 70.65 ± 28.01 29.00 252.00 (61.03 - 80.27)
Lactate dehydrogenase (IU/l) 53 414.85 ± 211.40 167.00 1323.00 (337.21 - 492.49)
Magnesium (si units) 59 0.86 ± 0.07 0.71 1.03 (0.83 - 0.88)
Phosphate (SI) 54 1.18 ± 0.18 0.74 1.73 (1.12 - 1.25)
Potassium (mmol/L) 60 4.44 ± 0.46 3.70 5.90 (4.28 - 4.60)
Albumin/creatinine ratio 40 18.49 ± 34.10 1.00 199.80 (3.89 - 33.09)
Sodium 60 138.43 ± 2.27 134.00 145.00 (137.65 - 139.21)
Total bilirubin (umol/l) 58 47.69 ± 37.15 10.00 171.00 (34.69 - 60.69)
Total protein (SI) 58 78.78 ± 5.29 69.00 95.00 (76.93 - 80.63)
Urea (mmol/l) 49 3.61 ± 1.46 0.90 10.10 (3.05 - 4.17)
ProBNP (pg/ml) 60 118.59 ± 317.35 6.60 2483.00 (9.54 - 227.64)
ProBNP, log 10 60 1.77 ± 0.43 0.82 3.40 (1.63 - 1.92)
6 minute walk total distance (m) 61 406.41 ± 74.29 180.00 615.00 (381.11 - 431.71)
Data are presented as mean±SD
Variables
99% CI
Sickle Cell Patients
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4.1.2. Echocardiography Derived Parameters of Cardiac Structure 
and Function 
 
4.1.2.1. Right and Left Cardiac Structure 
 
All studied subjects were in sinus rhythm. Measurements of cardiac structure, including 
LA and RA volumes indexed to BSA, LV mass, endsystolic and end-diastolic volume 
indexed, were significantly higher in the SCD group compared with the control group.  
Twenty seven patients (44%) had LV end-diastolic dilation. According to gender, female 
patients had increased LV volumes, systolic and diastolic, when compared to males. In 
the group of  33 patients with increased LV mass (indexed to BSA), 42% had concentric 
hypertrophy and 57% had eccentric hypertrophy defined by the regional left 
ventricular wall thickness index ≥ 0.41.  
 
Left atrium dilatation was present in 53 patients (87%), where in 34 patients (64%) the 
dilatation was severe (> 40 ml/m2), in 16 patients (30%) was moderately abnormal 
and in 3 patients (6%)  was mild.  Right atrium dilatation was present in 80% of the 
total patients.  
 
RV end-diastolic and end-systolic areas, as well as RV 3D end-diastolic and end-systolic 
volumes were larger in the SCD group compared with controls.  According to RV 3D 
volumetric assessment, 28 patients, of the 58 patients where RV volumes were 
measured (48%), had end-diastolic dilatation (≥101 ml/m2) (Table 4.6). 
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Table 4.6 – Left ventricular dilatation according to gender in all patients. 
 
 
 
4.1.2.2. LV and RV Systolic Function.  
 
Parameters of global LV function, including LV ejection fraction and global function 
index, were normal in both groups. Only 9.8% of patients had evidence of systolic 
dysfunction with an ejection fraction ≤55%. LV S´ wave septal (cm/s) was significantly 
different between patients and controls. As expected, the SCD group had greater 
Doppler-derived LV stroke volumes and cardiac output when compared with healthy 
volunteers (Table 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LV 2D diastolic volume indexed (ml/m2)
Reference range (<75) N (%) 24 (71%) 10 (37%) 34 (56%)
Mildly abnormal (76 - 86) N (%) 7 (21%) 6 (22%) 13 (21%)
Moderately abnormal (87 - 96) N (%) 2 (6%) 4 (15%) 6 (10%)
Severely abnormal (>=97) N (%) 1 (3%) 7 (26%) 8 (13%)
Total N (%) 34 (100%) 27 (100%) 61 (100%)
LV 2D systolic volume indexed (ml/m2)
Reference range (12 - 30) N (%) 28 (82%) 14 (52%) 42 (69%)
Mildly abnormal (31 - 36) N (%) 5 (15%) 7 (26%) 12 (20%)
Moderately abnormal (37 - 42) N (%) 1 (3%) 1 (4%) 2 (3%)
Severely abnormal (>=43) N (%) 0 (0%) 5 (19%) 5 (8%)
Total N (%) 34 (100%) 27 (100%) 61 (100%)
Female Male
Variable
Gender
Count All Patients
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Table 4.7 - Cardiac structure and function in patients with SCD compared with healthy volunteers. 
 
 
Parameters of RV systolic function, including RV myocardial performance index by DTI 
and RV 3D ejection fraction (%), were significantly different between the SCD group and 
healthy volunteers. Patients with SCD had lower RV EF, increased values of RV tMPI and 
RV S wave velocity when compared to controls. Tricuspid annular systolic motion was 
normal in both groups and significantly higher in patients with SCD. 
 
4.1.2.3. Diastolic Function Assessment 
 
Pulsed-wave Doppler–derived transmitral E-wave velocity was higher in subjects with 
SCD compared with controls. Mitral deceleration time and LV E/A ratio, were similar 
between the groups, however LV isovolumic relaxation time and LV E/E´ both septal 
and average values, were increased in the SCD group as seen in Table 4.8. 
Lower Upper
LV Structure
LV septum diameter (mm) 61 2.78 ± 11.73 42 9.19 ± 1.38 -6.41 0.00 1.46 0.01
LV posterior wall diameter (mm) 61 10.08 ± 1.62 42 9.45 ± 1.49 0.63 -0.20 1.45 0.05
LV 2D end-diastolic diameter (mm) 61 50.85 ± 6.70 42 44.45 ± 5.39 6.40 3.14 9.66 <0.001
LV 2D end-systolic diameter (mm) 61 32.82 ± 5.41 42 29.26 ± 4.70 3.56 0.85 6.26 0.001
LV 2D diastolic volume indexed (ml/m2) 61 74.04 ± 21.79 42 49.58 ± 11.61 24.46 15.75 33.18 <0.001
LV 2D systolic volume indexed (ml/m2) 61 26.25 ± 10.56 42 17.67 ± 4.53 8.58 4.56 12.58 <0.001
LV mass index (g/m2) 53 91.12 ± 29.59 38 51.10 ± 15.20 40.02 27.49 52.57 <0.001
RV structure
RV base to apex diamater (cm) 59 7.62 ± 1.05 42 6.36 ± 0.99 1.27 0.72 1.81 <0.001
RV mid diamater (cm) 59 3.17 ± 0.49 41 2.90 ± 0.49 0.27 0.01 0.54 0.01
RV base diameter (cm) 59 3.50 ± 0.58 42 3.33 ± 0.42 0.17 -2.10 1.18 0.46
RV diastolic area apical view (cm2) 61 21.04 ± 5.62 42 16.54 ± 3.86 4.50 1.88 7.12 <0.001
RV systolic area apical view (cm2) 61 11.87 ± 3.23 42 10.05 ± 2.36 1.82 0.29 3.35 0.002
3D RV end diastolic volume 58 109.93 ± 33.63 32 88.53 ± 18.51 21.40 6.93 35.87 <0.001
3D RV end systolic volume 58 49.70 ± 17.55 32 36.48 ± 8.78 13.22 5.90 20.53 <0.001
LA/RA structure
Left atrium volume indexed (ml/m2) 60 44.28 ± 15.20 42 22.75 ± 7.31 21.53 15.58 27.49 <0.001
RA volume indexed (ml/m2) 57 37.89 ± 11.82 42 20.11 ± 6.95 17.79 12.80 22.78 <0.001
LV systolic function
Global function index lateral 60 0.98 ± 0.32 41 0.74 ± 0.31 0.24 0.07 0.41 <0.001
Global function index septal 60 1.21 ± 0.32 39 1.08 ± 0.32 0.13 -0.04 0.31 0.04
LV 2D Ejection Fraction (%) 61 66.17 ± 7.24 42 63.95 ± 5.36 2.22 -1.22 5.67 0.09
LV 2D cardiac output (L/min) 61 6.35 ± 2.04 41 4.34 ± 0.95 2.01 1.23 2.81 <0.001
LV 2D stroke volume (mL) 60 83.42 ± 24.41 41 62.72 ± 14.47 20.70 10.51 30.89 <0.001
LV S´ wave lateral (cm/s) 60 9.42 ± 2.30 41 9.34 ± 1.89 0.08 -1.06 1.22 0.85
LV S' wave septal (cm/s) 60 8.28 ± 1.07 39 7.69 ± 0.72 0.59 0.08 1.11 0.003
RV systolic function
Estimated PASP (mmHg) 61 31.84 ± 6.81 38 15.69 ± 1.85 16.15 13.71 18.59 <0.001
Pulmonary valve accelaration time (ms) 60 127.82 ± 26.75 42 134.96 ± 23.47 -7.15 -20.59 6.30 0.17
PVR (Woods unit) 52 1.55 ± 0.32 36 1.32 ± 0.20 0.23 0.07 0.39 <0.001
RV myocardial performance index by TDI 57 0.34 ± 0.11 42 0.25 ± 0.07 0.09 0.04 0.14 <0.001
RV S´wave (cm/s) 61 14.81 ± 2.70 40 12.50 ± 2.39 2.32 0.94 3.70 <0.001
Tricuspid annular systolic motion (mm) 60 29.20 ± 5.59 42 24.10 ± 3.81 5.10 2.66 7.55 <0.001
RV fractional area change (%) 61 43.21 ± 8.72 42 38.74 ± 7.66 4.47 0.10 8.84 0.01
3D RV Ejection fraction (%) 58 54.90 ± 7.18 32 58.91 ± 4.17 -4.01 -7.16 -0.86 0.001
TRV velocity (m/sec)
TRV screening (m/s) 61 2.54 ± 0.30 38 1.96 ± 0.05 0.58 0.43 0.73 <0.001
 p-value Ɨ
 (N)  Mean  (N)  Mean± SD ± SD
Variable
Patients Healthy volunteers
Diff.
Mean
99% CI
of Difference
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Comprehensive diastolic assessment using tissue Doppler was available and we have 
found that the prevalence of diastolic dysfunction in the patients groups was 14 patients 
(23%) with SCD had mild diastolic dysfunction (Grade I),   4 (7%) had moderate 
diastolic dysfunction (Grade II), and none had severe diastolic dysfunction, using the 
current classification guidelines recommended by the American Society of 
Echocardiography (Nagueh et al., 2009b).  
 
Table 4.8 - Left and right ventricular diastolic function in patients with SCD compared with healthy 
volunteers. 
 
 
Further analysis were performed to characterise LV diastolic function regarding gender 
and mean age ( ≤ 40 years and > 40 years) (Nagueh et al., 2009b). No other age groups 
were possible to be compared due to the characteristics of the studied subjects (only 4 
patients were ≥ 60 years and 4 ≤ 20 years).  
 
No differences in LV diastolic parameters were observed regarding both gender, 
however, as expected, age played an important role as it is detailed in Appendix VI.  
 
Interestingly, the RV E/E´ ratio, a surrogate of RV filling pressures, was not significantly 
different among subjects with SCD compared with controls, as well as all the other RV 
parameters for assessing right ventricular diastolic function. 
 
Lower Upper
LV diastolic function
LV E wave (cm/s) 61 88.53 ± 14.57 42 73.76 ± 14.04 14.77 7.21 22.33 <0.001
LV E/A ratio 55 1.52 ± 0.54 38 1.46 ± 0.37 0.06 -0.16 0.34 0.36
MV decelaration time (ms) 60 201.42 ± 38.93 42 187.90 ± 24.70 13.52 -3.04 30.09 0.03
LV Isovolumic relaxation time (ms) 55 95.00 ± 17.04 38 83.50 ± 15.64 11.5 2.53 20.35 0.001
Pulmonary veins a wave duration (ms) 38 113.61 ± 19.86 25 112.64 ± 20.11 0.97 -12.70 14.63 0.85
Pulmonary veins a wave reversal (cm/s) 45 23.76 ± 5.96 26 21.76 ± 4.20 2 -1.52 5.52 0.14
Duration a wave LV 45 118.08 ± 24.59 14 109.00 ± 29.05 9.08 -11.86 30.02 0.25
LV E ´  lateral wall 60 11.72 ± 2.88 41 12.11 ± 2.74 -0.39 -1.89 1.12 0.50
LV E/E' lateral 60 7.99 ± 2.36 41 6.46 ± 1.89 1.53 0.37 2.69 0.001
MV E´ septal (cm/s) 60 9.26 ± 1.95 40 9.46 ± 2.22 -0.2 -1.30 0.91 0.64
LV E/E´septal 55 9.82 ± 2.10 38 8.08 ± 1.86 1.74 0.62 2.73 <0.001
LV E/E´avg 59 8.91 ± 2.00 41 7.33 ± 1.70 1.58 0.58 2.58 <0.001
RV diastolic function
RV E wave (cm/s) 55 47.37 ± 10.50 38 44.66 ± 10.09 2.71 -3.03 8.44 0.22
RV E/A 47 1.53 ± 0.44 40 1.36 ± 0.33 0.16 -0.06 0.39 0.06
RV E´wave (cm/s) 60 12.14 ± 3.46 40 10.94 ± 3.15 1.20 -0.59 2.99 0.08
RV E´/A´ 55 1.12 ± 0.45 36 1.25 ± 0.59 -0.12 -0.41 0.16 0.26
RV E/E´ 55 4.23 ± 1.71 37 4.30 ± 1.38 -0.07 -0.96 0.82 0.84
RV isovolumic relaxation time (ms) 46 60.26 ± 35.91 34 53.44 ± 22.69 6.82 -11.70 25.34 0.33
 (N)  Mean  (N)  Mean± SD ± SD
Patients Healthy volunteers
Variable
Diff.
Mean
99% CI
of Difference  p-value Ɨ
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4.1.2. LV Strain quantification by 3D speckle tracking 
 
Forty-three patients were eligible for LV Strain quantification by 3D speckle tracking. 
The quality tracking was not acceptable in 1197 segments (out of the total 3904 
segments analysed), which corresponds to 31 % of non trackable LV strain values. 
 The mean frame rate of the RT3DE data sets in our study subjects was 18.05±1.65 
frames per second in the patients group. The mean analysis duration was 10.5±1.28 
minutes in the patients groups, which was significantly higher than in the healthy 
subjects (8.54±1.30 min).  
 
LV volume time curves had similar general shape in subjects with SCD and healthy 
volunteers, although measurements of LV diastolic and systolic volumes were 
significantly different in the two study groups, which was consistent with the findings 
with 2D echocardiography.  
 
All global LV myocardial strain quantifications (3D, longitudinal, circumferential and 
radial strain) were preserved in patients with SCD (Table 4.9), with Table 4.9 shows 
longitudinal, radial, and circumferential components of the 3DSTE-derived strain 
obtained in patients with SCD and normal subjects.  As expected, the shape of the strain 
curves was similar to that of LV volume curves, with the exception of the radial strain 
curves which were inverted. Particularly, radial strain was positive throughout the 
cardiac cycle, reflecting a systolic increase in myocardial thickness, while the 
longitudinal and circumferential strains were negative reflecting systolic shortening of 
the ventricle in these two dimensions (Fig. 4.2). 
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Fig. 4.2 - Examples of time curves of the longitudinal (top) and radial (bottom) components of 3D strain 
obtained in the same two subjects at the lateral segment (mid-level of the left ventricle). 
 
Considering LV Global longitudinal strain, 10 patients (23%) had decreased values of 
strain (defined as ≥ -16%). However, no significant difference was found in the mean 
global strain between the patients with SCD and the normal subjects. Mean values of the 
3DSTE-derived indices of LV systolic function also showed no significant differences 
between the two groups for either twist angle or torsion (Table 4.9). In addition, 
patients with SCD showed a trend toward an increase in both longitudinal and radial 
strains. When regional myocardial function was assessed, a significant difference 
between patients and healthy volunteers was found in LV circumferential median 
segments and in LV longitudinal basal segments, but both had normal values.  A further 
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analysis concerning the segmental analysis (total of 64 segments) has showed an 
increase in the mean strain values of 29 segments (45%), when compared to healthy 
subjects. Nevertheless, only in 5 segments the mean difference was significant 
(Appendix V). No differences in strain values were observed regarding gender and age 
(Appendix VI). In addition, further analyses were taken to assess LV strain rate and no 
significant differences between patients and controls, which may reflect normal LV 
filling pressure on both groups, were found. 
 
Table 4.9 - 3-Dimensional Strain Indices of Systolic LV Function 
 
Lower Upper
LV Strain
3D Frame rate (Hz) 43 18.05 ± 1.65 26 17.23 ± 1.30 0.82 -0.19 1.82 0.04
3D analysis duration (min) 40 10.50 ± 1.28 26 8.54 ± 1.30 1.96 1.10 2.82 <0.001
LV 3D end diastolic volume (ml) 43 124.36 ± 39.48 26 96.30 ± 25.36 28.06 5.09 51.04 0.002
LV 3D end systolic volume (ml) 43 61.34 ± 22.90 26 46.63 ± 13.13 14.71 1.65 27.76 0.004
LV 3D stroke volume (ml) 43 63.02 ± 18.64 26 49.66 ± 13.85 13.36 2.15 24.56 0.002
LV 3D ejection fraction (%) 43 51.24 ± 4.96 26 51.52 ± 4.75 -0.28 -3.50 2.93 0.82
Global longitudinal strain (%) 43 -17.81 ± 3.00 26 -17.23 ± 2.77 -0.58 -2.50 1.34 0.43
3D LV strain twist (degree) 43 10.53 ± 6.40 26 10.43 ± 3.97 0.10 -3.60 3.80 0.94
3D LV strain torsion ( degree/cm) 43 1.28 ± 0.85 26 1.34 ± 0.56 -0.06 -0.55 0.44 0.76
LV 3D Strain (%)
Basal segments avg 43 -28.84 ± 3.03 26 -30.05 ± 3.38 1.21 -0.88 3.29 0.13
Median segments avg 43 -34.11 ± 4.91 26 -33.76 ± 3.93 -0.36 -3.36 2.65 0.75
Apical segments avg 43 -35.18 ± 7.26 26 -33.61 ± 5.68 -1.57 -6.00 2.85 0.35
Global (avg of all segments) 43 -32.40 ± 3.83 26 -32.33 ± 3.16 -0.07 -2.44 2.30 0.94
LV Circumferential Strain (CS%)
Basal segments avg 43 -18.48 ± 3.00 26 -19.22 ± 3.13 0.74 -1.27 2.75 0.33
Median segments avg 43 -26.52 ± 4.87 26 -26.05 ± 4.29 -0.46 3.58 11.77 <0.001
Apical segments avg 43 -26.75 ± 7.17 26 -25.44 ± 5.12 -1.31 -5.58 2.96 0.42
Global (avg of all segments) 43 -23.48 ± 3.73 26 -23.38 ± 3.51 -0.10 -2.50 2.31 0.92
LV Longitudinal Strain (%)
Basal segments avg 43 -17.31 ± 2.83 26 -19.80 ± 2.56 2.49 0.69 4.29 <0.001
Median segments avg 43 -18.61 ± 3.42 26 -17.89 ± 2.51 -0.72 -2.77 1.33 0.36
Apical segments avg 43 -18.45 ± 4.01 26 -17.73 ± 4.24 -0.72 -3.41 1.98 0.48
Global (avg of all segments) 43 -18.10 ± 2.79 26 -18.36 ± 2.05 0.26 -1.41 1.94 0.68
LV Radial Strain (%)
Basal segments avg 43 53.61 ± 9.93 26 55.44 ± 8.67 -1.82 -8.07 4.42 0.44
Median segments avg 43 77.26 ± 20.61 26 71.10 ± 12.16 6.16 -5.64 17.97 0.17
Apical segments avg 43 83.67 ± 31.48 26 72.85 ± 22.23 10.82 -7.87 29.51 0.13
Global (avg of all segments) 43 69.79 ± 15.67 26 65.61 ± 9.99 4.18 -4.93 13.28 0.23
LV 3D Strain Rate (%/ms)
Basal segments avg 43 -0.19 ± 0.02 26 -0.20 ± 0.04 0.01 -0.01 0.03 0.24
Median segments avg 43 -0.20 ± 0.03 26 -0.20 ± 0.03 -0.01 -0.03 0.01 0.41
Apical segments avg 43 -0.22 ± 0.07 26 -0.20 ± 0.04 -0.03 -0.07 0.01 0.06
Global (avg of all segments) 43 -0.20 ± 0.03 26 -0.20 ± 0.03 -0.01 -0.02 0.01 0.46
LV circumferential Strain Rate (%/ms)
Basal segments avg 43 -0.11 ± 0.02 26 -0.12 ± 0.02 0.00 -0.01 0.02 0.40
Median segments avg 43 -0.16 ± 0.03 26 -0.16 ± 0.03 -0.01 -0.03 0.01 0.32
Apical segments avg 43 -0.17 ± 0.06 26 -0.15 ± 0.03 -0.02 -0.05 0.01 0.13
Global (avg of all segments) 43 -0.10 ± 0.15 26 -0.10 ± 0.01 0.00 -0.02 0.01 0.23
LV Longitudinal Strain Rate (%/ms)
Basal segments avg 43 -0.11 ± 0.02 26 -0.11 ± 0.02 0.00 -0.01 0.02 0.67
Median segments avg 43 -0.10 ± 0.02 26 -0.10 ± 0.01 0.00 -0.01 0.01 0.26
Apical segments avg 43 -0.10 ± 0.02 26 -0.09 ± 0.02 -0.01 -0.02 0.01 0.22
Global (avg of all segments) 43 -0.10 ± 0.01 26 -0.10 ± 0.01 0.00 -0.01 0.01 0.42
LV Radial Strain Rate (%/ms)
Basal segments avg 43 0.30 ± 0.05 26 0.32 ± 0.07 -0.02 -0.06 0.02 0.23
Median segments avg 43 0.44 ± 0.14 26 0.39 ± 0.07 0.04 -0.02 0.11 0.08
Apical segments avg 43 0.55 ± 0.50 26 0.40 ± 0.11 0.14 -0.12 0.41 0.15
Global (avg of all segments) 43 0.41 ± 0.16 26 0.37 ± 0.06 0.04 -0.05 0.13 0.22
Ɨ Two-sided P values for continuous variables were calculated with the use of the t-test
 p-value Ɨ
99% CI of 
DifferenceVariable
Patients Healthy volunteers
Diff.
Mean (N)  Mean ± SD  (N)  Mean ± SD
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4.1.3. RV Strain quantification by 2D speckle tracking 
Data for the assessment RV Longitudinal Strain was obtained in 49 patients out of 61, by 
2D speckle tracking and this is summarised in Table 4.10.  The quality of tracking was 
not acceptable in 100 segments (out of the total 366 segments), which corresponds to 
27.3 % of non trackable RV strain values. 
 
Table 4.10 - Right ventricular 2-Dimensional Strain. 
 
Ɨ Two-sided P values for continuous variables were calculated with the use of the t-test. Significant 
difference between groups when p<0.01 
 
As is shown, RV longitudinal strain was universally increased in all free wall segments 
(basal, median and apical levels) when compared to healthy subjects. As it can be 
observed, the RV strain in septum had lower values, however these were not 
significantly different from those of the healthy subjects. It may be assumed that the 
interventricular dependence may influence the septum strain assessment, which should 
be analysed individually.  
 
The results for the RV Global Strain in patients with SCD, were within normal limits, 
with significant increased values when compared to healthy subjects (mean -
19.60±4.12 versus -17.52±1.86) (Fig. 4.3). There was no systematic variation in strain 
values (mean) between the different RV segments or from base to apex. 
 
Lower Upper
RV 2D Longitudinal strain (Free wall)
Basal free wall 43 -21.58 ± 7.52 22 -18.59 ± 1.33 -2.99 -6.16 0.18 0.01
Median free wall 44 -24.89 ± 8.89 22 -19.32 ± 2.85 -5.57 -9.49 -1.65 <0.001
Apical free wall 43 -24.23 ± 7.89 22 -17.82 ± 3.38 -6.41 -10.14 -2.69 <0.001
All free wall segments_avg 49 -23.54 ± 5.33 22 -18.58 ± 1.70 -4.96 -7.20 -2.73 <0.001
RV 2D Longitudinal strain (septum)
Basal septum 42 -13.76 ± 6.67 22 -15.45 ± 4.34 1.69 -2.49 5.88 0.29
Median septum 48 -17.67 ± 5.36 22 -16.45 ± 3.02 -1.21 -4.46 2.04 0.33
Apical septum 46 -15.87 ± 7.48 22 -16.86 ± 3.89 0.99 -2.67 4.66 0.47
All septum segments_avg 49 -15.85 ± 4.83 22 -16.26 ± 3.32 -2.35 -2.23 3.04 0.68
RV Global strain 49 -19.60 ± 4.12 22 -17.25 ± 1.86 -2.35 -4.23 -0.47 0.001
Patients Healthy volunteers 99% CI of 
Difference  p-value Ɨ
 (N)  Mean  (N)  Mean
Variable
± SD ± SD
Diff.
Mean
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Fig. 4.3 – Mean values of RV free wall strain (average of basal, mid and apical segments) and RV Global strain in 
patients with SCD and Healthy volunteers. 
 
4.1.4. Tricuspid regurgitant jet velocity  
 
RV systolic pressure was estimated from tricuspid regurgitation peak velocity in all 61 
patients and in 38 healthy volunteers. TRV was not detectable in 4 healthy subjects.  
In forty eight patients with SCD (78.7%), tricuspid regurgitation was graded as mild and 
in 13 patients (21.3%) was graded as trace tricuspid regurgitation. Regarding other 
valves, 9 patients (14.8%) had mild mitral regurgitation, 1 patient (1.6%) had mild 
aortic regurgitation and 4 patients (6.6%) had mild pulmonary regurgitation.  
Distribution of patients according to TRV and NYHA functional class was as follows: 
 
Table 4.11 – Distribution of TRV groups according to NYHA functional class. 
 
 
-23.54
-18.58
-19.60
-17.25
-30.00
-25.00
-20.00
-15.00
-10.00
-5.00
0.00
RV free wall_avg RV Global strain 
M
e
a
n
Patients 
Healthy volunteers
Class I
n=31
Class II
n=24
Class III
n=6 Test P-value
< 2.5 m/s 30 19 (63%) 11 (37%) 0 (0%)
>= 2.5 m/s 31 12 (39%) 13 (42%) 6 (19%)
317,5 0,018
TRV Group N
NYHA at screening Mann-Whitney U test
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Fig. 4.4 - Distribution of TRV groups according to NYHA functional class.  
 
TRV was higher in patients with SCD (mean 2.54±0.30 m/s; range 2.01-3.30 m/s) 
compared with healthy subjects (mean 1.96±0.23 m/s; p <0.001) and increased TRV (≥ 
2.5 m/sec) was present in 31 patients (51%) compared to 2 (5%) healthy volunteers. 
Five subjects with SCD (16%) had TRV ≥ 3.0 m/s as is detailed in Fig. 4.5. 
 
 
Fig. 4.5 – Detailed distribution by TRV group in patients with SCD. 
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4.1.5. Cardiac Magnetic Resonance  
 
From the 18 patients from Group A2 (LV diastolic dysfunction), only 11 patients had a 
CMR for further analysis regarding myocardial fibroses early diagnosis of iron overload. 
The reasons for not performing the CMR were: claustrophobia (2), failure to commit 
with appointment(3) and unstable on the day of the appointment (2). Therefore, results 
of comparison between 2DSTE and tagging MRI for quantification of LV circumferential 
strain by tagged CSPAMM images were available in 10 patients, since 1 patients 
requested an early termination during the MRI (Table 4.12). 
 
Table 4.12 – Cardiac Magnetic Resonance characterization in patients with LV diastolic dysfunction. 
 
The time required for 2DSTE acquisition and analysis of all studied LV parameters was 
generally 10 minutes, whereas acquisition and analysis by MRI required approximately 
15 to 20 min for LV volumes and EF, and at least 45 minutes for circumferential strain. 
No agreement was found between since the number of patients in these groups is very 
25 75
LV and RV Structure
LV end diastolic volume (ml) 11 179.27 ± 63.82 114.00 329.00 129.00 223.00
LV end systolic volume (ml) 11 66.00 ± 37.59 37.00 159.00 42.00 86.00
LV ejection fraction (%) 11 64.45 ± 8.77 47.00 75.00 61.00 71.00
LV mass (gr) 10 137.70 ± 34.13 93.00 194.00 108.00 163.25
Iron (ms) 7 37.57 ± 8.70 31.00 56.00 32.00 39.00
RV end diastolic volume (ml) 10 159.50 ± 42.70 114.00 230.00 116.75 194.75
RV end systolic volume (ml) 10 72.00 ± 26.93 43.00 123.00 49.50 88.50
RV ejection fraction (%) 10 60.50 ± 7.21 49.00 72.00 56.25 66.75
RV mass (gr) 10 40.90 ± 14.47 19.00 68.00 27.50 50.25
Midwall Circunferencial Strain (%)
Anterior Segment 10 -22.53 ± 3.20 -25.36 -16.03 -24.92 -19.29
Antero-septal segment 10 -20.81 ± 2.68 -22.96 -14.53 -22.81 -19.04
Infero-septal segment 10 -17.81 ± 3.63 -21.27 -9.06 -20.02 -15.71
Inferior segment 10 -16.51 ± 3.74 -20.90 -7.37 -18.53 -15.40
Infero-lateral segment 10 -20.89 ± 2.33 -24.67 -17.70 -23.03 -19.41
Antero-lateral segment 10 -24.50 ± 2.47 -29.97 -20.98 -25.91 -22.90
Strain_Average 10 -20.50 2.38 -22.55 -14.33 -21.95 -20.18
Transmural Circumferential Strain (5)
Anterior Segment 10 -21.77 ± 2.72 -24.75 -16.38 -23.96 -19.51
Antero-septal segment 10 -20.06 ± 2.32 -22.50 -14.74 -21.75 -18.92
Infero-septal segment 10 -17.54 ± 3.52 -21.49 -9.05 -19.71 -15.87
Inferior segment 10 -16.11 ± 3.95 -20.59 -6.81 -18.79 -13.77
Infero-lateral segment 10 -18.95 ± 2.04 -21.64 -15.74 -21.19 -17.00
Antero-lateral segment 10 -22.71 ± 2.09 -26.86 -18.81 -23.71 -21.99
Strain_Average 10 -19.52 2.15 -21.62 -13.89 -20.31 -19.52
Cardiac magnetic resonanse N Mean ± SD Min Max
Percentiles
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small, no attempt was made to compare the parameters obtained with different 
methods. None of the patients had signs of myocardial fibroses or iron overload (mean 
37.6, range 31-56 ms). 
 
4.2. Distribution of Clinical and Echocardiography Variables 
According to TRV Groups  
 
Sickle cell disease genotype (p=0.83) and clinical conditions (i.e. Alcohol History, 
Smoking history Total Number of Transfusion In Lifetime, Leg ulcers, Vaso occlusive 
pain episodes Lung Problems Acute Chest Syndrome and Spleen Problems) were not 
statistically significant different between TRV groups (Table 4.13) . Although the level of 
statistical significance in this study was 1%, there was a tendency to an association of 
increased TRV with the presence of leg ulcers (p=0.03), smoking history (p=0.02) and 
lung problems (p=0.03).  
 
Table 4.13 - Clinical conditions in patients with SCD according to TRV groups  
 
  
Clinical 
conditions 
Alcohol History 30 28,58 31 33,34 0,24
Total Number of Transfusion In Lifetime 30 27,50 31 34,39 0,11
Leg ulcers 30 26,50 30 34,50 0,03
Vaso occlusive pain episodes 28 27,00 28 30,00 0,32
Smoking history 30 26,40 31 35,45 0,02
Lung Problems 30 27,33 31 34,55 0,03
Spleen Problems 30 27,63 31 34,26 0,08
Lung  Pneumonia/Acute Chest Syndrome 30 30,32 31 31,66 0,72
TRV < 2.5 m/s TRV ≥ 2.5 m/s
 p -value
Mann-Whitney (N) Mean Rank  (N) Mean Rank
Variable
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In patients with TRV of 2.5 m/s or more, LV structure, chamber size, LV ejection fraction 
and LA volume, did not differ from patients with TRV < 2.5 m/s (Appendix VII). LV 
Global function index lateral that evaluates both systole and diastole function, was 
significantly reduced in patients with increased TRV (mean 0.86±0.21 versus mean 
1.10±0.36) (Table 4.12). This may be explained by decreased DTI velocities at lateral 
level. 
 
Furthermore, RV structure and RA volume did not differ between TRV groups as well.   
 Although there was a trend towards RV and RA enlargement with increasing estimated 
pulmonary pressures, RV systolic function was preserved at higher pressures, 
suggesting no evidence of resting RV functional impairment (Table 4.14) .  No 
differences were found between TRV groups regarding LV and RV strain and strain rate 
data (Appendix VII). 
 
Table 4.14 - Cardiac structure and function in patients with SCD according to TRV groups 
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Additional analysis was performed to asses LV diastolic function in both TRV groups. In 
the group of patients with TRV≥ 2.5 m/s, 17 (55%) patients had normal LV diastolic 
function and 14 patients (45%) had abnormal LV diastolic function. Distribution of 
patients is summarised in Fig. 4.6. 
 
Lower Upper
LV Structure
LV septum diameter (mm) 28 9.54 ± 1.37 29 10.29 ± 1.34 -0.74 -1.44 -0.05 0.04
LV posterior wall diameter (mm) 29 9.80 ± 1.57 29 10.34 ± 1.65 -0.54 -1.37 0.28 0.19
LV 2D diastolic volume indexed (ml/m2) 26 72.30 ± 17.24 27 75.73 ± 25.62 -3.44 -14.66 7.79 0.54
LV 2D systolic volume indexed (ml/m2) 29 27.10 ± 9.77 30 25.42 ± 11.37 1.68 -3.76 7.12 0.54
LV mass index (g/m2) 29 86.34 ± 20.76 29 95.39 ± 35.54 -9.05 -25.36 7.26 0.27
RV structure
RV diastolic area apical view (cm2) 30 19.97 ± 5.21 31 22.09 ± 5.88 -2.12 -4.97 0.73 0.14
RV systolic area apical view (cm2) 30 11.35 ± 3.22 31 12.36 ± 3.20 -1.01 -2.66 0.63 0.22
3D RV end diastolic volume (ml) 29 99.56 ± 23.39 29 120.31 ± 39.15 -20.74 -37.71 -3.78 0.02
3D RV end systolic volume (ml) 29 44.16 ± 14.94 29 55.23 ± 18.46 -11.08 -19.91 -2.24 0.015
LA/RA structure
Left atrium volume indexed (ml/m2) 30 41.08 ± 12,46 30 47.48 ± 17,13 -6.40 -16.69 3.91 0.10
RA volume indexed (ml/m2) 28 37.99 ± 10.12 29 37.80 ± 13.44 0.20 -6.14 6.53 0.95
LV systolic function
Global function index lateral 30 0.86 ± 0.21 30 1.10 ± 0.36 -0.24 -0.39 -0.09 0.003
Global function index septal 27 1.12 ± 0.27 25 1.30 ± 0.35 -0.17 -0.34 -0.01 0.04
LV 2D Ejection Fraction (%) 30 64.34 ± 6.93 31 67.94 ± 7.20 -3.60 -7.22 0.02 0.05
LV 2D cardiac output (L/min) 28 5.85 ± 1.70 29 6.84 ± 2.24 -0.98 -2.00 0.04 0.06
LV 2D stroke volume (mL) 29 77.40 ± 18.75 29 89.05 ± 27.85 -11.65 -24.00 0.71 0.06
LV S´ wave lateral (cm/s) 30 9.95 ± 1.92 30 8.93 ± 2.55 1.02 -0.16 2.19 0.09
LV S' wave septal (cm/s) 29 8.31 ± 1.24 25 8.25 ± 0.91 0.06 -0.50 0.62 0.84
RV systolic function
Estimated PVR (Woods unit) 27 1.44 ± 0.35 25 1.67 ± 0.25 -0.23 -0.40 -0.06 0.010
RV MPI by TDI 28 0.34 ± 0.09 29 0.34 ± 0.12 0.00 -0.05 0.06 0.92
RV S´wave (cm/s) 30 14.10 ± 1.99 31 15.50 ± 3.12 -1.41 -2.75 -0.06 0.04
TAPSE (mm) 30 28.03 ± 5.12 30 30.37 ± 5.88 -2.33 -5.18 0.51 0.11
RV fractional area change (%) 30 43.08 ± 9.60 31 43.33 ± 7.92 -0.25 -4.75 4.26 0.91
3D RV Ejection fraction (%) 29 56.15 ± 7.66 29 53.65 ± 6.55 2.50 -1.25 6.25 0.19
 (N)  Mean ±
Variable
TRV < 2.5 m/s TRV ≥ 2.5 m/s
Diff.
Mean
99% CI
of Difference  p-value Ɨ
SD  (N)  Mean ± SD
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Fig. 4.6 – Detailed distribution by TRV group in patients with SCD. 
 
Further analysis was carried out to assess the estimated LV diastolic filling pressures 
with the use of LV E/E´ lateral wall, LV E/E´septal and LV E/E´average (mean value from 
basal septal and lateral walls). All of these LV parameters were significantly increased 
among TRV groups which therefore seemsto show an association between increased 
pulmonary pressures with LV diastolic dysfunction. Results are detailed in Table 4.15. 
 
 
 
 
 
 
 
 
Table 4.15 - Left and right ventricular diastolic assessment in patients with SCD according to TRV groups 
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ƗTwo-sided P values for continuous variables were calculated with the use of the t-test or spearman correlation 
according to variable distribution. Significant difference between groups when p<0.01 
 
 
4.3. Distribution of Clinical and Echocardiography Variables 
According to LV Diastolic function Groups  
 
The prevalence of LV diastolic dysfunction was 29.5% corresponding to 18 patients. As 
expected, age was significantly different between Group A1 and Group A2, with an 
increased mean age value in the Group A2. Global function index lateral, TRV and 
estimated PVR by echocardiography were all increased in LV diastolic dysfunction 
patients. Detailed data can be seen in Table 4.16.  
  
Lower Upper
LV diastolic function
LV E wave (cm/s) 30 86.46 ± 15.04 31 90.53 ± 14.06 -4.07 -13.99 5.85 0.28
LV E/A ratio 29 1.72 ± 0.55 31 1.35 ± 0.45 0.37 0.02 0.71 0.006
MV decelaration time (ms) 29 194.79 ± 39.59 31 207.61 ± 37.88 -12.82 -39.46 13.82 0.21
LV Isovolumic relaxation time (ms) 26 92.53 ± 15.38 29 97.21 ± 18.38 -4.68 -16.97 7.61 0.31
PV a wave duration (ms) 19 114.79 ± 23.70 19 112.42 ± 15.69 2.37 -15.37 20.10 0.72
PV a wave reversal (cm/s) 21 22.10 ± 4.12 24 25.21 ± 6.97 -3.11 -7.80 1.57 0.08
Duration a wave LV 18 117.06 ± 34.34 27 118.77 ± 15.84 -1.71 -22.10 18.68 0.82
LV E ´  lateral wall 29 12.70 ± 2.77 31 10.80 ± 2.72 1.90 0.01 3.79 0.01
LV E/E' lateral 29 7.03 ± 1.69 31 8.90 ± 2.57 -1.87 -3.37 -0.36 0.002
MV E´ septal (cm/s) 29 9.65 ± 1.87 31 8.90 ± 1.98 0.75 -0.57 2.08 0.14
LV E/E´septal 29 9.13 ± 1.77 31 10.48 ± 2.06 -1.36 -2.68 -0.03 0.008
LV E/E´avg 29 8.08 ± 1.51 30 9.71 ± 2.10 -1.63 -2.90 -0.35 0.001
RV diastolic function
RV E wave (cm/s) 28 47.93 ± 10.93 27 46.79 ± 10.21 1.15 -4.58 6.87 0.69
RV E/A 24 1.70 ± 0.43 23 1.34 ± 0.38 0.36 0.11 0.60 0.005
RV E´wave (cm/s) 29 11.98 ± 3.46 31 12.29 ± 3.50 -0.31 -2.11 1.49 0.73
RV E´/A´ 27 1.27 ± 0.49 28 0.98 ± 0.36 0.29 0.06 0.52 0.01
RV E/E´ 28 4.30 ± 1.68 27 4.16 ± 1.77 0.15 -0.78 1.08 0.75
RV isovolumic relaxation time (ms) 25 50.68 ± 26.92 21 71.67 ± 42.20 -20.99 -41.69 -0.28 0.05
Variable  p-value Ɨ
 (N)  Mean ± SD  (N)  Mean
TRV < 2.5 m/s
± SD
TRV ≥ 2.5 m/s
Diff.
Mean
99% CI
of Difference
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Table 4.16 - Cardiac structure and function in patients with SCD according to LV diastolic function 
 
 
4.4. Associations between measures of LV diastolic function with Left 
Ventricular Structure and Function 
 
Body mass index, LV mass index and diastolic blood pressures were strongly associated 
with increased LV volumes, both systolic and diastolic. A positive correlation was found 
between LV end diastolic volume and TRV, supporting previous findings. In addition, a 
negative relationship was found between haemoglobin and LV end-diastolic volume 
(p<0.001, r=0.51) (Fig. 4.7). 
 Demographics 
Age(years) 43 36.70 10.82 18 50.12 8.42 <0,001
Height (cm) 43 168.64 9.72 18 169.24 10.51 0.838
Weight (kg) 43 67.77 9.31 18 73.34 13.74 0.149
 Body surface area (kg/m^2) 43 1.78 0.15 18 1.85 0.22 0.141
 Body Mass Index (kg/m^2) 43 23.92 3.51 18 25.51 3.79 0.134
Heart rate (bpm) 43 74.96 9.52 18 78.88 11.32 0.183
Oxygen saturation on air (%) 43 97.20 3.76 18 97.19 2.46 0.990
Systolic BP (mmHg) 43 118.36 11.17 18 122.75 20.58 0.427
Diastolic BP  (mmHg) 43 69.69 9.58 18 73.75 12.04 0.179
LV  and RV Structure
LV septum diameter (mm) 43 9.98 1.39 18 9.75 1.46 0.572
LV posterior wall diameter (mm) 43 10.08 1.67 18 10.11 1.54 0.953
LV 2D diastolic volume indexed (ml/m2) 43 75.11 23.48 18 71.05 16.41 0.527
LV 2D systolic volume indexed (ml/m2) 43 27.02 11.22 18 24.06 8.36 0.339
LV 2D mass index (g/m2) 43 93.41 31.52 18 83.32 21.02 0.304
RV structure
RV 2D diastolic area apical view (cm2) 43 21.03 5.98 18 21.08 4.62 0.976
RV 2D systolic area apical view (cm2) 43 12.02 3.35 18 11.42 2.92 0.529
RV 3D end diastolic volume (ml) 43 112.64 35.64 18 101.42 25.59 0.281
RV 3D end systolic volume (ml) 43 51.03 18.80 18 45.52 12.53 0.311
LA/RA structure
Left atrium volume indexed (ml/m2) 43 44.15 17.11 18 44.66 8.31 0.910
RA volume indexed (ml/m2) 43 38.20 12.12 18 37.03 11.28 0.746
LV and RV systolic function
Global function index lateral 43 0.87 0.23 18 1.28 0.34 <0,001
Global function index septal 43 1.15 0.32 18 1.39 0.27 0.010
LV 3D ejection fraction (%) 32 51.38 5.16 11 50.84 4.51 0.759
LV S´ wave lateral (cm/s) 43 9.62 2.50 18 8.88 1.59 0.270
LV S' wave septal (cm/s) 43 8.35 1.18 18 8.07 0.71 0.362
RV systolic function
Estimated PASP (mmHg) 43 30.61 6.72 18 35.28 5.98 0.017
TRV screening (m/s) 43 2.46 0.28 18 2.72 0.27 0.002
Estimated PVR (Woods unit) 43 1.47 0.29 18 1.79 0.30 0.002
RV MPI by TDI 43 0.32 0.11 18 0.38 0.10 0.073
RV S´wave (cm/s) 43 14.53 2.36 18 15.60 3.44 0.174
TAPSE (mm) 43 28.84 5.99 18 30.27 4.13 0.398
RV fractional area change (%) 43 42.34 8.82 18 45.66 8.20 0.193
RV 3D Ejection fraction (%) 43 54.95 7.39 18 54.74 6.72 0.924
Variable
Group A1 (normal LV 
diastolic function)
Group A2 (abnormal LV 
diastolic function)  p-value Ɨ
SD SD Mean (N)  Mean ±±  (N)
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Fig. 4.7 - Relationship between LV end diastolic volume by 2D echocardiography and haemoglobin (p=<0.001; 
r= -0.51) (top) and red blood count (p=<0.001; r =-0.58) (bottom) 
 
In a univariate analysis (spearman correlation), LV E/E´ lateral ratio was strongly 
correlated with age (r= 0.41, p=0.001). In addition, there was a negative correlation 
with platelet count (r= -0.33, p= 0.009) and no association with haemolysis markers.  
There was a tendency towards a positive relationship with proBNP (r= 0.29, p=0.02) 
which has been associated with increase pressures in the pulmonary arteries. 
Supporting this finding, a significant relationship was obtained between  LV E/E´lateral, 
LV E/E´septal, LV E/E´average with TRV (r=0.39, p= 0.002 ; r= 0.35 , p <0.001 ; r= 0.43 , 
p = 0.007). A comparison between patients with or without clinical features (i.e. 
smoking and alcohol history, transfusions in lifetime, leg ulcer, vaso-occlusive episodes, 
lung problems and spleen problems) did not show significant differences between LV 
diastolic dysfunction parameters, in terms of patients demographics. There was also no 
association of LV E/E´ratio parameters with LV Strain and Strain rate data. 
 
4.5. Risk Factors for increase TRV 
 
Older age was strongly associated with a TRV ≥ 2.5 m/s (r =0.35; p = 0.005). Mean age 
was significantly higher in patients with increased TRV compared to TRV< 2.5 m/s 
(35.91±10.95 vs. 44.38±11.16, p<0.01). As expected, TRV was strongly associated with 
PVR (r=0.44, p< 0.001) and RV end diastolic (r= 0.43; p= 0.001) and end systolic 
volumes (r=0.39; p= 0.003) (Table 4.16).  Associations of TRV with laboratory tests and 
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echocardiographic parameters have been explored (Appendix IX). No significant 
association was found with markers of haemolysis (haemoglobin, lactate 
dehydrogenase, reticulocytes and total bilirubin). No association was found with BNP 
(p=0.12). LV systolic function did not correlate significantly with Tricuspid 
Regurgitation (p=0.1), however there was a tendency for an association with the global 
function index lateral (r= 0.31; p = 0.017).  Moreover, none of the LV and RV myocardial 
deformation parameters, strain and strain rate, were significantly associated with TRV.  
 
Increased pulmonary pressures have been described extensively in SCD, however its 
severity is commonly mild and the contribution of LV systolic or diastolic dysfunction 
remains controversial. 
  
As mentioned earlier, significant differences were found between TRV groups regarding 
LV diastolic function parameters.  Conventional Doppler-derived measurements of LV 
diastolic filling (i.e., mitral E, E/A, MV DT, and IVRT) were not correlated with TRV 
velocity. However, mitral E/E´lat and LV E/E´ (average) ratios (Fig. 4.8) were correlated 
moderately with TRJ velocity which may represent an association increase in LV filling 
pressures. 
 
 
Fig. 4.8 - Positive linear correlation between tricuspid regurgitation velocity and left ventricular E/E´ lateral (r=0.63; 
p= 0.005) and LV E/E´average (r= 0.38; p=0.0038) 
 
Associations with Chi-Square non parametric test, between LV diastolic function groups 
(with and without dysfunction) and the TRV groups, has shown that patients who have 
LV diastolic dysfunction also tend to have increased pulmonary pressures. A strong 
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association was found in 14 (77.8%) of the subjects with LV DD (n=18) which had a TRV 
≥ 2.5 m/s (p= 0.006).  
Furthermore, a patient with LV DD had 5.35 times more risk of developing pulmonary 
hypertension (OR=5.35 ; 95%CI 1.5 – 19.02). 
 
Table 4.17 - Significant associations with TRV, Pearson Rank Correlation Coefficient 
 
 
4.5.1. Predictors of Increased tricuspid regurgitant jet velocity 
 
In the logistic regression, LV E/E´ average (p= 0.007) was the only variable that 
contributed significantly to the model to identify predictors of an association with 
increased TRV (≥ 2.5 m/s). The chances of developing increased pulmonary pressures 
(TRV> 2.5 m/s) is 2.2 for each unit of LV E/E´.  In other words, the chances of having 
TRV ≥ 2.5 m/s increases 120% for each unit of LV E/E´average. 
 
Table 4.18 - Independent predictor of TRV ≥2.5 m/s 
 
 
 
 
Pearson Correlation  
(r )
P-value
Right ventricle E/A 47 -0.40 0.006
Pulmonary vascular resistance (Woods unit) 52 0.50 <0,001
RV base diameter (cm) 59 0.36 0.006
3D RV end diastolic volume 58 0.43 0.001
3D RV end systolic volume 58 0.39 0.003
Tricuspid annular systolic motion (mm) 60 0.38 0.003
Left ventricle E/E' lateral 60 0.36 0.005
Left ventricle  E/E´avg 59 0.38 0.003
LV 2D end-diastolic diameter (mm) 61 0.37 0.003
Variable N
Tricuspid regurgitant jet velocity (m/s)
B 0.788 -6.34
S.E. 0.29 2.414
Wald 7.403 6.895
df 1 1
p-value 0.007 0.009
Exp(B) 2.2 0.002
95% C.I.for EXP(B)
Lower 1.247
Upper 3.881
C o nstant
LV E/ E´avg
Variable in the equatio n
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Table 4.19 - Variables not in the equation of the model 
 
 
 
Fig. 4.9 - Predictive effect of LV E/E´ ratio average into TRV≥ 2.5 m/s 
Variables no t  in the equatio n Sco re df P -value
Age .889 1 .346
LV E/E' lateral .540 1 .462
Left atrium vo lume indexed (ml/m2) 3.027 1 .082
Duration a wave LV .878 1 .349
LV E ´  lateral wall .169 1 .681
LV E wave (cm/s) .021 1 .884
LV E/A ratio 1.662 1 .197
LV E/E´septal .597 1 .440
LV Isovolumic relaxation time (ms) .148 1 .701
M V E´ septal (cm/s) .290 1 .590
M V decelaration time (ms) .370 1 .543
Overall Statistics 10.496 11 .486
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Fig. 4.10 – Receiving operator curve for the LV average E/E´ for predicting a TRV≥ 2.5 m/s. 
 
The area under the ROC curve for the E/E´ average ratio predicting a TRV≥ 2.5 m/s was 
0.7 (95% CI 1.24 – 3.88, P=0.007). An E/E´average ratio > 7 was the optimal cut off, with 
a sensitivity of 70.8% and a specificity of 64.7%. 
 
4.6. Associations with increasing LV lateral E/E´ ratio 
 
In the univariate and multivariate analysis, 22 independent variables were included in 
the model for the multiple linear regression analysis which was used to ascertain the 
most useful independent predictor of elevated LV filling pressures. This model 
identified 4 echocardiographic variables which determine increasing LV lateral E/E´ 
ratio. Global function index lateral (p=0.000), haemoglobin (p=0.000), global function 
index septal (p=0.006) and left atrium volume indexed (p=0.035) were each 
independently associated with a higher LV lateral E/E´ratio. These model explains 92% 
of the increase of LV E/E´lateral (R2=0.92). Table 4.20 summarizes this analysis.  
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Table 4.20 - Independent preditors of Left ventricular lateral wall E/E' ration in Multiple Linear Regression 
analysis (n=34) 
 
 
4.7. Prospective serial study  
 
The mean duration of follow up was 17.13±3 months with a range of 10-23 months. No 
significant change in the usage of hydroxyurea or participation in a chronic transfusion 
program was found. The prevalence of elevated tricuspid regurgitation velocity at 
follow-up was 45% compared to 51% at baseline.  
 
4.7.2. Changes from baseline to follow-up results 
 
In our 5 year survival retrospective published cross-sectional analysis, we observed 
that TRV was associated with the risk of death by more than four-fold. 
 
In the present study, we evaluated how baseline screening observations change at 
follow-up. The same echocardiographic protocol was repeated. All 61 patients at 
baseline had measurable TRV at follow-up.  
 
The difference in values between the screening and follow-up time points was analysd. 
The choice of statistical method was dependent on the nature of the variable being 
compared. 
 
The analysis results are summarised in Table 4.19. The figures presented are the 
number of patients in the analysis, along with the mean and standard deviation at each 
time point. The mean change over time is also presented, along with a corresponding 
confidence interval.  Due to the large number of variables, Table 4.21 includes only 
Variables Beta 95% CI P -value R² ANOVA F P- value
Global function index 
lateral
1.063 (6.74 to 8.74) 0.000
Haemoglobin(g/dl) -0.28 (-0.54 to -0.20) 0.000
Global function index 
septal
-0.207 (-2.33 to -0.43) 0.006
Left atrium volume 
indexed (ml/m2)
-0.14 (-0.03 to -0.001) 0.035
0.917
(4. 29) 
91.887
0.000
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variables with a significant change between the two time points. Complete data is 
presented inthe Appendix section. 
 
Table 4.21 - Difference in mean values between the screening and follow-up time points 
 
 
Left ventricular function, analysed by 2D and 3D Ejection fraction, has decreased at 
follow up (p=0.003 and p=0.001 respectively).  In respect to myocardial deformation, all 
global values (Area Strain, longitudinal and radial strain) decrease at follow-up. 
Although not significant, there was also a tendency for change in the mean value of LV 
Circumferential Strain (p=0.02).  
 
Screening Follow-up Change
Mean (SD) Mean (SD) Mean (99% CI)
Right ventricle
RV end diastolic volume 3D 55 110 (34) 118 (41) 8 (4, 12) <0.001
RV end systolic volume 3D 55 49.3 (17.9) 53.0 (2.9) 3.7 (1.8, 5.7) <0.001
RV Global strain (average of 6 segments) 54 -16.3 (8.6) -20.8 (4.1) -4.6 (-8.1, -1.0)  0.001
 RV longitudinal strain basal septum 46 -10.8 (8.3) -17.5 (6.8) -6.7 (-11.0, -2.3) <0.001
RV longitudinal strain median septum 54 -14.5 (8.3) -18.8 (5.7) -4.3 (-8.3, -0.4)  0.005
Left ventricle
Inter ventricular septum diameter (mm) 61 9.9 (1.4) 10.5 (1.3) 0.6 (0.2, 1.0) <0.001
LV 2D end-diastolic diameter (mm) 61 50.9 (6.7) 49.4 (7.0) -1.4 (-2.4, -0.4) <0.001
Ejection Fraction by 2D (%) 60 66.3 (7.2) 63.4 (5.8) -2.9 (-5.5, -0.4)  0.003
LV 3D ejection fraction (%) 41 51.3 (5.1) 48.5 (5.3) -2.7 (-4.9, -0.6)  0.001
LV 3D Strain
LV 3DST median segments average 41 -34.1 (5.0) -31.7 (5.1) 2.4 (0.5, 4.4)  0.002
LV 3DST global average of all segments 41 -32.4 (3.9) -30.5 (4.5) 1.9 (0.2, 3.6)  0.003
LV longitudinal strain median segments average 41 -18.6 (3.5) -16.5 (2.5) 2.1 (0.7, 3.6) <0.001
LV longitudinal strain global average of all segments 41 -18.1 (2.9) -16.5 (2.2) 1.6 (0.4, 2.8) <0.001
LV radial strain median segments average 39 74.9 (17.8) 64.0 (12.3) -10.8 (-17.9, -3.8) <0.001
LV radial strain apical segments average 40 83.1 (32.1) 63.9 (17.4) -19.2 (-33.4, -5.0) <0.001
LV radial strain global average of all segments 41 69.7 (15.9) 58.9 (10.1) -10.7 (-16.4, -5.1) <0.001
LV longitudinal strain rate global 41 -0.10 (0.01) -0.10 (0.01) 0.01 (0.00, 0.02)  0.006
LV Diastolic function
LV E/E' lateral 58 8.0 (2.4) 8.9 (2.7) 0.9 (0.1, 1.7)  0.005
LV E ´  lateral wall 58 11.7 (2.9) 10.6 (3.3) -1.2 (-1.9, -0.4) <0.001
LV E/A ratio 60 1.53 (0.53) 1.38 (0.45) -0.15 (-0.30, -0.01)   0.007
MV decelaration time 60 201 (39) 217 (37) 16 (1, 31)  0.006
Blood tests
Aspartate aminotransferase (u/l) 55 41 (23) 52 (26) 11 (3, 18) <0.001
Platelet count (x10^3 cells/ul) 58 333 (173) 291 (127) -42 (-79, -5)  0.003
Demographics
Systolic blood pressue 60 118.8 (14.3) 123.2 (16.3) 4.3 (0.5, 8.6)  0.009
Variables N P -value
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Right ventricular volumes were significantly increased at follow-up (p<0.001) while RV 
Free wall Strain, besides normal values, has significantly decreased (p=0.001).   
 
4.7.3. Increase in tricuspid regurgitation velocity during follow up 
 
Four patients (6.6%) with a baseline tricuspid regurgitation velocity of less than 2.50 
m/sec had a follow-up elevation (TRV≥ 2.5 m/sec).  Seven patients (11.5%) who had at 
the baseline, a TRV≥2.5 m/s, reduced to < 2.5 m/s at follow-up (Table 4.22). 
 
Table 4.22 - Tricuspid regurgitant velocity change at follow-up 
 
The mean (SD) follow-up tricuspid regurgitation velocity was 2.54 (±0.30) m/sec and 
was not significantly different when compared to the mean TRV at baseline of 2.54±30 
(p=0.39). Further analysis was performed to evaluate changes between TRV groups at 
the 2 time points. However no significant changes were found.  
 
4.7.4. Predictor of increased LV lateral E/E´at follow-up 
 
At follow-up, 24 patients had LV Diastolic dysfunction, from where 15 patients on Grade 
I (24.6%) and 9 patients in Grade 9 (14.8%).  Analysis was done for the change in LV 
diastolic dysfunction and NYHA class at follow-up. Eight patients had worsened LV DD 
class at follow-up, corresponding to 9.8% of the study subjects (p=0.002). Nine patients 
worsened in the NHYA functional class (p<0.001) (Table 4.23). 
 
Frequency Percent
Regular (kept TRV <2.5 m/s) 26 42.60%
Stable (kept TRV >=2.5 m/s) 24 39.3%
worsened (increased TRV >=2.5 m/s) 4 6.6%
Improved (decreased TRV <2.5 m/s) 7 11.5%
N= 61 100%
TRV change screening to follow-up
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Fig. 4.11 – LV diastolic dysfunction grade and mean LV lateral and average E/E´ratios from screening to follow-
up. 
 
Table 4.23 - Change in NYHA class from screening to follow-up 
 
 
In a univariate and multivariate analysis, 22 independent variables were included in the 
model for the multiple linear regression analysis which was used to ascertain the most 
useful independent predictor of elevated LV filling pressures at follow-up. This model 
identified only 2 echocardiographic variables which determine increasing LV lateral 
E/E´ ratio. Global function index lateral (p<0.001) (already a predictor at baseline) and 
blood urea nitrogen (mmol/L) which was new finding comparing to baseline model, 
both were independently associated with a higher LV lateral E/E´ratio. This model 
explains 73.7% of the increase of LV E/E´lateral (R2=0.74). Table 4.24 summarises this 
analysis.  
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Table 4.24 - Independent predictors of Left ventricular lateral wall E/E' ratio in Multiple Linear Regression 
analysis (n=34) 
 
 
4.7.5. Change in LV diastolic function Grade  
 
The change in LV diastolic dysfunction grade was measured according to the LV E/E’ 
lateral ratio. The analysis was performed using linear regression and a normal 
distribution was found. Subsequently, univariate analysis was performed between each 
factor and the outcome.  
 
Initially the separate association between each factor and the outcome was examined in 
a series of univariate analyses, and the results are summarised in the table 4.25. The 
figures presented are the regression coefficients, along with their corresponding 
confidence intervals. For predictor variables measured on a categorical scale, the 
coefficients represent the difference in the outcome between categories. For predictor 
variables measured on a continuous scale, the coefficients represent how the outcome 
varies for a one-unit increase in the predictor variable, unless otherwise indicated. 
Effects for other sized increases are reported where one-unit was either a very small or 
large change in the predictor variable. P-values indicating the significance of the results 
are also present. 
 
 
 
 
 
 
 
 
 
Variables N Beta 95% CI P -value R² ANOVA F P- value
Global function index lateral 34 0.64 (4.23 to 6.83) p<0.001
Blood urea nitrogen (mmol/L) 34 0.12 (0.06 to 0.54) 0.017
0.74 (2.31) 47.18 p<0.001
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Table 4.25 - Multivariate analysis for the association with change in Diastolic function 
 
 
 
The results suggested that initial LV E/E’ lat value was strongly associated with the 
change in diastolic dysfunction.  
The regression results and the graph above suggest that patients with higher blood urea 
values had a greater change in LV E/E’ lat. A 1 mmol/l increase in urea was associated 
with the change in LV E/E’ lat increasing by 0.4 units. 
 
Variable Coefficient (95% CI) P-value
E/E Lat (screening) -0.33 (-0.57, -0.10) 0.007
Age (***) 0.38 (-0.13, 0.88) 0.14
Male gender -0.75 (-1.96, 0.46) 0.22
BMI (**) 0.01 (-0.83, 0.84) 0.99
Systolic blood pressure (***) 0.37 (-0.05, 0.79) 0.08
Hydorxyurea (currently use) 1.06 (-0.33, 2.45) 0.13
Bun blood urea nitrogen (mmol/l) 0.43 (0.11, 0.75) 0.009
Hematocrit (*) -0.24 (-1.56, 1.07) 0.71
Haemoglobin -0.10 (-0.45, 0.26) 0.59
Creatinine (***) 0.13 (-0.09, 0.34) 0.24
Right atrium volume indexed 
(ml/m2) (***)
0.11 (-0.43, 0.64) 0.69
Left atrium volume indexed (ml/m2) 
(***)
0.12 (-0.29, 0.53) 0.88
Right ventricle  end diastolic 
volume (***)
-0.14 (-0.33, 0.05) 0.14
Right ventricle ejection fraction (**) -0.27 (-0.69, 0.15) 0.2
Left ventricle end diastolic volume 
(ml) (***)
-0.08 (-0.27, 0.10) 0.36
 LV 3D ejection fraction (%) (**) 0.59 (0.15, 1.02) 0.009
LV mass index  (***) 0.04 (-0.20, 0.28) 0.76
6-minute walk test (****) -0.21 (-0.61, 0.19) 0.3
(*)      Coefficients reported for a 0.1-unit increase in predictor variable
(**)    Coefficients reported for a 5-unit increase in predictor variable
(***)  Coefficients reported for a 10-unit increase in predictor variable
(****) Coefficients reported for a 50-unit increase in predictor variable
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Fig. 4.12 - Regression line for the association between LV E/E´lateral and Blood urea nitrogen (mmo/L).  
 
A third and final statistically significant result was for LV 3D ejection fraction. Here 
there was also a positive relationship with the change in LV E/E’ lat. This suggests that 
patients with a higher ejection fraction had a greater change in scores. The data also 
providded some evidence that systolic blood pressure was also associated with the 
change in diastolic dysfunction. However, the result for these variables was not quite 
statistically significant.  
 
The second part of the analysis examined the joint effect of the variables in a 
multivariable analysis. A backwards selection procedure was used to retain only the 
statistically significant variables, and the final model is summarised in the Table 4.26. 
 
Table 4.26 - Multiple regression for identifying independent predictors of change in LV diastolic function 
grade 
 
 
The results of the selection procedure indicated that, as in the univariate analyses, all of 
LV E/E’ lat at screening, blood urea and LV 3D ejection fraction were statistically 
significant. In addition, age was also found to besignificant. This was not significant in 
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Bun blood urea nitrogen (mmol/l)
Variable Coefficient (95% CI) P-value
E/E Lat (screening) -0.54 (-0.75, -0.33) <0.001
Age 0.47 (0.02, 0.92) 0.04
Bun blood urea nitrogen (mmol/l) 0.46 (0.19, 0.72) 0.001
LV 3D ejection fraction (%) (**) 0.60 (0.25, 0.95) 0.001
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the univariate analyses, but after adjusting for the other variables in the final model, this 
variable was now statistically significant. 
 
LV E/E’ lat at screening was negatively correlated with the change in LV E/E’ lat, with a 
one-unit increase in LV E/E’ lat at baseline was associated with a change that was 0.47 
units lower. Age, blood urea and LV 3D EF were all positively associated with the change 
in LV E/E’ lat. A 5% increase in ejection fraction was associated with a 0.6 unit increase 
in the change in LV E/E’ lat. 
 
After adjusting for the effects of these four variables, no further variables were found to 
be statistically significant. 
 
4.7.6. Change in TRV Groups  
 
An examination of the change in tricuspid regurgitant velocity from screening to follow 
up was performed. The results are provided on figure 3. Subsequently, univariate 
analysis was performed in order to demonstrate the individual association between 
each factor and the change in tricuspid regurgitant velocity. The results suggested that 
there was no strong evidence that any of the variables examined was strongly 
associated with the change in TRV. However, there was a small amount of evidence that 
creatinine was associated with the change in TRV (p=0.05). Higher creatinine values 
were associated with a greater change in TRV. A 10-unit increase in creatinine was 
associated with a 0.02 m/s increase in TRV. 
When multivariate analysis was performed, only creatinine was slightly associated with 
the change in TRJV. After adjusting for this variable, no further variables were 
statistically significant. 
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Chapter 5 Associations with short term 
clinical outcomes 
 
5.1. Associations with short term clinical outcomes 
 
The aim of this chapter is to analyse how the level of LV diastolic dysfunction is 
associated with three patient outcomes.  
The factors of interest were a measure of the patient’s diastolic dysfunction. This was 
assessed in two different ways. Firstly the LVDD at screening was used, and secondly 
the change in LV diastolic dysfunction from screening to follow-up. Diastolic 
dysfunction at screening was originally measured in three categories (none, grade I, 
grade II) (Nagueh et al., 2009a). However, there were only a small number of grade II 
patients, and so these were combined with the class I patients for the purposes of 
analysis. The change in LV DD was categorised as patients worsening their dysfunction 
(i.e. a higher grade), or there being no change or improved dysfunction. 
 
The first set of analyses examined if the LV DD groups differed in terms of the 
demographics of the patients in each group. This was examined, as if there were 
differences between groups, then these differences could potentially confound the 
relationships between dysfunction and the outcomes.  
 
The next analyses examined the associations between the LV DD measures and the 
three patient outcomes. The patient outcomes were increased NYHA class, the number 
of hospital admissions and a high TRV value at follow-up (≥2.5 m/s) . 
 
For each outcome two sets of analyses were performed. Initially a simple analysis was 
performed to examine the association between LV DD and the outcome. Subsequently 
regression methods were used to examine the same relationships, but this time to 
adjust for potentially confounding variables, where necessary. 
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Increased NYHA class and a high TRV value were binary outcomes. Therefore, the initial 
analyses were performed using Fisher's exact test, with logistic regression used for the 
subsequent analysis.  For the TRV outcome, an additional adjustment was made in the 
regression analyses for TRV category at screening, because it is likely that patients with 
high TRV values at follow-up might also have high TRV values at baseline. 
 
The number of admissions were measured on a continuous scale, and were found to 
have a highly skewed distribution, which could not be transformed to normality. 
Therefore, the Mann-Whitney test was used for the initial analyses, and Poisson 
regression used for the further analyses. This is a regression method suited to positively 
skewed data. 
 
5.1.1. Association between diastolic dysfunction and possible 
confounding variables 
 
The analyses were initially performed to compare between the LV DD at baseline 
categories, and the results are summarised in table 5.1. The results suggested that there 
was a significant difference between the two LV diastolic dysfunction groups in terms of 
their age and body mass index (BMI). Patients with class I or II dysfunction were older 
and had higher BMI values. Additionally patients with class I or II dysfunction were 
more likely to use hydroxyurea, although this result was not quite statistically 
significant. As there were some evidence of a difference between the two groups for 
these factors, it was necessary to consider adjusting for these factors in the subsequent 
comparison between the two groups. 
 
Table 5.1 - Association of potential confounding factors with Left ventricular diastolic function groups. 
 
No LV DD(n=43)
LV DD grade I /II 
(n=18)
Mean (SD) or N(%) Mean (SD) or N(%)
Age (years) 36.0 (10.4) 50.4 (8.3) <0.007
Male gender 19 (44%) 8 (44%) 1.00
BMI (kg/m^2) 23.6 (3.2) 26.1 (4.0) 0.01
Systol ic blood 
pressure (mmHg)
118.2 (11.3) 122.6 (19.5) 0.27
Hydroxyurea (current 
use)
7 (16%) 7 (39%) 0.09
Variable P-value
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A similar set of analyses was performed to compare the demographics of patients who 
had worsening LV DD between baseline and follow-up, and those whose LV DD showed 
no change or was better. No significant differences between the two groups in terms of 
the patient demographics were found. As there were no differences between the two 
groups for these factors, it was not necessary to consider adjusting for any of the 
demographic factors in the subsequent comparison between the two groups. 
 
5.1.2. Increase in NYHA 
 
It was investigated how LV diastolic dysfunction variables were associated with 
whether there was an increase in New York Heart Association class (NYHA) from 
screening to follow-up. The data suggested that of the 61 patients, there was an increase 
in NYHA class in 13 patients (21%), and no change in the remaining 48 patients. The 
results are demonstrated on Table 5.2. The results indicated that there was no 
association between the LV dysfunction at screening and the change in NYHA class. 
However, there was a significant association between the change in LV dysfunction and 
the change in NYHA class. Patients with worsening LV dysfunction from screening to 
follow-up had a higher likelihood of an increase in NYHA class. 70% of patients in this 
group had an increase in class, compared to only 12% of patients whose LV dysfunction 
did not worsen. 
 
Table 5.2 - Associations between LV diastolic dysfunction change and NYHA functional class. 
Variable 
LV DD 
grade 
NYHA no 
change 
NYHA 
increase 
N(%) 
P-value 
N (%) 
     
LV  diastolic dysfuntion 
at Screening 
None 33 
(77%) 
10 (23%) 0.74 
  Class I/II 15 
(83%) 
3 (17%)   
     
Change in LV diastolic 
dysfunction 
Same / no 
change 
45 
(88%) 
6 (12%) <0.001 
171 
 
  Worsening 3 (30%) 7 (70%)   
 
Logistic regression was employed to analyse the same relationships. After adjusting for 
potentially confounding variables, there was little change in the difference in outcome 
between those with and without LV DD at screening. Patients with a change in LV DD 
were again at an increased risk of an increase in NYHA class. (p<0.001).  
 
5.1.3. Number of admissions 
 
The next set of analyses examined how diastolic dysfunction was associated with the 
number of admissions. The number of admissions was found to have a positively 
skewed distribution. Initially a simple comparison of the number of admissions 
between dysfunction groups was made and the results suggested that there was no 
significant difference in the number of admissions depending on patients LV DD at 
screening, or on their change in dysfunction from screening to follow-up. 
Regression analysis examined the association between LV DD and the number of 
admissions. The analysis results are summarised in the Table 5.3. Due to the analysis 
used, the differences between groups are reported in the form of ratios. These are given 
as the number of admissions in patients with dysfunction relative to the number in 
patients without dysfunction. The results for dysfunction in screening suggested no 
significant difference when potentially confounding variables were not considered. 
However, after adjusting for age, BMI and hydroxyurea, there was now slight evidence 
of an association, although this result was only of borderline statistical significance 
(p=0.06). Patients with LV DD at screening (grade I or II) had a larger number of 
admissions, around twice as many as patients without LV DD at screening. There was 
again no evidence of an association between the change in diastolic dysfunction and the 
number of admissions.  
 
Table 5.3 - Associations between LV diastolic dysfunction change and NYHA functional class. 
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5.1.4. Increase in tricuspid regurgitant velocity 
 
The final set of analyses examined if the measures of dysfunction were associated with 
TRV ≥ 2.5m/s at follow-up. Initially a simple analysis was performed using Fisher's 
exact test, and the results are summarised in Table 5.4. The results indicated that LV DD 
at screening was significantly associated with TRV at follow-up. Patients with class I/II 
dysfunction had a higher occurrence of TRV above 2.5. 72% of patients with dysfunction 
had a high TRV value, compared to only 35% of patients with no dysfunction.  
 
There was no significant association between the change in LV DD and the TRV category 
at follow-up. Logistic regression was further used to examine the association between 
dysfunction and TRV, adjusting for potentially confounding variables. The analyses 
were performed unadjusted, and then adjusted for TRV category at screening. 
Additional adjustments were made for three potentially confounding demographics as 
well as for LV DD at screening.  
 
Table 5.4 - Associations between LV diastolic dysfunction change and NYHA functional class. 
 
 
LV diastol ic dysfunction 
at screening
None 1.24 (0.76, 2.02) 0.38
Age, BMI, 
hydroxurea
1.97 (0.98, 3.97) 0.06
Change in LV diastol ic 
dysfunction grade
None 0.91 (0.47, 1.78) 0.79
Variable Adjustments P-valueRatio (95% CI)
Dysfunction at screening None 4.85 (1.45, 16.2) 0.01
TRV at screening 2.52 (0.57, 11.2) 0.22
 Age, BMI, hydroxurea 2.42 (0.36, 16.5) 0.37
TRV at screening 1.16 (0.20, 6.70) 0.87
Variable Adjustments
Odds Ratio
 (95% CI)
P-value
Change in dysfunction None 1.98 (0.50, 7.87) 0.33
173 
 
The results of the unadjusted analysis suggested that patients with dysfunction at 
screening were significantly more likely to have a high TRV value. The difference 
between the two groups was no longer found to be significant after adjusting for 
whether the patient had a TRV above 2.5 at screening. Although the result was no longer 
statistically significant, those with LV DD had a higher occurrence of a high TRV value at 
follow-up. 
 
Furthermore, there was no significant association between the change in dysfunction 
and a high TRV value, both before and after adjusting for the TRV category at baseline.  
 
5.2. Associations between haemolysis markers and patients outcomes  
 
 The association between the haemolysis markers (haemoglobin, lactate 
dehydrogenase, reticulocytes and total bilirubin) and the patients´ outcomes was 
assessed by comparing the values of the markers between outcome groups. For 
haemoglobin, which was normally distributed, the unpaired t-test was used for the 
analyses. For the three remaining markers, with skewed distributions, the Mann-
Whitney test was used for the analyses. The fourth outcome, number of hospital 
admissions, was measured on a continuous scale, and was found to be heavily positively 
skewed in its distribution. As a result, Spearman’s rank correlation was used to examine 
the association with the markers. 
 
Table 5.5 - Associations between haemolysis markers and TRV category at follow-up. 
 
 
 
The results suggested that none of the four markers of haemolysis was significantly 
associated with the change in NYHA class, number of admission and change in diastolic 
Haemoglobin 9.2 (1.5) 9.1 (2.0) 0.74
Lactate dehydrogenase 317 (269, 418) 387 (319, 636) 0.05
Reticulocytes 7.6 (3.9, 12.4) 8.4 (5.3, 11.7) 0.73
Tota l  Bi l i rubin 32 (15, 60) 41 (28, 82) 0.05
Haemolysis Marker P-valueTRJV < 2.5 m/s TRJV ≥ 2.5 m/s
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dysfunction. As expected, the results suggested slight evidence that both LDH (p=0.05) 
and bilirubin (p=0.05) were associated with TRV category at follow-up (Table 5.5). 
However, both results were only of borderline statistical significance. Patients with a 
high TRV value had higher LDH and higher bilirubin values than patients with lower 
TRV values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6: Reproducibility Study 
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Chapter 6 Reproducibility Study 
 
 
6.1. Reproducibility Data for 3D Left Ventricular Strain analysis 
 
A group of 37 patients (randomly selected) with SCD underwent a series of 3D strain 
measurements for the assessment of  inter-observer, intra-observer and test re-test of 
the LV Strain variables. Data sets measurements and analysis were performed at least 2 
weeks apart in random order. 
 
6.1.1. Inter-observer variability 
 
A second observer (J.G.) with equal experience in echocardiography performed the 
measurement of inter-observer variability of 3D- left ventricular strain analysis. The 
analysis consisted of 37 patients.  
 
Left ventricular volumes, ejection fraction and stroke volume 
As is demonstrated in Fig. 6.1 the results of the original evaluation and those from 
observer 2 are lower when compared to the first observer. Rather than being 
distributed evenly around the fitted line (which shows equal values for the two 
observers), for most outcomes the second observer seems to have values which are 
consistently higher or lower.  
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Fig. 6.1 – Reliability of left ventricular volumes, ejection fraction and stroke volume measurements by 
linear regression.  
 
Bland-Altman graphs, as demonstrated on figure Fig. 6.2, employ the inter-observer 
agreement for LV end-diastolic volume (EDV), LV end-systolic volume (ESV), LV stroke 
volume 
and LV 
ejection 
fraction. 
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Fig. 6.2 - Inter-observer agreement  for LV end-diastolic volume (EDV) , LV end-systolic volume (ESV), LV stroke 
volume (SV), LV ejection fraction (EF)  for the same values (N = 37 patients) 
LV global longitudinal strain, LV twist (Twist), LV torsion (Torsion), LV 3D strain (3D strain) 
 
Fig. 6.3 demonstrates the inter-observer agreement for LV strain variables (Global, 3D 
Strain, Circumferential, Longitudinal and Radial), LV twist (Twist), LV torsion.   
The mean difference between measurements is shown along with the Bland-Altman 
limits of agreement. The Bland-Altman results suggest that generally there were mean 
differences between the results from the two observers. This suggests that there was 
consistent tendency of one or both observers to under or overestimate the results.  
 
Fig. 6.3 - Inter-observer agreement for LV LV twist (Twist), LV torsion, LV strain variables (3D Strain, 
Longitudinal, Circumferential and Radial), for the same values (N = 37 patients) 
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The ICC value is also reported using both methods in the table 6.1. The ICC values 
suggest that using the first (more standard) method the ICC values were all fairly poor, 
with values generally below 0.6. There was relatively good agreement for LV SV with an 
ICC value over 0.9, and a relatively high value for LV EDV. However, the agreement was 
not so good for the other variables. The agreement was especially poor for twist and 
torsion, and also not very high for any of the 4 strain variables. 
 
 
Table 6.1 – Inter-observer reliability of left ventricular volumes and function measurements using 3D 
speckle tracking echocardiography 
 
6.1.2. Intra-observer variability  
 
Both the Bland-Altman and ICC methods were used to examine the agreement between 
the original and the repeat measurements, and the results are summarised in Table 6.2.  
Mean difference 95% B-A limits Method 1 (†) Method 2 (††)
EDV LV 3D end diastolic volume (ml) -33.60 (-73.0, 5.7) 0.59 0.85
ESV LV 3D end systolic volume (ml) -22.90 (-52.2, 6.5) 0.45 0.73
SV LV 3D Stroke volume (ml) -10.80 (-24.2, 2.7) 0.79 0.93
EF LV 3D ejection fraction (%) 5.10 (-3.5, 13.6) 0.52 0.72
GLS Global longitudinal strain (%) -2.40 (-6.9, 2.0) 0.38 0.57
Twist 3D LV strain twist (degree) -3.10 (-16.4, 10.2) 0.05 0.06
Torsion
3D LV strain torsion ( 
degree/cm)
-0.24 (1.83, 1.40) 0.18 0.19
3D strain (*) LV 3D Strain (Area strain) -4.00 (-10.3, 2.3) 0.48 0.70
Circumferential strain (*)
LV 3D Circumferential global 
strain
-2.80 (-10.1, 4.4) 0.46 0.57
Longitudinal strain (*)
LV 3D Longitudinal global 
strain
-2.70 (-7.6, 2.2) 0.26 0.42
Radial strain (*) LV 3D Radial global strain 14.70 (-8.7, 38.1) 0.48 0.69
Bland-Altman Results ICC
Variable Label
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Table 6.2 – Intra-observer reliability of left ventricular volumes and function measurements using 3D 
speckle tracking echocardiography 
 
The Bland-Altman results suggest that generally there were little average differences 
between the two sets of results. This suggests that there was no consistent tendency for 
the repeat measurements to be higher or lower than the original measurements. 
 
The ICC values suggest very good agreement for LV EDV, ESV and SV, with values over 
0.9. There was also a relatively high value for EF. However, agreement was poor for 
twist and torsion, with ICC values of less than 0.4. Agreement was moderate, although 
not that strong, for the strain variables, with the ICC values typically around 0.8. 
 
6.1.3.  Test re-test reproducibility     
 
A group of patients with SCD underwent a series of 3D strain measurements. These 
patients were then re-tested one hour after the first set of acquisitions.  The aim of the 
analysis was to examine the agreement between the two sets of measurements. All 3D 
strain outcomes were measured on a continuous scale. Table 6.3 summarises the test 
retest analysis results.  
 
Mean difference
95% B-A limits 
agreement
LV 3D end diastolic volume (ml) 0.10 (-16.7, 17.0) 0.98
LV 3D end systolic volume (ml) -0.20 (-15.9, 15.4) 0.95
LV 3D Stroke volume (ml) 0.30 (-6.2, 6.9) 0.99
LV 3D ejection fraction (%) 0.10 (-6.1, 6.4) 0.86
Global longitudinal strain (%) 0.10 (-3.2, 3.4) 0.78
3D LV strain twist (degree) -0.60 (-13.3, 12.1) 0.31
3D LV strain torsion ( degree/cm) -0.05 (-1.51, 1.40) 0.39
LV 3D Strain (Area strain) -0.10 (-5.5, 5.3) 0.80
LV 3D Circumferential global 
strain
-0.10 (-5.3, 5.2) 0.78
LV 3D Longitudinal global strain 0.00 (-3.7, 3.6) 0.73
LV 3D Radial global strain -1.20 (-24.2, 21.8) 0.81
ICC
Bland-Altman Results
Variable
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Table 6.3 – Test re-test reliability of left ventricular volumes and function measurements using 3D 
speckle tracking echocardiography 
 
Test retest agreement was very poor for twist and torsion and moderate for 
circumferential, longitudinal and radial strain.  LV 3D strain (area strain) had the best 
ICC value reflecting good reliability.  
 
6.2. Agreement for 4D Right ventricle volumes 
 
A group of 56 patients with SCD (randomly selected) underwent a series of 3D strain 
measurements for RV volumes. Data sets measurements and analysis were performed 
at least 2 weeks apart in random order. As for the LV 3D strain analysis, these patients 
were then re-assessed by the same observer again, retest again, and also observed by 
second observer. The aim of the analysis was to examine the agreement between the 
various measurements.  
 
6.2.1. Inter-Observer Agreement  
 
The agreement analyses were repeated for this data, and the results are shown in the 
table 6.4. The results suggested that for diastolic volume, the second observer tended to 
give values that were slightly higher than the first observer, with a mean difference of 
5ml. There was also a slight difference for systolic volume, but little average difference 
for ejection fraction. 
Mean difference
95% B-A limits 
agreement
LV 3D end diastolic volume (ml) -1.40 (-24.6, 21.8) 0.96
LV 3D end systolic volume (ml) 0.20 (-17.1, 17.4) 0.93
LV 3D Stroke volume (ml) -1.60 (-14.1, 10.9) 0.94
LV 3D ejection fraction (%) -0.70 (-7.8, 6.4) 0.77
Global Longitudinal  strain (%) 0.20 (-3.0, 3.5) 0.71
3D LV strain twist (degree) -1.60 (-14.9, 11.8) 0.16
3D LV strain torsion ( degree/cm) -0.20 (1.76, 1.37) 0.18
LV 3D Strain (Area strain) 0.00 (-5.6, 5.6) 0.76
LV 3D Circumferential global strain 0.20 (-7.0, 7.5) 0.55
LV 3D Longitudinal global strain 0.20 (-3.1, 3.5) 0.67
LV 3D Radial global strain -1.00 (-27.5, 25.6) 0.65
Bland-Altman Results
Variable ICC
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Fig. 6.4 - Reliability of right ventricular volumes and ejection fraction measurements by linear regression. 
 
The ICC values for diastolic and systolic volume were very high, suggesting very good 
agreement between the two observers, with values of 0.95 or higher. There was a much 
lower value for ejection fraction, suggesting fairly poor agreement between the two 
observers. 
 
Table 6.4 - Inter-observer, intra-observer and test re-test reliability of right ventricular volumes and 
function measurements using 4D echocardiography. 
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6.2.2. Intra-observer agreement 
 
The initial graphs suggest that the agreement between the two sets of results of the two 
observers is quite high for systolic and diastolic volume, as the values typically lie close 
to the fitted line (which shows equal values for the two measurements). The agreement 
appears less good for ejection fraction, where the values are scattered further away 
from the line of equality. 
 
 The ICC values suggest that there was good agreement between the two measurements 
for diastolic and systolic volume, with high values of 0.9 or higher (Table 6.4). There 
was poor agreement for ejection fraction, with the value of 0.6 suggesting that a 
relatively large proportion of the total variation was due to differences of repeat 
measurements of the same patients. 
 
The result can be also be displayed graphically in a series of Bland-Altman plots, which 
plot the differences in the pairs of values against the average of the two values. The 
Bland-Altman graphs suggest that generally there was little average difference between 
the two sets of measurements. This suggests that the second measurements were not 
consistently higher or lower than the first. 
 
6.2.3. Test-Retest Agreement  
 
The results suggested little average difference between the two sets of measurements, 
which implies no consistent bias in the results. The width of the limits of agreement 
were slightly wider than those obtained for the intra-observation variation. The ICC 
values (Table 6.4) were relatively high for diastolic and systolic volume, although low 
for ejection fraction. The ICC value below 0.5 suggests that there was more variation 
between repeat measurements of the same patient than there was between patients.  
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Fig. 6.5 - Test re-test agreement for RV volumes and ejection fraction by 4D echocardiography, for the same values (N 
= 56 patients) 
 
6.3. Comparison between LV 2D speckle tracking and 3D speckle 
tracking for myocardial deformation 
 
A subgroup of 52 randomly selected patients with SCD had LV strain measures using 
two methods: 2D and 3D speckle tracking .The aim of the analysis was to examine the 
agreement between the two modalities.  
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Table 6.5 – Mean difference between 2D Strain and 3D Strain parameters according to Longitudinal and 
Circumferential showing Bias between the methods. 
 
 
Table 6.5 presents the difference between 2D and 3D measures (2D mean - 3D mean), 
the standard deviation of the difference, the confidence interval of the difference and 
the result of hypothesis testing that the mean value of 2D measure is the same as the 
mean value of 3D measure. If the mean of 2D measure is the same as the mean of 3D 
measure, one would expect to observe a small mean difference (positive or negative), 
zero within confidence interval and a p value greater than 0.05.  
 
If the p value is less than 0.05 that means the 2D mean is not the same as 3D mean. 
Paired t-test has been used for this hypothesis testing as each patient provides both 2D 
and 3D measures.  About half of the measures in the above table have p value less than 
0.05 and hence suggest that the mean difference between 2D and 3D methods are 
statistically significant.   There are only 6 segments (19%) that have significant but 
weak agreement between 2D and 3D evaluation method.  
Mean ± SD p  value ICC (95% CI)
LV_2DLSTbasalAvg -16.29 ± 3.27 0.14 0.76 (5%) 3.63 (22%) 0.41
LV_2DLSTmedianAvg -19.14 ±  3,49 0.000 -2.60 (14%) 3.91 (20%) 0.15
2DLSTApicalAvg -17.08 ±  3,80 0.32 -0.67 (4%) 4.79 (28%) 0.11
LV_2DLongglobalST -30.50 ± 2.54 0.003 -13.82 (45%) 2.77 (9%) 0.02
LV_2DCSTbasalAvg -23.29 ± 7.32 0.000 -6.76 (29%) 7.37 (32%) 0.13
LV_2DCSTmedianAvg -25.63 ± 9.32  0,06 -3.91 (15%) 14.32 (56%) -0.10
LV_2DCSTApicalAvg -29.97 ± 12.61 0.000 -7.28 (24%) 15.36 (51%) -0.07
LV_2DCircunfglobalST -26.08 ± 6.72 0.16 -4.71 (18%) 7.36 (28%) 0.10
BIAS (%)
Limit of
agreement
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Chapter 7 Discussion 
 
 
7.1. Retrospective survival study  
 
Raised tricuspid regurgitant velocity occurs in approximately 30% of adults with sickle 
cell disease and has been shown to be an independent risk factor for death. In our 5 year 
retrospective follow-up study of adults with sickle cell disease, TRV was assessed in 164 
SCD patients who were subsequently followed up for survival (Zimbarra Cabrita et al., 
2013a).  Higher values of TRV were associated with a greater than 4 fold increased risk 
of death (HR: 4.48, 99%CI 1.01-19.8), although we showed a lower overall mortality 
rate (16.67% in patients with a TRV ≥2.5 m/s) than has been shown in previous studies. 
Importantly, in our cohort TRV was not an independent risk factor for death. We have 
confirmed the association between raised TRV and mortality in a UK SCD population 
whose disease severity appears to be less than that reported in previous studies 
(Gladwin et al., 2004, Sutton et al., 1994).   
Castro et al. (Castro et al., 2003) in a study with 34 adults patients, reported a 2 year 
mortality rate of 55% in patients with a raised mean pulmonary artery pressure (> 25 
mmHg) obtained by right heart catheterisation, compared to a mortality rate of 21% in 
SCD without raised mean pulmonary artery pressure (≤25 mmHg) .    
  
Two older studies also reported increased mortality.  Sutton et al found that a raised 
TRV was associated with a 40% mortality rate at 22 months in 60 patients, with an odds 
ratio for death of 7.86 (2.63-23.4) (Sutton et al., 1994). Powars et al found a mean 
survival of 2.5 years in patients with chronic lung disease and elevated TRV (Powars et 
al., 1988).  
In order to extend our analysis, we have re-analysed the data using the conservative cut 
off value of TRV ≥ 3 m/s.  Interestingly, we have found no change in the results. Of the 
164 patients included in our study, only 10 patients (6, 1%) had a TRV value of 3.0 m/s 
or higher. Using the same time point as Gladwin´s Study (24 months) we have found 
similar survival estimates of 99% for TRV<3.0 m/s and 80% for TRV≥3.0 m/s. 
Nonetheless, using a time point of 68 months, there was no significant difference 
(p=0.125) in the survival estimates: 95% for TRV<3.0 m/s and 80% for TRV≥3.0 m/s.  
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We also found that patients with higher TRV values had a higher risk of death (HR: 6.52; 
95% CI 2.97-20.6; p=0.001) when other factors are not considered (in comparison to a 
HR of 11.14 found in Gladwin’s Study). However, this risk disappears after adjustment 
for other variables associated with survival.  
There was no significant difference in the sickle cell genotypes between the two studies 
(HbSS p=0.45; HbSC p=0.7; HbS β thalassemia p=0.68) and no significant difference in 
the mean TRV (p=0.15).  In both studies the overall number of deaths was small which 
is reflected by the width of the CI for TRV ≥2.5 m/s relative to TRV<2.5 m/s.  This means 
that the true hazard ratio in Gladwin’s study could be from 2.2 to 47 (p<0.001), whereas 
in our study the limits are from 0.71 to 10.4 although not significant (p=0.06). One 
explanation could be that the National Health Service in the UK ensures that health care 
is free at the point of access and this may lead to patients with milder phenotypic 
disease being more likely to attend outpatients clinic and increase the number of 
patients with milder disease (and lower mortality) in the UK cohorts. On the other hand, 
we speculate that easier NHS access to specialist sickle cell centres in the UK may result 
in better outcomes in terms of severity and overall quality of life. 
 In addition, the mortality figures from the US data seem very high when compared with 
the UK experience. Although there are not sufficient longitudinal data for mortality of 
patients with SCD in the UK. The recent National Confidential Enquiry into Patient 
Outcome and Death (Lucas et al., 2008), report which collected data on all deaths in 
patients with haemoglobinopathies between January 2005 and December 2006, had 
only 81 reported deaths, which in an estimated population of 12,000 for SCD in the UK, 
is a very low mortality rate.  In essence, the reasons for this difference in mortality with 
United States cohorts is not explained by the clinical measurements which were made 
and further studies to confirm our findings are necessary. 
 
In conclusion, we have confirmed the association between raised TRV and mortality in a 
UK SCD population attending two North West London specialist SCD centres, whose 
disease severity appears less than that reported in previous studies.  
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7.2. Prospective study – heart characterisation 
 
In the prospective study, the mean follow-time was 17.13±3 months with a range of 
10-23 months. The prevalence of increased TRV defined as a TRV≥ 2.5 m/s, was 51% 
at baseline and 45% at follow-up.  We have decided to use TRV as a dichotomous 
variable, following the methodology of several previous studies ((Parent et al., 2011, 
Fonseca et al., 2012, Gladwin et al. 2004), allowing for the possibility of groups comparison 
(high and low TRV) to assess associations between clinical and echocardiographic 
parameters. 
In our study cohort, no significant change in the usage of hydroxyurea or participation 
in a chronic transfusion program was found between the two time points. In addition, as 
has been previously described we have found a tendency for the association of history 
of lung problems (e.g. asthma, COPD, bronchitis, emphysema, pneumonia, tuberculosis) 
with increased TRV. These independent factors may have contributed to the 
development of PH in this population, but the results were not statistically significant.  
 
2D echocardiography, pulsed-wave Doppler-derived mitral and tricuspid inflow 
velocities, as well as DTI, were used to assess cardiac structure and function in adult 
patients with SCD and in race-age matched controls.   
Compared with the control group, subjects with SCD had larger LA and RA volumes, 
increased LV mass and LV volumes. Furthermore, LA dilatation was severe in 64% of 
the patients.  
Also, right heart chambers were larger in the SCD subjects compared to controls, where 
48% of the patients had increased RV end-diastolic volume.  
Although the presence of left ventricular diastolic dysfunction in patients with SCD is 
well established, it is not clear whether they have subtle LV systolic dysfunction despite 
preserved ejection fraction. In our study, we used three-dimensional speckle tracking 
echocardiography to assess changes in both systolic and diastolic LV function and it 
demonstrated minor differences between patients and controls regarding LV strain. 
These results are in agreement with previous studies where global LV systolic function 
was not only preserved but increased compared to controls (Ahmad et al., 2012).  
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Additionally, RV longitudinal strain was universally increased in all free wall segments 
and significantly different from the healthy subjects. This was the first study to use 
3DSTE for the evaluation of systolic LV function in patients with SCD in UK.  
 
As expected, parameters of LV and RV function were normal in both groups and 
increased stroke volumes and cardiac output were found among patients with SCD. The 
results suggested that chronic anaemia and the increased intravascular volume in 
patients with SCD, are primarily contributing factors for the findings regarding cardiac 
structure and systolic function. It is well known that the increasing circulating blood 
volume due to chronic anaemia in SCD (Bunn, 1997, Varat et al., 1972, Raphael, 2005).   
 
7.3. Increase in LV lateral  E/E´ratio during follow up 
 
Echocardiographic estimation of pulmonary artery pressure by measuring the tricuspid 
regurgitant jet velocity has been validated as a useful screening method for pulmonary 
hypertension in adult patients with sickle cell disease (Gladwin et al., 2004). A TRV of 
2.5 m/sec or more has been used for research purposes to define elevated pulmonary 
artery pressure in adults with sickle cell disease (Kenneth I. Ataga, 2006). The 
prevalence and natural history of elevated jet velocity in adults with sickle cell disease 
at steady state are mostly unknown, despite the mild elevations in pulmonary artery 
pressure that have been reported.  
In subjects with SCD, a positive correlation was found between TRV and LV end 
diastolic volume. LV lateral E/E´, an important estimator of increased left ventricular 
filling pressures, was strongly correlated with age, as expected but no association with 
haemolysis markers was found which may suggest that cardiac adaptations to anaemia 
have more of an effect on diastolic function than direct effects of haemolysis. These 
findings are consistent with the study by Sachdev et al  (Sachdev et al., 2007) .   
In our study, with a prevalence of LV DD of 29.5 %, as assessed by Doppler 
echocardiography, we have shown that a patient with LV DD had five times more risk of 
developing pulmonary hypertension. Of note, these patients had diastolic dysfunction 
based on current guidelines (Nagueh et al., 2009a), using 2D and Doppler criteria, and 
the prevalence of diastolic dysfunction was considerably higher than reported in 
previous studies using older criteria. 
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Furthermore, in this study, elevations of both TRV and LV lateral E/E´ ratio were 
associated with NYHA functional severity. 
This SCD study confirms independent associations of increased TRV with elevated LV 
filling pressure. Renal dysfunction may have an important role in contributing to LV 
diastolic dysfunction in SCD patients. In mean pulmonary artery pressure addition we 
have found slight evidence that creatinine was associated with the change of TRV group 
(≥2.5 m/s) at follow-up. The vascular involvement of the microvascular circulation 
where the sickling process takes place may explain specific haemodynamics alterations 
and arterial stiffness in SCD may warrant further investigations. Furthermore, the 
independent association of increased blood urea nitrogen and global function index 
lateral with an increased LV lateral E/E´ ratio is consistent with previous reports 
(Gordeuk et al., 2008) suggesting an association of renal disease with LV diastolic 
dysfunction which may lead to elevated pulmonary pressures. 
 
Our present findings confirm that echocardiographic markers of LV DD are prevalent in 
SCD and point to independent associations of older age, worse haemoglobin levels, and 
elevated left atrial volume index with an elevated LV lateral E/E´ratio. 
 
The results are supportive of echocardiographic screening for increased tricuspid 
regurgitation and early identification of LV diastolic dysfunction, a marker of increased 
mortality in adults with SCD (Sachdev et al., 2007).  These observations may have 
functional and prognostic relevance in terms of assessing sub-clinical identification of 
early myocardial impairment.  
 
7.4. Ventricular myocardial deformation  
 
Several studies have used 2DST to assess myocardial strain in different pathologies. 
2DSTE can only track motion within the imaging plane, while through-plane motion 
adversely compromises endocardial tracking when speckles move out of imaging plane 
(Kleijn et al., 2012a) the accuracy of this technique becomes limited. 3D speckle tracking 
echocardiography has been initially applied to the left ventricle and used for the 
myocardial motion analysis that aims to overcome the limitations of 2D speckle tracking 
191 
 
(Abate et al., 2012, Gorcsan and Tanaka, 2011). It proved excellent reproducibility with 
CMR left ventricular ejection fraction (Kleijn et al., 2012b) and also it has proven 
predictive value in patients who recover from myocardial infarction (Abate et al., 2012). 
From the current literature, 3D speckle tracking appears to be superior to 2-
dimensional speckle tracking and it is promising for the regional myocardial analysis of 
the left ventricle. Furthermore, our finding concerning the poor agreement between LV 
2D strain and 3D strain, confirm that careful use of 2D strain data must be take into 
consideration, in particular in dilated chambers, which is very frequent in SCD.  
Our hypothesis was that this novel methodology could detect subtle changes in systolic 
myocardial deformation, which may presumably be present in these patients despite 
preserved LV EF.   Our results have shown a significant decrease in all global LV strain 
parameters from baseline to follow-up. Such early signs of systolic dysfunction could 
potentially be used to predict which patients are likely to develop more overt systolic 
dysfunction in the future. 
As in several studies that reported normal systolic function in patients with SCD 
(Westwood et al., 2007, Ahmad et al., 2012), in our patients, global systolic function was 
not only preserved but there was even a tendency for increased values when compared 
to healthy volunteers. This may be explained by compensatory mechanisms within the 
cardiovascular system aimed at maintaining adequate oxygenation in the anaemic 
patients. 
 
7.5. Reproducibility study  
 
This study assessed the different components of strain values in 16 LV segments, by 
using newly developed 3D strain imaging, and comparing the data with those measured 
by conventional 2D strain imaging. Our results showed that the 3D myocardial tracking 
technique is a simple, feasible, and reproducible method to measure LV strains. 
However, the mean strain values of 16 segments between 3DT and 2DT showed 
discordant values in a large number of segments. The reason for these discordant 
results can be explained by the influence of large LV volumes and increased LVEF. On 
the other hand, the lower frame rate of 3D technique may have effected the discordance 
between 3DT and 2DT. 
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Chapter 8 Conclusions  
 
8.1. Conclusions and Contributions of this Research Study  
 
This thesis includes two major studies. In the retrospective 5 year-survival study, an 
association between raised TRV and mortality in a UK SCD population was confirmed. It 
was found that higher values of TRV were associated with a greater than 4 fold 
increased risk of death (HR: 4.48, 99%CI 1.01-19.8). However, it showed a lower overall 
mortality rate than has been shown in previous studies. Importantly, TRV was not an 
independent risk factor for death and we have confirmed the association between 
raised TRV and mortality in a UK SCD population whose disease severity appears to be 
less than that reported in previous studies. 
In the prospective study, 61 patients with SCD and 42 healthy volunteers were 
evaluated with a mean follow-up duration of 17.13±3 months. Significant changes were 
found between patients and healthy subjects in terms of systolic blood pressure, right 
and left ventricular structure. Twenty-three percent of the patients had decreased 
global longitudinal strain, as assessed by 3DSTE. In the serial echocardiographic study, 
left ventricular average E/E´ ratio was independently associated with an increased 
tricuspid regurgitation velocity (p=0.007). In addition, blood urea nitrogen and global 
function index lateral showed independent association with an increased LV lateral E/E´ 
ratio. Biventricular myocardial deformation by 2D and 3D speckle tracking revealed 
significant changes in the serial measurements of systolic function. In addition, inter-
observer, intra-observer and Test-retest provided good reproducibility and superiority 
when compared to 2DSTE. 3DSTE is considered as a new tool in the cardiac assessment 
of SCD that combines the usefulness of wall motion tracking with a better integration of 
the anatomic structures of the heart. No myocardial fibroses or iron overload was found 
in the sub-group of patients with LV DD.   
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These findings provide novel insight into the pathophysiology of the cardiovascular 
complications of SCD and support the implementation of echocardiographic screening 
of adult patients with SCD to identify high-risk individuals for further evaluation. 
 
8.2. Limitations of the study  
This study had several notable limitations. For the retrospective survival study, the 
main weakness was in collecting patient records from two different centres with limited 
access to echocardiographic data. Also, patient´s echocardiograms were requested 
according to clinical indications, creating a bias in favour of more symptomatic patients, 
Therefore, the reported prevalence of increased TRV should be interpreted with 
caution. Also, the echocardiograms were performed with different equipment and the 
protocol was different in the centres (e.g. left atrial area was not measured in one 
centre).  
For the prospective study important limitations concerning referral bias are important 
to address.  Firstly, the patients were identified through the WALK-PHaSST study where 
patients that were participating in the interventional study could not take part in my 
study, potentially excluding patients with increased TRV.  
In addition, SCD is a complex genetic disorder with multisystem manifestations and 
where the conventional cardiac risk factors are powerful risk factors for SCD and may 
have complex interactions. The stratification of populations based on clinical phenotype 
and risk factor would be important for the individualized risk assessment in SCD, which 
has not been done in this study. Another limitation of the study is the fact that the 
healthy volunteer’s values could have been used as reference values for the SCD group. 
When the healthy volunteers TRV data was analyzed the reference values (Mean±2*SD) 
were TRV<1,86 m/s and TRV>2,06 m/s. According to SCD patient´s data, only 2 patients 
had a TRV < 2,06 m/s. 
Left ventricle diastolic function 
Guidelines for assessing left ventricle diastolic function by echocardiography have been 
continuously updated and the ability to use the latest recommendations effectively in 
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SCD population, has been challenging because of loading conditions and anaemia status 
which my interfere in the results.. In this study, algorithms for interpretation of diastolic 
grade have been used according to the current Recommendations for the Evaluation of 
Left Ventricular Diastolic Function by Echocardiography (Nagueh et al, 2009a).  This 
approach has important limitations, since it requires the integration of multiple 
parameters. Additionally, for the purposes of sample size and power calculation, due to 
the reduced number of published results in SCD, we have used exclusively 
the   parameter E/E´ average of lateral and septal walls, which may have 
underestimated the sample size, since its use alone and not integrated with other 
parameters such as LV E/A, may be not reliable in the SCD population.  A meticulous 
search for the underlying aetiology and precipitant causes of LV diastolic dysfunction is 
needed for an individualized treatment approach. 
Right ventricular assessment  
In order to acquire a full-volume dataset that encompasses the complete RV, four high-
resolution sub volumes were acquired over consecutive heartbeats in a short breath-
hold. These sub volumes were subsequently assembled by the computer to build a 
complete 3DE dataset. Thus, although RT3DE data acquisition and display are fast (6 to 
8 s in the present study), it is not intrinsically Real Time.  
In this study, 3DSTE could not be applied for RV strain analyses since its complex 
anatomy does not allow reliable endocardial tracking of the RV Free wall. 2DSTE has 
been used to analyse RV myocardial deformation parameters.   
 
3-Dimensional Speckle tracking 
One might view the lack of an independent reference technique to compare the 3DSTE-
derived measurements as a limitation of our study. As far as myocardial strain is 
concerned, there is no noninvasive “gold standard” technique that can be used in 
humans to validate strain in three dimensions. 
Another limitation was the fact that we did not use 3DSTE for the assessment of LV 
diastolic function. The inter-observer variability in measuring the diastolic component 
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of the strain curves was tested prior to the study starts, and a poor agreement was 
found. 
 
Cardiac magnetic resonance 
The original intention was to include a larger number of patients so that regression 
analyses could be performed to investigate independent predictors of LV DD. The small 
sample size that was eventually recruited did not allow this. Moreover, no sufficient 
data was obtained for a reliable comparison between LV 2D strain and myocardial 
tagging. Therefore, further studies are needed to confirm the superiority of 2DSE data 
over that of CMR in the assessment of regional strain. 
 
8.3. Further Research  
 
3-Dimensional Strain Validation  
The ability to obtain comparable data with other equipment need to be evaluated. A 
validation study is currently in place to demonstrate the agreement of different 
platforms and to establish normal values for LV and RV strain parameters. 
 
Regional heart motion abnormality detection via multiview fusion in cine cardiac MR 
images would give precise information from several other long-axis image sequence i.e., 
2-chamber, 3-chamber and 4-chamber magnetic resonance images. 
 
Finally genomic signatures as potential biomarkers in sickle cell disease maybe clinical 
useful.  Desai et al found that genome-wide gene and miRNA expression profiles were 
correlated against TRV, yielding 631 transcripts and 12 miRNAs. In addition, support 
vector machine analysis identified a 10-gene signature including GALNT13 (encoding 
polypeptide N-acetylgalactosaminyltransferase ) that discriminates patients with and 
without increased TRV with 100% accuracy (Desai et al., 2012).  
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These genomic signatures may provide a novel approach as a biomarker for increased 
TRV in patients with SCD.  
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Two-Dimensional and Doppler Echocardiographic Examination 
Protocol 
 
General procedures 
 
 Screening visit: Echo should be done prior of 6MW. If not possible there should 
be an hour delay (30 minutes lay down on the echo couch or 10 minutes if 6MW 
was not performed). 
 Studies should be recorded on a DVD and sent to Prosolv. 
 Record HR ; Height; Weight; Blood pressure. 
 Record 3-5 beats using harmonic imaging. 
 Doppler tracings: 
o  recorded at end-expiration 
o with low filter 
o performed at 50-100 mm/s sweep speed 
3-5 sequential complexes should be include 
 
The echocardiographic examination required the following tomographic views 
(recorded as listed):   
 
1. Parasternal long axis view  
2. Parasternal long axis view right ventricle 
3.  Parasternal short axis view 
 3. Apical four chamber view  
 4. Apical long axis view  
 5. Apical two chamber view  
 6. Subcostal long axis view  
 7. Subcostal short axis view  
 8. Suprasternal notch view 
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Echocardiography data to obtain from each view:   
 
1. Parasternal long axis view  
 
Aortic root diameter 
LV outflow tract diameter for calculation of stroke volume  
 LV dimensions (end-diastolic and end-systolic diameter) 
 LV wall thickness  
 Mitral valve structure/regurgitation 
 Wall motion analysis  
 Left atrial size  
 Aortic valve structure/regurgitation  
Estimation of right ventricular impairment, degree of trabeculation, size and  
interventricular septal flattening 
 
2. Parasternal long axis view right ventricle inflow and outflow 
 
RV outflow tract diameter 
Pulmonary artery and branches diameter 
RV isovolumetric contraction and ejection time 
Peak velocity and velocity-time integral of pulmonary artery ejection flow 
Assessment of pulmonary and tricuspid structure/regurgitation 
 
3. Parasternal short axis view  
 
Basal level  
Papillary muscle level  
Apical level  
M-mode of LV at papillary muscle level 
LV dimensions  
 
4.  Apical four chamber view  
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 LV dimensions, long axis dimension  
 LV volume for single plane and biplane volumes  
Mitral regurgitation (colour and continuous wave Doppler)  
Tricuspid regurgitation (colour Doppler)  
Peak velocity and velocity-time integral of left ventricular outflow tract and 
aortic flow 
 LA size and volume  
RA size and volume  
Measure of RV end-diastolic area 
Measure of RV end-systolic area  
Separate acquisition of RV including all free wall 
 Wall motion analysis  
 Tricuspid regurgitation velocity (continuous wave Doppler)  
Time duration from QRS complex to opening of tricuspid valve (start of E wave) 
Tricuspid valve inflow 
Tissue Doppler of mitral septal and lateral annulus velocity  
Tissue Doppler recording of tricuspid annulus velocity 
TAPSE: RV tricuspid annulus (sweep speed at 100 m/s) 
 Diastolic function assessment of left ventricle: 
 
 PW of MV E/A ( ate the tips) 
 Deceleration time;  
 IVRT ( include MV inflow and LVOT flow) 
 Propagation velocity ( Color M-Mode) 
 PW of Pulmonary vein ( S, D, A reversal waves; A duration) 
 
5. Apical two chamber view  
 
 LV volume for biplane volumes  
 Wall motion analysis  
 Mitral regurgitation  
 LA size and volume  
6. Sub-costal views  
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 Inferior vena cava  
 Hepatic vein 
 
6. Apical long axis view  
 
 LV outflow tract velocity and velocity time integral 
 Wall motion analysis  
 Mitral regurgitation  
 Aortic regurgitation (colour and continuous wave Doppler) if present  
Tricuspid regurgitation velocity (continuous wave Doppler) 
 
7. Sub-costal views 
 
Determination of the diameter of inferior vena cava and its respiratory collapse 
(ask patient to sniff and record in 2D and M-Mode) 
PW of hepatic vein 
 
8. Suprasternal notch view  
  
 Aortic Arch  
 Pulmonary Artery  
 Descending thoracic aorta 
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3D Echocardiography  
 
Optimise ECG tracing to increase R wave peaks. 
 
LEFT VENTRICLE 
 
1. Using 2D imaging, find the best apical window to image the entire left ventricle 
(use ISCAN) 
2. Scan with 3D live; decrease TGC at apex, increase gains. 
3. Go to “Full Volume” – evaluate whether ventricle fits within sector; readjust 
transducer position if necessary to include apex. Use Low scan density to 
maximize sector width. 
4. Observe image relative to patient’s respiration to determine optimal time to 
acquire. 
5. Instruct patient to hold breathing at optimal time and acquire. 
6. Countdown as machine acquires and instruct patient to continue breath-hold 
while acquiring image. 
7. Select “autocrop” and inspect for artifact. 
 
RIGHT VENTRICLE 
 
1. Use the best window available in a modified apical transducer location to center 
the RV. RV free wall must be visible within sector (use ISCAN). 
2. Follow steps 2-7 above. 
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Appendix V. Left ventricular 3-Dimensional Strain and Strain Rate: segmental 
data 
 
Lower Upper
LV Strain
3D Frame rate (Hz) 43 18,05 ± 1,65 26 17,23 ± 1,30 0,82 -0,19 1,82 0,04
3D analysis duration (min) 40 10,50 ± 1,28 26 8,54 ± 1,30 1,96 1,10 2,82 <0.001
LV 3D end diastolic volume (ml) 43 124,36 ± 39,48 26 96,30 ± 25,36 28,06 5,09 51,04 0,002
LV 3D end systolic volume (ml) 43 61,34 ± 22,90 26 46,63 ± 13,13 14,71 1,65 27,76 0,004
LV 3DST stroke volume (ml) 43 63,02 ± 18,64 26 49,66 ± 13,85 13,36 2,15 24,56 0,002
LV 3DST ejection fraction (%) 43 51,24 ± 4,96 26 51,52 ± 4,75 -0,28 -3,50 2,93 0,82
LV Global longitudinal strain 43 -17,81 ± 3,00 26 -17,23 ± 2,77 -0,58 -2,50 1,34 0,43
LV tw ist (degree) 43 10,53 ± 6,40 26 10,43 ± 3,97 0,10 -3,60 3,80 0,94
LV torsion ( degree/cm) 43 1,28 ± 0,85 26 1,34 ± 0,56 -0,06 -0,55 0,44 0,76
LV 3D Strain (%)
Basal antero-septal segment 43 -28,51 ± 6,12 26 -30,14 ± 3,38 1,63 -4,72 2,94 0,54
Basal anterior segment 43 -29,59 ± 6,01 26 -30,06 ± 4,42 0,47 -3,13 4,07 0,73
Basal lateral segment 43 -31,21 ± 5,22 26 -31,07 ± 5,06 -0,14 -3,54 3,26 0,91
Basal posterior segment 43 -29,60 ± 6,35 26 -30,00 ± 6,59 0,39 -3,85 4,63 0,81
Basal inferior segment 43 -27,83 ± 6,76 26 -29,35 ± 5,56 1,53 -2,65 5,70 0,34
Basal infero-septal segment 43 -25,83 ± 7,34 26 -31,72 ± 4,14 5,89 1,71 10,06 <0.001
Basal segments avg 43 -28,84 ± 3,03 26 -30,05 ± 3,38 1,21 -0,88 3,29 0,13
Median antero-septal segment 42 -34,91 ± 8,32 26 -33,05 ± 6,11 -1,87 -6,87 3,14 0,33
Median anterior segment 43 -35,90 ± 5,48 26 -33,89 ± 7,20 -2,01 -6,08 2,06 0,19
Median lateral segment 43 -34,87 ± 5,44 26 -36,20 ± 6,57 1,32 -2,56 5,20 0,37
Median posterior segment 43 -37,01 ± 6,58 26 -34,87 ± 5,46 -2,14 -6,22 1,94 0,17
Median inferior segment 42 -33,60 ± 7,74 26 -33,56 ± 6,67 -0,04 -4,90 4,83 0,98
Median infero-septal segment 41 -28,12 ± 9,07 26 -30,99 ± 7,96 2,87 -2,89 8,63 0,19
Median segments avg 43 -34,11 ± 4,91 26 -33,76 ± 3,93 -0,36 -3,36 2,65 0,75
Apical anterior segment 42 -35,33 ± 10,06 26 -30,73 ± 8,47 -4,59 -10,87 1,69 0,06
Apical lateral segment 42 -36,05 ± 9,14 26 -32,66 ± 9,60 -3,40 -9,56 2,77 0,15
Apical inferior segment 43 -38,45 ± 11,66 26 -39,53 ± 7,33 1,08 -4,98 7,14 0,64
Apical infero-septal segment 41 -31,16 ± 10,33 24 -31,60 ± 10,22 0,45 -6,58 7,47 0,87
Apical segments avg 43 -35,18 ± 7,26 26 -33,61 ± 5,68 -1,57 -6,00 2,85 0,35
Global (avg of all segments) 43 -32,40 ± 3,83 26 -32,33 ± 3,16 -0,07 -2,44 2,30 0,94
LV Circumferential Strain (CS%)
Basal antero-septal segment 41 -18,60 ± 6,10 24 -19,23 ± 5,91 0,63 -3,48 4,75 0,68
Basal anterior segment 42 -18,27 ± 5,03 24 -17,36 ± 4,33 -0,90 -4,16 2,35 0,46
Basal lateral segment 41 -20,36 ± 5,81 25 -19,86 ± 5,80 -0,51 -4,42 3,40 0,73
Basal posterior segment 43 -20,49 ± 6,40 25 -22,43 ± 5,89 1,94 -2,21 6,09 0,22
Basal inferior segment 39 -15,88 ± 5,64 25 -16,50 ± 5,70 0,61 -3,24 4,47 0,67
Basal infero-septal segment 42 -17,04 ± 6,26 22 -20,55 ± 6,09 3,51 -0,83 7,84 0,04
Basal segments avg 43 -18,48 ± 3,00 26 -19,22 ± 3,13 0,74 -1,27 2,75 0,33
Median antero-septal segment 43 -26,59 ± 9,26 26 -24,61 ± 5,70 -1,98 -7,33 3,36 0,33
Median anterior segment 43 -30,15 ± 7,30 26 -27,77 ± 7,63 -2,38 -7,28 2,51 0,20
Median lateral segment 43 -29,02 ± 6,69 26 -29,24 ± 9,22 0,22 -4,87 5,31 0,91
Median posterior segment 43 -30,74 ± 6,92 26 -28,67 ± 7,04 -2,07 -6,66 2,51 0,24
Median inferior segment 42 -22,89 ± 8,09 25 -23,56 ± 8,10 0,67 -12,72 1,20 0,03
Median infero-septal segment 35 -18,38 ± 7,60 23 -21,95 ± 7,62 3,57 -6,41 4,52 0,65
Median segments avg 43 -26,52 ± 4,87 26 -26,05 ± 4,29 -0,46 3,58 11,77 <0.001
Apical anterior segment 41 -28,07 ± 10,59 26 -23,84 ± 8,99 -4,23 -7,90 2,55 0,17
Apical lateral segment 42 -29,57 ± 9,85 26 -25,61 ± 10,02 -3,96 -9,35 4,45 0,35
Apical inferior segment 42 -29,32 ± 13,36 25 -32,57 ± 8,65 3,25 -3,32 9,32 0,21
Apical infero-septal segment 32 -17,99 ± 9,42 23 -19,22 ± 10,22 1,23 -5,90 8,36 0,65
Apical segments avg 43 -26,75 ± 7,17 26 -25,44 ± 5,12 -1,31 -5,58 2,96 0,42
Global (avg of all segments) 43 -23,48 ± 3,73 26 -23,38 ± 3,51 -0,10 -2,50 2,31 0,92
LV Longitudinal Strain (%)
Basal antero-septal segment 42 -19,05 ± 4,84 25 -19,85 ± 6,41 0,80 -2,87 4,47 0,57
Basal anterior segment 42 -18,69 ± 5,46 25 -21,79 ± 5,44 3,10 -0,55 6,76 0,03
Basal lateral segment 43 -19,35 ± 5,12 26 -19,09 ± 6,15 -0,26 -3,90 3,38 0,85
Basal posterior segment 41 -16,05 ± 4,49 26 -15,75 ± 6,12 -0,29 -3,74 3,15 0,82
Basal inferior segment 42 -15,43 ± 5,37 26 -18,90 ± 5,49 3,47 -0,11 7,05 0,01
Basal infero-septal segment 41 -15,29 ± 5,03 26 -19,92 ± 4,80 4,63 1,34 7,92 <0.001
Basal segments avg 43 -17,31 ± 2,83 26 -19,80 ± 2,56 2,49 0,69 4,29 <0.001
Median antero-septal segment 43 -18,68 ± 5,94 26 -16,52 ± 5,24 -2,16 -5,91 1,59 0,13
Median anterior segment 43 -18,65 ± 3,30 26 -19,18 ± 3,63 0,53 -1,73 2,78 0,54
Median lateral segment 43 -19,63 ± 3,15 26 -19,23 ± 3,06 -0,40 -2,45 1,65 0,61
Median posterior segment 43 -17,42 ± 4,04 26 -15,68 ± 3,21 -1,74 -4,22 0,73 0,07
Median inferior segment 43 -18,91 ± 5,72 26 -18,83 ± 4,01 -0,08 -3,47 3,31 0,95
Median infero-septal segment 43 -18,35 ± 4,45 26 -17,89 ± 4,05 -0,46 -3,29 2,38 0,67
Median segments avg 43 -18,61 ± 3,42 26 -17,89 ± 2,51 -0,72 -2,77 1,33 0,36
Apical anterior segment 43 -16,78 ± 4,59 22 -15,52 ± 4,31 -1,26 -4,39 1,88 0,29
Apical lateral segment 43 -18,53 ± 4,24 26 -17,37 ± 4,75 -1,16 -4,08 1,77 0,30
Apical inferior segment 43 -18,72 ± 4,44 25 -19,22 ± 6,13 0,50 -2,92 3,91 0,70
Apical infero-septal segment 43 -19,76 ± 5,77 26 -19,11 ± 5,29 -0,65 -4,33 3,04 0,64
Apical segments avg 43 -18,45 ± 4,01 26 -17,73 ± 4,24 -0,72 -3,41 1,98 0,48
Global (avg of all segments) 43 -18,10 ± 2,79 26 -18,36 ± 2,05 0,26 -1,41 1,94 0,68
Variable
99% CI of 
Difference
 (N)  Mean  (N)  Mean
Diff.
Mean  p-value Ɨ± SD ± SD
Patients Healthy volunteers
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Appendix V. Left ventricular 3-Dimensional Strain and Strain Rate: segmental 
data (cont.) 
 
 
 
 
 
 
Lower Upper
LV Radial Strain (%)
Basal antero-septal segment 43 55,10 ± 17,07 23 50,06 ± 13,27 5,04 -5,84 15,92 0,22
Basal anterior segment 43 56,03 ± 17,52 26 55,79 ± 15,40 0,24 -10,80 11,28 0,95
Basal lateral segment 43 62,08 ± 18,98 25 57,08 ± 14,48 5,00 -6,66 16,66 0,26
Basal posterior segment 42 55,21 ± 16,28 25 54,29 ± 11,96 0,92 -9,03 10,86 0,81
Basal inferior segment 43 48,08 ± 17,92 25 52,15 ± 12,93 -4,07 -14,93 6,79 0,32
Basal infero-septal segment 43 45,64 ± 21,36 26 59,75 ± 14,54 -14,11 -26,69 -1,53 0,004
Basal segments avg 43 53,61 ± 9,93 26 55,44 ± 8,67 -1,82 -8,07 4,42 0,44
Median antero-septal segment 43 82,66 ± 36,90 26 68,65 ± 16,65 14,01 -3,27 31,29 0,04
Median anterior segment 43 83,39 ± 22,81 25 74,18 ± 24,38 9,21 -6,39 24,81 0,12
Median lateral segment 43 82,04 ± 22,82 26 83,46 ± 23,28 -1,42 -16,56 13,72 0,80
Median posterior segment 43 85,00 ± 25,70 25 71,62 ± 18,31 13,38 -2,16 28,92 0,03
Median inferior segment 43 75,32 ± 38,72 25 66,86 ± 23,04 8,46 -14,14 31,05 0,32
Median infero-septal segment 43 55,15 ± 25,56 26 60,41 ± 22,09 -5,25 -21,27 10,76 0,39
Median segments avg 43 77,26 ± 20,61 26 71,10 ± 12,16 6,16 -5,64 17,97 0,17
Apical anterior segment 43 82,84 ± 40,01 26 63,95 ± 26,90 18,89 -4,62 42,39 0,04
Apical lateral segment 42 88,53 ± 36,51 26 73,62 ± 34,18 14,91 -8,69 38,50 0,10
Apical inferior segment 41 95,12 ± 45,75 24 92,38 ± 38,44 2,73 -26,78 32,24 0,81
Apical infero-septal segment 43 65,95 ± 37,26 25 62,31 ± 32,45 3,64 -20,10 27,38 0,69
Apical segments avg 43 83,67 ± 31,48 26 72,85 ± 22,23 10,82 -7,87 29,51 0,13
Global (avg of all segments) 43 69,79 ± 15,67 26 65,61 ± 9,99 4,18 -4,93 13,28 0,23
LV 3D Strain Rate (%/ms)
Basal antero-septal segment 43 -0,19 ± 0,05 26 -0,18 ± 0,05 -0,01 -0,04 0,02 0,46
Basal anterior segment 43 -0,20 ± 0,05 26 -0,19 ± 0,05 -0,01 -0,04 0,03 0,62
Basal lateral segment 43 -0,19 ± 0,04 26 -0,19 ± 0,06 0,00 -0,03 0,03 0,99
Basal posterior segment 43 -0,18 ± 0,04 26 -0,20 ± 0,10 0,02 -0,03 0,06 0,26
Basal inferior segment 43 -0,19 ± 0,05 26 -0,20 ± 0,06 0,01 -0,02 0,04 0,43
Basal infero-septal segment 43 -0,18 ± 0,04 26 -0,22 ± 0,08 0,04 0,00 0,08 0,01
Basal segments avg 43 -0,19 ± 0,02 26 -0,20 ± 0,04 0,01 -0,01 0,03 0,24
Median antero-septal segment 43 -0,20 ± 0,05 26 -0,20 ± 0,06 0,01 -0,03 0,04 0,57
Median anterior segment 43 -0,21 ± 0,04 26 -0,20 ± 0,04 -0,01 -0,04 0,02 0,30
Median lateral segment 43 -0,21 ± 0,05 26 -0,21 ± 0,07 0,00 -0,04 0,04 0,96
Median posterior segment 43 -0,21 ± 0,05 26 -0,18 ± 0,04 -0,03 -0,06 0,01 0,03
Median inferior segment 43 -0,20 ± 0,06 26 -0,21 ± 0,05 0,00 -0,03 0,04 0,75
Median infero-septal segment 43 -0,20 ± 0,06 26 -0,19 ± 0,04 -0,01 -0,05 0,03 0,41
Median segments avg 43 -0,20 ± 0,03 26 -0,20 ± 0,03 -0,01 -0,03 0,01 0,41
Apical anterior segment 43 -0,20 ± 0,05 26 -0,18 ± 0,05 -0,03 -0,06 0,01 0,03
Apical lateral segment 43 -0,23 ± 0,10 26 -0,20 ± 0,09 -0,03 -0,09 0,03 0,19
Apical inferior segment 43 -0,22 ± 0,09 26 -0,24 ± 0,07 0,01 -0,04 0,07 0,50
Apical infero-septal segment 43 -0,23 ± 0,14 26 -0,17 ± 0,05 -0,06 -0,14 0,01 0,03
Apical segments avg 43 -0,22 ± 0,07 26 -0,20 ± 0,04 -0,03 -0,07 0,01 0,06
Global (avg of all segments) 43 -0,20 ± 0,03 26 -0,20 ± 0,03 -0,01 -0,02 0,01 0,46
LV circumferential Strain Rate (%/ms)
Basal antero-septal segment 43 -0,11 ± 0,03 26 -0,11 ± 0,04 -0,01 -0,03 0,02 0,47
Basal anterior segment 43 -0,12 ± 0,03 26 -0,11 ± 0,04 -0,01 -0,03 0,01 0,22
Basal lateral segment 43 -0,12 ± 0,03 26 -0,12 ± 0,03 0,01 -0,01 0,03 0,36
Basal posterior segment 43 -0,12 ± 0,03 26 -0,13 ± 0,03 0,01 -0,01 0,03 0,30
Basal inferior segment 43 -0,11 ± 0,03 26 -0,12 ± 0,04 0,01 -0,01 0,03 0,29
Basal infero-septal segment 43 -0,11 ± 0,03 26 -0,12 ± 0,04 0,01 -0,01 0,04 0,17
Basal segments avg 43 -0,11 ± 0,02 26 -0,12 ± 0,02 0,00 -0,01 0,02 0,40
Median antero-septal segment 43 -0,16 ± 0,05 26 -0,15 ± 0,04 -0,02 -0,05 0,01 0,11
Median anterior segment 43 -0,18 ± 0,04 26 -0,17 ± 0,05 -0,02 -0,04 0,01 0,17
Median lateral segment 43 -0,17 ± 0,04 26 -0,17 ± 0,06 0,00 -0,03 0,03 0,86
Median posterior segment 43 -0,17 ± 0,05 26 -0,16 ± 0,03 -0,01 -0,04 0,02 0,35
Median inferior segment 43 -0,15 ± 0,05 26 -0,15 ± 0,05 0,00 -0,03 0,03 0,91
Median infero-septal segment 43 -0,14 ± 0,05 26 -0,13 ± 0,05 0,00 -0,03 0,03 0,90
Median segments avg 43 -0,16 ± 0,03 26 -0,16 ± 0,03 -0,01 -0,03 0,01 0,32
Apical anterior segment 43 -0,17 ± 0,06 26 -0,15 ± 0,05 -0,03 -0,06 0,01 0,07
Apical lateral segment 43 -0,18 ± 0,06 26 -0,16 ± 0,06 -0,02 -0,06 0,01 0,10
Apical inferior segment 43 -0,18 ± 0,10 26 -0,18 ± 0,05 0,01 -0,05 0,06 0,77
Apical infero-septal segment 43 -0,16 ± 0,11 26 -0,12 ± 0,06 -0,04 -0,10 0,03 0,14
Apical segments avg 43 -0,17 ± 0,06 26 -0,15 ± 0,03 -0,02 -0,05 0,01 0,13
Global (avg of all segments) 43 -0,10 ± 0,15 26 -0,10 ± 0,01 0,00 -0,02 0,01 0,23
Diff.
Mean
99% CI of 
Difference
 (N)  Mean ± SD  (N)  Mean ± SD
Variable
Patients Healthy volunteers
 p-value Ɨ
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Appendix V. Left ventricular 3-Dimensional Strain and Strain Rate: segmental 
data (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lower Upper
LV Longitudinal Strain Rate (%/ms)
Basal antero-septal segment 43 -0,12 ± 0,03 26 -0,12 ± 0,03 0,00 -0,02 0,02 0,92
Basal anterior segment 43 -0,11 ± 0,03 26 -0,12 ± 0,03 0,00 -0,02 0,02 0,63
Basal lateral segment 43 -0,12 ± 0,03 26 -0,11 ± 0,03 -0,01 -0,03 0,01 0,25
Basal posterior segment 43 -0,10 ± 0,03 26 -0,10 ± 0,04 0,00 -0,02 0,02 0,92
Basal inferior segment 43 -0,10 ± 0,03 26 -0,11 ± 0,03 0,01 -0,01 0,03 0,35
Basal infero-septal segment 43 -0,11 ± 0,04 26 -0,12 ± 0,04 0,01 -0,02 0,04 0,28
Basal segments avg 43 -0,11 ± 0,02 26 -0,11 ± 0,02 0,00 -0,01 0,02 0,67
Median antero-septal segment 43 -0,11 ± 0,03 26 -0,09 ± 0,03 -0,01 -0,03 0,01 0,10
Median anterior segment 43 -0,09 ± 0,02 26 -0,10 ± 0,02 0,00 -0,01 0,02 0,59
Median lateral segment 43 -0,10 ± 0,02 26 -0,10 ± 0,01 0,00 -0,02 0,01 0,45
Median posterior segment 43 -0,10 ± 0,02 26 -0,08 ± 0,02 -0,01 -0,03 0,00 0,03
Median inferior segment 43 -0,11 ± 0,03 26 -0,10 ± 0,02 0,00 -0,02 0,01 0,54
Median infero-septal segment 43 -0,10 ± 0,03 26 -0,10 ± 0,02 0,00 -0,01 0,02 0,76
Median segments avg 43 -0,10 ± 0,02 26 -0,10 ± 0,01 0,00 -0,01 0,01 0,26
Apical anterior segment 43 -0,08 ± 0,02 26 -0,08 ± 0,02 -0,01 -0,02 0,01 0,28
Apical lateral segment 43 -0,10 ± 0,02 26 -0,09 ± 0,02 -0,01 -0,02 0,01 0,29
Apical inferior segment 43 -0,10 ± 0,02 26 -0,10 ± 0,03 0,00 -0,02 0,01 0,65
Apical infero-septal segment 43 -0,11 ± 0,03 26 -0,10 ± 0,03 -0,01 -0,03 0,01 0,21
Apical segments avg 43 -0,10 ± 0,02 26 -0,09 ± 0,02 -0,01 -0,02 0,01 0,22
Global (avg of all segments) 43 -0,10 ± 0,01 26 -0,10 ± 0,01 0,00 -0,01 0,01 0,42
LV Radial Strain Rate (%/ms)
Basal antero-septal segment 43 0,31 ± 0,09 26 0,31 ± 0,11 0,01 -0,06 0,07 0,77
Basal anterior segment 43 0,31 ± 0,10 26 0,31 ± 0,11 0,00 -0,07 0,07 0,96
Basal lateral segment 43 0,33 ± 0,09 26 0,31 ± 0,10 0,02 -0,04 0,08 0,42
Basal posterior segment 43 0,30 ± 0,10 26 0,30 ± 0,10 0,00 -0,06 0,07 0,87
Basal inferior segment 43 0,27 ± 0,10 26 0,31 ± 0,13 -0,04 -0,12 0,03 0,14
Basal infero-septal segment 43 0,26 ± 0,13 26 0,35 ± 0,11 -0,09 -0,17 0,00 0,01
Basal segments avg 43 0,30 ± 0,05 26 0,32 ± 0,07 -0,02 -0,06 0,02 0,23
Median antero-septal segment 43 0,50 ± 0,28 26 0,38 ± 0,11 0,11 -0,01 0,24 0,02
Median anterior segment 43 0,45 ± 0,13 26 0,40 ± 0,13 0,05 -0,03 0,13 0,12
Median lateral segment 43 0,43 ± 0,14 26 0,44 ± 0,14 -0,01 -0,10 0,08 0,77
Median posterior segment 43 0,47 ± 0,18 26 0,40 ± 0,11 0,07 -0,04 0,17 0,10
Median inferior segment 43 0,44 ± 0,29 26 0,42 ± 0,19 0,03 -0,14 0,20 0,68
Median infero-septal segment 43 0,34 ± 0,15 26 0,33 ± 0,10 0,01 -0,08 0,10 0,72
Median segments avg 43 0,44 ± 0,14 26 0,39 ± 0,07 0,04 -0,02 0,11 0,08
Apical anterior segment 43 0,51 ± 0,37 26 0,36 ± 0,17 0,16 -0,05 0,36 0,05
Apical lateral segment 43 0,51 ± 0,28 26 0,41 ± 0,20 0,10 -0,07 0,26 0,12
Apical inferior segment 43 0,72 ± 1,19 26 0,54 ± 0,26 0,18 -0,45 0,81 0,45
Apical infero-septal segment 43 0,43 ± 0,37 26 0,37 ± 0,23 0,06 -0,15 0,28 0,43
Apical segments avg 43 0,55 ± 0,50 26 0,40 ± 0,11 0,14 -0,12 0,41 0,15
Global (avg of all segments) 43 0,41 ± 0,16 26 0,37 ± 0,06 0,04 -0,05 0,13 0,22
 p-value Ɨ
Healthy volunteers
Diff.
Mean
99% CI of 
Difference
 (N)  Mean ± SD  (N)  Mean ± SD
ƗTwo-sided P values for continuous variables were calculated with the use of the t-test. Significant difference between groups when p<0.01
Patients 
Variable
Appendix VI -  LV Diastolic Function and 3D LV strain parameters according to age and gender 
Table 1 - LV Diastolic Function parameters 
 
 
Table 2 - LV 3D Strain and Strain Rate 
Mean ± SD  Mean ± SD Mean ± SD  Mean ± SD Mean ± SD  Mean ± SD
Left atrium volume indexed (ml/m2) 38,28 ± 13,81 45,12 ± 15,91 0,20 49,06 ± 17,02 44,56 ± 12,43 0,45 43,67 ± 16,19 44,89 ± 14,39 0,76
LV E wave (cm/s) 95,86 ± 11,20 83,80 ± 14,02 0,01 92,94 ± 12,90 81,34 ± 16,45 0,05 94,40 ± 11,96 82,85 ± 14,79 0,001
LV E/A ratio 1,85 ± 0,49 1,32 ± 0,41 0,002 1,82 ± 0,48 1,09 ± 0,32 < 0.001 1,84 ± 0,48 1,23 ± 0,39 0,000
LV Isovolumic relaxation time (ms) 85,48 ± 14,62 100,50 ± 17,30 0,02 93,38 ± 18,52 100,50 ± 13,96 0,29 89,29 ± 16,77 100,50 ± 15,67 0,01
MV decelaration time (ms) 191,40 ± 39,65 204,44 ± 37,82 0,34 195,93 ± 38,79 216,25 ± 39,60 0,19 193,67 ± 38,61 209,17 ± 38,31 0,12
LV E ´  lateral wall 14,33 ± 2,31 9,98 ± 1,68 < 0.001 12,97 ± 2,57 9,51 ± 1,84 0,001 13,65 ± 2,50 9,79 ± 1,73 0,000
MV E´ septal (cm/s) 10,46 ± 1,67 8,12 ± 1,56 < 0.001 10,48 ± 1,50 7,93 ± 1,45 < 0.001 10,47 ± 1,56 8,05 ± 1,50 0,000
LV E/E' lateral 6,87 ± 1,42 8,71 ± 2,61 0,02 7,49 ± 2,04 8,94 ± 2,77 0,13 7,18 ± 7,00 8,80 ± 2,63 0,007
LV E/E´septal 9,41 ± 1,97 10,49 ± 2,14 0,14 8,97 ± 1,47 10,43 ± 2,21 0,05 9,19 ± 1,72 10,47 ± 2,13 0,01
LV E/E´avg 8,13 ± 1,55 9,61 ± 2,08 0,03 8,16 ± 1,57 9,68 ± 2,31 0,06 8,15 ± 1,53 9,64 ± 2,14 0,003
Mitral A wave - PV a wave (difference) -19,67 ± 10,23 -8,10 ± 22,31 0,26 -5,18 ± 50,13 -23,24 ± 45,83 0,45 -10,29 ± 40,67 -14,34 ± 33,57 0,75
Pulmonary veins a wave reversal (cm/s) 21,06 ± 3,55 25,38 ± 7,07 0,07 22,80 ± 3,74 26,61 ± 8,22 0,17 21,93 ± 3,68 25,85 ± 7,35 0,03
<= 40 y > 40 y
P-value
Variable
Female Male Both Gender
<= 40 y > 40 y
P-value
<= 40 y > 40 y
P-value
Mean ± SD  Mean ± SD Mean ± SD  Mean ± SD Mean ± SD  Mean ± SD
LV global longitudinal strain (%) -20,25 ± 2,32 -16,30 ± 1,92 0,00 -18,18 ± 3,32 -16,37 ± 2,67 0,19 -19,22 ± 2,99 -16,34 ± 2,25 0,00
3D LV strain twist (degree) 9,05 ± 4,76 14,69 ± 7,69 0,05 9,23 ± 5,87 9,02 ± 5,79 0,94 9,14 ± 5,22 12,00 ± 7,28 0,146
3D LV strain torsion ( degree/cm) 1,10 ± 0,57 1,89 ± 1,05 0,041 1,03 ± 0,73 1,07 ± 0,77 0,906 1,07 ± 0,64 1,50 ± 0,99 0,097
LV 3D strain global (%) -33,07 ± 2,95 -35,13 ± 3,02 0,12 -30,99 ± 3,87 -30,23 ± 3,83 0,66 -32,03 ± 3,52 -32,80 ± 4,18 0,52
LV circunferential strain global (%) -23,38 ± 3,58 -26,72 ± 2,18 0,02 -21,37 ± 3,50 -22,35 ± 3,48 0,53 -22,37 ± 3,60 -24,64 ± 3,58 0,04
LV longitudinal strain global (%) -19,85 ± 2,24 -17,33 ± 2,33 0,017 -18,27 ± 3,50 -16,84 ± 2,21 0,281 -19,06 ± 2,98 -17,09 ± 2,23 0,019
LV radial strain global (%) 73,19 ± 13,22 78,04 ± 16,11 0,449 65,81 ± 15,30 61,37 ± 14,39 0,503 69,50 ± 14,46 70,10 ± 17,20 0,901
LV 3D strain rate (%/ms) -0,20 ± 0,02 -0,22 ± 0,03 0,01 -0,20 ± 0,03 -0,19 ± 0,03 0,88 -0,20 ± 0,02 -0,21 ± 0,03 0,140
LV circumferential strain rate (%/ms) -0,14 ± 0,02 -0,16 ± 0,03 0,05 -0,14 ± 0,02 -0,14 ± 0,03 0,47 -0,14 ± 0,02 -0,15 ± 0,03 0,06
LV longitudinal strain rate (%/ms) -0,11 ± 0,01 -0,10 ± 0,01 0,35 -0,10 ± 0,02 -0,10 ± 0,02 0,93 -0,10 ± 0,02 -0,10 ± 0,01 0,608
LV radial strain rate (%/ms) 0,40 ± 0,07 0,51 ± 0,27 0,21 0,37 ± 0,10 0,36 ± 0,10 0,72 0,39 ± 0,08 0,44 ± 0,22 0,32
ƗTwo-sided P values for continuous variables were calculated with the use of the t-test. Significant difference between groups when p<0.01
<= 40 y > 40 y
P-value
<= 40 y > 40 y
P-value
Variable
Female Male Both Gender
<= 40 y > 40 y
P-value
Appendix VII – Cardiac structure and clinical conditions in patients with SCD 
according to TRV groups 
 
Table 1 - Cardiac structure and function in patients with SCD according to TRV 
groups 
 
Lower Upper
LV Structure
LV septum diameter (mm) 28 9,54 ± 1,37 29 10,29 ± 1,34 -0,74 -1,44 -0,05 0,04
LV posterior wall diameter (mm) 29 9,80 ± 1,57 29 10,34 ± 1,65 -0,54 -1,37 0,28 0,19
LV 2D diastolic volume indexed (ml/m2) 26 72,30 ± 17,24 27 75,73 ± 25,62 -3,44 -14,66 7,79 0,54
LV 2D systolic volume indexed (ml/m2) 29 27,10 ± 9,77 30 25,42 ± 11,37 1,68 -3,76 7,12 0,54
LV mass index (g/m2) 29 86,34 ± 20,76 29 95,39 ± 35,54 -9,05 -25,36 7,26 0,27
RV structure
RV diastolic area apical view (cm2) 30 19,97 ± 5,21 31 22,09 ± 5,88 -2,12 -4,97 0,73 0,14
RV systolic area apical view (cm2) 30 11,35 ± 3,22 31 12,36 ± 3,20 -1,01 -2,66 0,63 0,22
3D RV end diastolic volume (ml) 29 99,56 ± 23,39 29 120,31 ± 39,15 -20,74 -37,71 -3,78 0,02
3D RV end systolic volume (ml) 29 44,16 ± 14,94 29 55,23 ± 18,46 -11,08 -19,91 -2,24 0,015
LA/RA structure
Left atrium volume indexed (ml/m2) 30 41,08 ± 12,46 30 47,48 ± 17,13 -6,40 -16,69 3,91 0,10
RA volume indexed (ml/m2) 28 37,99 ± 10,12 29 37,80 ± 13,44 0,20 -6,14 6,53 0,95
LV systolic function
Global function index lateral 30 0,86 ± 0,21 30 1,10 ± 0,36 -0,24 -0,39 -0,09 0,003
Global function index septal 27 1,12 ± 0,27 25 1,30 ± 0,35 -0,17 -0,34 -0,01 0,04
LV 2D Ejection Fraction (%) 30 64,34 ± 6,93 31 67,94 ± 7,20 -3,60 -7,22 0,02 0,05
LV 2D cardiac output (L/min) 28 5,85 ± 1,70 29 6,84 ± 2,24 -0,98 -2,00 0,04 0,06
LV 2D stroke volume (mL) 29 77,40 ± 18,75 29 89,05 ± 27,85 -11,65 -24,00 0,71 0,06
LV S´ wave lateral (cm/s) 30 9,95 ± 1,92 30 8,93 ± 2,55 1,02 -0,16 2,19 0,09
LV S' wave septal (cm/s) 29 8,31 ± 1,24 25 8,25 ± 0,91 0,06 -0,50 0,62 0,84
RV systolic function
Estimated PVR (Woods unit) 27 1,44 ± 0,35 25 1,67 ± 0,25 -0,23 -0,40 -0,06 0,010
RV MPI by TDI 28 0,34 ± 0,09 29 0,34 ± 0,12 0,00 -0,05 0,06 0,92
RV S´wave (cm/s) 30 14,10 ± 1,99 31 15,50 ± 3,12 -1,41 -2,75 -0,06 0,04
TAPSE (mm) 30 28,03 ± 5,12 30 30,37 ± 5,88 -2,33 -5,18 0,51 0,11
RV fractional area change (%) 30 43,08 ± 9,60 31 43,33 ± 7,92 -0,25 -4,75 4,26 0,91
3D RV Ejection fraction (%) 29 56,15 ± 7,66 29 53,65 ± 6,55 2,50 -1,25 6,25 0,19
LV 3D Strain
LV 3D ejection fraction (%) 30 50,88 ± 5,06 30 51,61 ± 4,94 -0,73 -3,81 2,35 0,64
LV global longitudinal strain (%) 22 -18,38 ± 3,19 21 -17,22 ± 2,74 -1,16 -3,61 1,30 0,21
LV 3D strain global (%) 22 -31,70 ± 3,57 21 -33,14 ± 4,04 1,43 -1,70 4,57 0,22
LV circunferential strain global (%) 22 -22,54 ± 3,43 21 -24,47 ± 3,85 1,93 -1,07 4,93 0,09
LV longitudinal strain global (%) 22 -18,30 ± 2,89 21 -17,89 ± 2,74 -0,40 -2,73 1,92 0,64
LV radial strain global (%) 22 67,01 ± 13,39 21 72,71 ± 17,60 -5,70 -18,54 7,14 0,24
LV 3D strain rate (%/ms) 22 -0,20 ± 0,02 21 -0,21 ± 0,04 0,01 -0,02 0,03 0,34
LV circumferential strain rate (%/ms) 22 -0,14 ± 0,02 21 -0,15 ± 0,03 0,01 -0,01 0,03 0,19
LV longitudinal strain rate (%/ms) 22 -0,10 ± 0,01 21 -0,10 ± 0,02 0,00 -0,01 0,01 0,70
LV radial strain rate (%/ms) 22 0,37 ± 0,06 21 0,45 ± 0,22 -0,08 -0,21 0,05 0,09
LV RV Strain
 RV longitudinal strain free wall_avg 23 -23,63 ± 11,12 26 -23,46 ± 9,61 -0,17 -4,30 3,97 0,91
 RV longitudinal strain basal free wall 19 -21,42 ± 11,58 24 -21,71 ± 10,51 0,29 -6,02 6,60 0,90
RV longitudinal strain median free wall 22 -25,77 ± 13,00 22 -24,00 ± 12,82 -1,77 -9,06 5,51 0,51
RV longitudinal strain apical free wall 22 -23,00 ± 11,62 21 -25,52 ± 12,52 2,52 -3,97 9,02 0,30
 RV longitudinal strain basal septum 19 -12,79 ± 8,25 23 -14,57 ± 7,97 1,78 -3,84 7,39 0,40
RV longitudinal strain median septum 23 -18,22 ± 8,82 25 -17,16 ± 8,19 -1,06 -5,24 3,13 0,50
 RV longitudinal strain apical septum 21 -13,90 ± 8,39 25 -17,52 ± 9,53 3,62 -2,23 9,46 0,10
All septum segments_avg 23 -15,20 ± 4,35 26 -16,42 ± 5,24 1,22 -2,50 4,94 0,16
RV Global strain (avg of 6 segments) 23 -19,37 ± 8,98 26 -19,80 ± 7,98 0,42 -2,78 3,62 0,72
ƗTwo-sided P values for continuous variables were calculated with the use of the t-test. Significant difference between groups when p<0.01
SD
Variable
TRV < 2.5 m/s TRV ≥ 2.5 m/s
Diff.
Mean
99% CI
of Difference  p-value Ɨ
 (N)  Mean ± SD  (N)  Mean ±
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Appendix VIII - Pearson correlation of clinical and laboratory variables with LV 
2D volumes in Univariate analysis 
 
 
 
 
r P-value r P-value
Age (years) 61 -0,36 0,00 -0,30 0,02
Heart rate echo (bpm) 61 -0,17 0,18 -0,11 0,41
Body mass index (kg/m^2) 61 -0,41 0,001 -0,43 0,001
LV mass index (g/m2) 53 0,59 <0.001 0,69 <0.001
Systolic blood pressue (mmHg) 61 -0,31 0,01 -0,26 0,04
Diastolic blood pressue  (mmHg) 61 -0,50 <0.001 -0,54 <0.001
TRV screening (m/s) 61 0,04 0,76 0,23 0,08
ProBNP, log 10 60 0,20 0,13 0,27 0,04
Clinical history
Alcohol history 55 0,01 0,96 0,05 0,69
Total number of transfusion in lifetime 46 -0,04 0,81 -0,13 0,37
Leg ulcers 54 -0,05 0,72 0,11 0,42
Vaso-occl, pain crisis 52 -0,06 0,65 -0,07 0,60
History of smoking 55 -0,02 0,90 -0,03 0,81
Lung problems 55 0,19 0,17 0,20 0,14
Spleen problems 55 -0,15 0,28 -0,07 0,58
Blood Tests
Alkaline phosphatase (uL) 58 0,24 0,07 0,25 0,05
Absolute reticulocyte count (x10^3 cells/lL) 60 0,51 <0.001 0,58 <0.001
Aspartate aminotransferase (u/L) 57 0,46 <0.001 0,58 <0.001
Blood urea nitrogen (mmol/L) 60 -0,14 0,30 -0,24 0,06
Creatinine (umol/l) 60 0,05 0,73 -0,12 0,36
Hematocrit (SI units) 59 -0,27 0,04 -0,51 <0.001
Haemoglobin(g/dl) 60 -0,30 0,02 -0,51 <0.001
LDH (IU/l) 53 0,49 <0.001 0,64 <0.001
Mean cell volume (fl) 60 0,24 0,06 0,29 0,03
oxygen saturation on air 61 -0,29 0,02 -0,47 <0.001
Platelet count (x10^3 cells/ul) 60 0,32 0,01 0,35 0,006
Red blood count (x10^6/ul) 60 -0,38 0,003 -0,58 <0.001
Red cell distribution width (%) 58 0,22 0,10 0,40 0,002
Reticulocytes (%) 60 0,55 <0.001 0,67 <0.001
Total bilirubin (umol/l) 58 0,42 0,001 0,47 <0.001
White blood cell count (x10^3 cells/ul) 60 0,25 0,05 0,34 0,007
LV Diastolic function 
LV E wave (cm/s) 61 0,16 0,21 0,26 0,05
LV E/A ratio 60 0,18 0,18 0,16 0,21
MV decelaration time (ms) 60 0,14 0,30 0,07 0,60
LV Isovolumic relaxation time (ms) 55 -0,02 0,88 0,01 0,93
LV E ´  lateral wall 60 0,13 0,33 0,08 0,55
LV E/E' lateral 60 -0,03 0,84 0,08 0,56
MV E´ septal (cm/s) 60 0,23 0,08 0,28 0,03
LV E/E´septal 60 -0,09 0,47 -0,08 0,52
LV E/E´avg 59 -0,07 0,58 0,00 0,99
Left atrium volume indexed (ml/m2) 60 0,36 0,005 0,54 <0.001
ƗTwo-sided P values for continuous variables were calculated with the use of the t-test. Significant difference 
between groups when p<0.01
Variable N
LV 2D systolic volume 
indexed (ml/m2)
LV 2D diastolic volume 
indexed (ml/m2)
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Appendix IX – Associations with Haemolysis markers 
 
N r P -value N r P -value N r P -value N r P -value
LV function and structure
Global function index lateral 60 -0,01 0,94 53 -0,12 0,37 58 0,08 0,56 60 -0,12 0,37
Global function index septal 60 0,18 0,18 53 -0,20 0,13 58 -0,01 0,94 60 -0,20 0,13
LV 3D ejection fraction (%) 43 -0,04 0,82 37 -0,11 0,47 42 -0,14 0,36 43 -0,11 0,47
LV S´ wave lateral (cm/s) 60 -0,21 0,10 53 0,18 0,16 58 -0,19 0,15 60 0,18 0,16
LV S' wave septal (cm/s) 60 -0,43 0,001 53 0,36 0,005 58 0,15 0,25 60 0,36 0,005
LV 2D diastolic volume indexed (ml/m2) 60 -0,51 <0,001 53 0,67 <0,001 58 0,47 <0,001 60 0,67 <0,001
LV 2D systolic volume indexed (ml/m2) 60 -0,30 0,02 53 0,55 <0,001 58 0,42 0,001 60 0,55 <0,001
LV mass index (g/m2) 52 -0,22 0,12 45 0,27 0,05 50 0,22 0,13 52 0,27 0,05
Left ventricular strain and strain rate
3D LV strain twist (degree) 43 0,02 0,92 37 -0,01 0,93 42 0,11 0,50 43 -0,01 0,93
3D LV strain torsion ( degree/cm) 43 0,07 0,68 37 -0,08 0,61 42 0,05 0,74 43 -0,08 0,61
LV 3DST global avg of all segments 43 0,09 0,58 37 0,14 0,36 42 0,17 0,27 43 0,14 0,36
LV longitudinal strain global avg of all 
segments
43 0,13 0,40 37 -0,15 0,32 42 0,00 0,99 43 -0,15 0,32
LV circunferential strain  global 43 0,11 0,48 37 0,21 0,17 42 0,03 0,84 43 0,21 0,17
LV radial strain global avg of all segments 43 -0,03 0,87 37 -0,16 0,30 42 -0,09 0,57 43 -0,16 0,30
LV 3D  Strain rate global 43 -0,04 0,81 37 0,18 0,24 42 0,12 0,45 43 0,18 0,24
LV longitudinal strain rate global 43 0,05 0,75 37 -0,03 0,85 42 0,10 0,51 43 -0,03 0,85
LV circunferential strain rate global 43 -0,07 0,66 37 0,33 0,03 42 0,12 0,44 43 0,33 0,03
LV radial  strain rate global 43 0,18 0,24 37 -0,31 0,05 42 -0,17 0,28 43 -0,31 0,05
Right ventricular function
Tricuspid regurgitant jet velocity 
screening (m/s)
60 -0,22 0,10 53 0,18 0,17 58 0,27 0,04 60 0,18 0,17
Estimated pulmonary systolic pressure 
(mmHg)
60 -0,21 0,11 53 0,18 0,16 58 0,31 0,02 60 0,18 0,16
Pulmonary vascular resistance (Woods 
unit)
51 -0,03 0,84 47 0,02 0,88 49 0,07 0,62 51 0,02 0,88
RA volume indexed 2D (ml/m2) 56 -0,40 0,002 49 0,50 <0,001 54 0,28 0,04 56 0,50 <0,001
3D RV Ejection fraction (%) 57 -0,20 0,13 51 0,14 0,30 56 0,01 0,94 57 0,14 0,30
3D RV end diastolic volume 57 -0,19 0,16 51 0,40 0,002 56 0,46 <0,001 57 0,40 0,002
3D RV end systolic volume 57 -0,08 0,55 51 0,28 0,03 56 0,38 0,004 57 0,28 0,03
RV diastolic area apical view (cm2) 60 -0,23 0,08 53 0,43 0,001  58 0,40 0,002 60 0,43 0,001
RV systolic area apical view (cm2) 60 -0,04 0,77 53 0,27 0,04 58 0,42 0,001 60 0,27 0,04
RV fractional area change (%) 60 -0,30 0,02 53 0,21 0,12 58 -0,04 0,78 60 0,21 0,12
RV E wave (cm/s) 55 0,05 0,72 49 -0,01 0,93 53 -0,11 0,45 55 -0,01 0,93
RV E/A 47 0,28 0,05 43 -0,10 0,48 45 -0,25 0,09 47 -0,10 0,48
RV E´/A´ 55 0,13 0,36 48 0,05 0,74 54 -0,01 0,94 55 0,05 0,74
RV E´wave (cm/s) 60 -0,16 0,22 53 0,26 0,05 58 0,15 0,28 60 0,26 0,05
RV E/E´ 55 0,23 0,09 49 -0,25 0,06 53 -0,18 0,21 55 -0,25 0,06
RV isovolumic relaxation time (ms) 46 -0,24 0,10 42 0,19 0,21 44 0,06 0,72 46 0,19 0,21
RV myocardial performance index by TDI 57 -0,16 0,23 50 0,03 0,81 55 0,06 0,66 57 0,03 0,81
RV S´wave (cm/s) 60 -0,39 0,002 53 0,30 0,02 58 0,26 0,05 60 0,30 0,02
Tricuspid annular systolic motion (mm) 59 -0,43 0,001 52 0,38 0,003  57 0,04 0,75 59 0,38 0,003
 RV longitudinal strain free wall_avg 59 0,03 0,80 52 0,04 0,75 57 -0,05 0,69 49 0,24 0,10
RV Global strain (avg of 6 segments) 59 0,09 0,52 52 -0,01 0,97 57 -0,05 0,70 49 0,15 0,32
 LV diastolic function 
LV E wave (cm/s) 60 -0,20 0,13 53 0,12 0,39 58 0,15 0,25 60 0,32 0,014
MV decelaration time (ms) 60 -0,11 0,40 53 0,13 0,36 58 0,21 0,11 60 0,10 0,44
LV Isovolumic relaxation time (ms) 55 0,00 0,99 49 0,26 0,07 53 -0,03 0,83 55 -0,16 0,23
LV E/A ratio 60 0,07 0,57 53 -0,14 0,31 58 -0,01 0,93 60 0,17 0,20
LV E/E' lateral 60 -0,20 0,12 53 0,13 0,34 58 0,17 0,21 60 0,02 0,89
LV E/E´septal 60 -0,06 0,65 53 0,00 0,99 58 0,13 0,33 60 -0,01 0,94
LV E/E´avg 59 -0,16 0,23 52 0,09 0,53 57 0,17 0,21 59 0,01 0,96
Variables
Markers of Hemolysis
Hemoglobin (g/dl) LDH (IU/l) Total bilirubin (umol/l) Reticulocytes (%)
255 
 
Appendix X - Associations with TRV by Pearson Rank Correlation Coefficient   
 
Pearson Correlation  
(r )
P -value
LV systolic function 
Global function index lateral 60 0,31 0,02
Global function index septal 60 0,21 0,11
LV 3D ejection fraction (%) 43 0,05 0,77
LV S´ wave lateral (cm/s) 60 -0,21 0,11
LV S' wave septal (cm/s) 60 0,05 0,69
LV 2D diastolic volume indexed (ml/m2) 61 0,23 0,08
LV 2D systolic volume indexed (ml/m2) 61 0,04 0,76
Interventricular septum diameter (mm) 61 0,17 0,19
LV posterior wall diameter (mm) 61 0,25 0,05
LV 2D end-diastolic diameter (mm) 61 0,37 0,003
LV 2D end-systolic diameter (mm) 61 0,14 0,28
LV 2D Ejection fraction (%) 61 0,25 0,05
LV mass index (g/m2) 53 0,28 0,04
LV 2D stroke volume 60 0,32 0,01
LV cardiac output (L/min) 61 0,32 0,01
Right ventricular function:
Pulmonary vascular resistance (Woods unit) 52 0,50 <0,001
RA volume indexed 2D (ml/m2) 57 0,28 0,04
3D RV Ejection fraction (%) 58 -0,10 0,46
3D RV end diastolic volume 58 0,43 0,001
3D RV end systolic volume 58 0,39 0,003
RV base to apex diamater (cm) 59 0,22 0,10
RV base diameter (cm) 59 0,36 0,006
RV mid diamater (cm) 59 0,27 0,04
RV diastolic area apical view (cm2) 61 0,28 0,03
RV systolic area apical view (cm2) 61 0,16 0,21
RV fractional area change (%) 61 0,14 0,28
RV E wave (cm/s) 55 0,02 0,91
RV E/A 47 -0,40 0,006
RV E´/A´ 55 -0,31 0,02
RV E´wave (cm/s) 60 0,04 0,74
RV E/E´ 55 -0,05 0,72
RV isovolumic relaxation time (ms) 46 0,22 0,14
RV myocardial performance index by TDI 57 0,07 0,59
RV S´wave (cm/s) 61 0,27 0,04
Tricuspid annular systolic motion (mm) 60 0,38 0,003
Pulmonary valve accelaration time (ms) 60 -0,03 0,82
RV longitudinal strain free wall_avg 60 0,01 0,93
RV Global strain (avg of 6 segments) 60 0,00 1,00
LV diastolic function variables
LV E wave (cm/s) 61 0,14 0,29
LV E/A ratio 60 -0,28 0,03
MV decelaration time (ms) 60 0,19 0,14
LV Isovolumic relaxation time (ms) 55 0,09 0,53
LV E ´  lateral wall 60 -0,29 0,02
Left ventricle E/E' lateral 60 0,36 0,005
MV E´ septal (cm/s) 60 -0,17 0,20
LV E/E´septal 60 0,31 0,02
Left ventricle  E/E´avg 59 0,38 0,003
Mitral A wave - PV a wave (difference) 34 -0,09 0,60
Pulmonary veins a wave reversal (cm/s) 45 0,22 0,15
Left atrium volume indexed (ml/m2) 60 0,31 0,02
LV Strain 3D variables
3D LV strain twist (degree) 43 0,33 0,03
3D LV strain torsion ( degree/cm) 43 0,31 0,05
LV 3DST global avg of all segments 43 -0,06 0,71
LV longitudinal strain global avg of all segments 43 0,09 0,56
LV circunferential strain  global 43 -0,15 0,34
LV radial strain global avg of all segments 43 0,08 0,60
LV 3D  Strain rate global 43 -0,11 0,49
LV longitudinal strain rate global 43 0,00 0,99
LV circunferential strain rate global 43 -0,03 0,85
LV radial  strain rate global 43 0,13 0,39
Variable N
Tricuspid regurgitant jet velocity (m/s)
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Appendix XI - Cardiac structure and function in patients with SCD according to LV 
diastolic function (COMPLETE) 
 
 Demographics 
Age(years) 43 36,70 10,82 18 50,12 8,42 <0,001
Height (cm) 43 168,64 9,72 18 169,24 10,51 0,838
Weight (kg) 43 67,77 9,31 18 73,34 13,74 0,149
 Body surface area (kg/m^2) 43 1,78 0,15 18 1,85 0,22 0,141
 Body Mass Index (kg/m^2) 43 23,92 3,51 18 25,51 3,79 0,134
Heart rate (bpm) 43 74,96 9,52 18 78,88 11,32 0,183
Oxygen saturation on air (%) 43 97,20 3,76 18 97,19 2,46 0,990
Systolic BP (mmHg) 43 118,36 11,17 18 122,75 20,58 0,427
Diastolic BP  (mmHg) 43 69,69 9,58 18 73,75 12,04 0,179
LV  and RV Structure
LV septum diameter (mm) 43 9,98 1,39 18 9,75 1,46 0,572
LV posterior wall diameter (mm) 43 10,08 1,67 18 10,11 1,54 0,953
LV 2D diastolic volume indexed (ml/m2) 43 75,11 23,48 18 71,05 16,41 0,527
LV 2D systolic volume indexed (ml/m2) 43 27,02 11,22 18 24,06 8,36 0,339
LV 2D mass index (g/m2) 43 93,41 31,52 18 83,32 21,02 0,304
RV structure
RV 2D diastolic area apical view (cm2) 43 21,03 5,98 18 21,08 4,62 0,976
RV 2D systolic area apical view (cm2) 43 12,02 3,35 18 11,42 2,92 0,529
RV 3D end diastolic volume (ml) 43 112,64 35,64 18 101,42 25,59 0,281
RV 3D end systolic volume (ml) 43 51,03 18,80 18 45,52 12,53 0,311
LA/RA structure
Left atrium volume indexed (ml/m2) 43 44,15 17,11 18 44,66 8,31 0,910
RA volume indexed (ml/m2) 43 38,20 12,12 18 37,03 11,28 0,746
LV and RV systolic function
Global function index lateral 43 0,87 0,23 18 1,28 0,34 <0,001
Global function index septal 43 1,15 0,32 18 1,39 0,27 0,010
LV 3D ejection fraction (%) 32 51,38 5,16 11 50,84 4,51 0,759
LV S´ wave lateral (cm/s) 43 9,62 2,50 18 8,88 1,59 0,270
LV S' wave septal (cm/s) 43 8,35 1,18 18 8,07 0,71 0,362
RV systolic function
Estimated PASP (mmHg) 43 30,61 6,72 18 35,28 5,98 0,017
TRV screening (m/s) 43 2,46 0,28 18 2,72 0,27 0,002
Estimated PVR (Woods unit) 43 1,47 0,29 18 1,79 0,30 0,002
RV MPI by TDI 43 0,32 0,11 18 0,38 0,10 0,073
RV S´wave (cm/s) 43 14,53 2,36 18 15,60 3,44 0,174
TAPSE (mm) 43 28,84 5,99 18 30,27 4,13 0,398
RV fractional area change (%) 43 42,34 8,82 18 45,66 8,20 0,193
RV 3D Ejection fraction (%) 43 54,95 7,39 18 54,74 6,72 0,924
 Strain and Strain Rate
LV global longitudinal strain (%) 32 -18,22 3,09 11 -16,62 2,46 0,130
LV 3D strain global (%) 32 -32,44 3,77 11 -32,30 4,18 0,920
LV circunferential strain global (%) 32 -23,14 3,79 11 -24,47 3,52 0,314
LV longitudinal strain global (%) 32 -18,31 3,02 11 -17,48 1,97 0,400
LV radial strain global (%) 32 69,90 16,00 11 69,48 15,40 0,940
LV 3D strain rate (%/ms) 32 -0,20 0,02 11 -0,20 0,04 0,774
LV circumferential strain rate (%/ms) 32 -0,14 0,02 11 -0,15 0,04 0,396
LV longitudinal strain rate (%/ms) 32 -0,10 0,02 11 -0,10 0,01 0,832
LV radial strain rate (%/ms) 32 0,40 0,10 11 0,46 0,28 0,279
RV 2D Strain
RV Global strain 43 -15,66 8,25 15 -17,04 9,45 0,591
RV Free wall (average) 43 -18,56 9,84 15 -21,21 11,96 0,396
RV Septum (average) 37 -15,60 4,62 12 -16,64 5,59 0,521
Markers of hemolysis
Haemoglobin (g/dl) 43 9,23 1,88 16 8,93 1,28 0,564
Lactate dehydrogenase (IU/l) 43 408,37 219,66 15 431,27 195,12 0,726
Reticulocytes (%) 43 8,99 5,46 16 7,75 3,70 0,405
Total bilirubin (umol/l) 43 45,17 31,92 16 54,31 48,93 0,407
Hematocrit (SI units) 43 0,26 0,05 16 0,25 0,03 0,663
Creatinine (umol/l) 43 68,75 31,65 16 75,88 13,20 0,388
Blood urea nitrogen (mmol/L) 43 3,93 3,38 16 4,29 2,09 0,690
Aspartate aminotransferase (U/L) 43 40,76 22,02 16 41,44 28,50 0,923
Urate (mmol/L) 40 0,33 0,12 15 0,35 0,12 0,513
ƗTwo-sided P values for continuous variables were calculated with the use of the t-test. Significant difference 
between groups when p<0.01
Group A2 (abnormal LV 
diastolic function)  p-value ƗVariable
Group A1 (normal LV 
diastolic fucntion )
± SD (N)  Mean ± SD  (N)  Mean
